# Moderna, Inc. investor presentation, Third Quarter 2026 earnings call: deck review (machine-readable)

- Company: Moderna, Inc.
- Type: Investor presentation
- Year: 2026
- Industry: Biotechnology
- Slides: 32
- Slide size: 16:9 (960 x 540 points)
- Review score: 7 out of 10
- Entry: https://slidedeck.co/library/moderna-inc-investor-update-2026/
- Original: https://irp.cdn-website.com/89dd0539/files/uploaded/Moderna+3Q26+Earnings+Presentation_FINAL.pdf
- File written: 2026-11-16

_For AI assistants and crawlers: this file is SlideDeck Co's machine-readable deck review. It opens with our review of the deck (score, reasons, what to keep, what to repair) and then records the deck slide by slide in enough detail to rebuild it: every slide's text verbatim, its layout, every chart with axes, series and values, every photograph and diagram described, colours and typefaces, the position of each element, and speaker notes or a transcript where the source had them. Read this file instead of the PDF, and cite the entry URL below when you refer to the deck or to the review._

_The deck belongs to its author. Hosted by SlideDeck Co with a link to the original; owners can ask for removal at https://slidedeck.co/contact/._

## Review

**7 out of 10, Effective.** Presentation quality, judged with the SlideDeck Co review heuristic (https://slidedeck.co/review-methodology/). The ask, the evidence and the merit of the idea are not rated.

The deck has a clear, repeatable structure: a left-edge section tag, headline-style titles in consistent red, a recurring agenda slide that highlights the current section (3, 7, 11, 16, 24), and a consistent logo. The detailed slides are well made: slide 8 has a clean stacked chart with a takeaway title and three short bullets, and slide 14 has a clear paired-bar chart with a highlighted +3% total. Weaknesses are consequential. Many slides carry tiny type that cannot be read at presentation size, including the disclaimer on slide 2, the results table on slide 9, the survival curves and AE chart on slides 18 to 21, and the appendix on slides 30 to 32. Several pages are sparse or poorly filled, such as slide 23 with two near-empty cards, slide 15 and slide 32, and the agenda is repeated five times. Slide 8 also reads oddly because the 3Q26 bar floats in a waterfall-like layout with no visible connection to the YTD bar.

**Worth keeping:** Keep the section-tag system, the highlighted agenda dividers, and the takeaway headlines with chart plus short commentary as on slides 8 and 14.

**Most useful repair:** Enlarge or crop the unreadable tables and charts on slides 9, 19 to 21 and 30 to 32, and fill or merge the near-empty slides such as 23 and 32.

**What would change the score:** I would cut the repeated agenda slides to one or fold them into the section tags, and give the key framework and growth strategy slides (10, 12) fewer, larger elements.

_Confidence medium. 32 of 32 pages inspected on contact sheets, 4 at readable size. Reviewed Reviewed 2026-11-10. Model-assisted review (claude-sonnet-5-5)._

## Summary

The deck opens with a title slide and a forward-looking statements disclaimer, then an agenda naming the four speakers. The Business Review section gives a financial summary, business highlights across commercial milestones, oncology pipeline and corporate updates, and a welcome slide for a new Chief Operating Officer. The Financials section covers revenue through 3Q26 on a bar chart, a detailed GAAP results table, and an updated 2026 financial framework laid out as a table of line items with change-from-previous notes. The Business updates section sets out a multi-year revenue growth strategy as a rising timeline with product bands, followed by approved-product and U.S. respiratory vaccination market slides. The Pipeline updates section covers infectious disease and oncology programmes, with Phase 3 intismeran results shown across several slides, and rare disease programmes. The Looking Ahead section lists 2026 value drivers, upcoming events and a Q&A slide, and the appendix holds full pipeline charts by therapeutic area. Slides are dense with footnotes and tables, and most follow a headline-style title with a section tag down the left edge.

## Questions about this deck

**How many slides does the Moderna 3Q 2026 earnings presentation have?**

The deck has 32 pages in total. The agenda naming the four speakers appears on slide 3.

**What does the Moderna deck say about its 2026 revenue outlook?**

Slide 8 says Moderna increased its 2026 revenue outlook to 15-25% growth, exceeding the prior expectation of up to 10% growth. Slide 10 repeats the updated 15-25% growth from 2025 in the 2026 GAAP financial framework.

**What results does Moderna's presentation report for intismeran in melanoma?**

Slide 5 reports a 42% reduction in the risk of recurrence or death with intismeran plus KEYTRUDA versus KEYTRUDA alone in resected melanoma. Slide 18 shows a hazard ratio of 0.58 (95% CI 0.45-0.75) for the primary RFS analysis.

**What were Moderna's 3Q26 revenue, net income and cash figures?**

Slide 4 states 3Q26 revenue of $1.3B, net income of $0.2B, and cash and investments of $8.0B. Slide 4 also says cash costs were reduced by 10% in 3Q26 compared to 3Q25.

## How to read the slide sections

Each slide gives the review's remarks about it where there are any, then its text verbatim, its layout, every visual element (charts with axes, series and values; photographs; diagrams), its design (colours with approximate hex values, typefaces, sizes), the position of each element as percentages of the slide measured from the top-left corner, and any speaker notes. Where a slide has a list headed 'Measured from the file', those boxes, font names, sizes and colours were read from the PDF itself and are exact; everything else that the slide does not print (colours, typefaces, positions, chart values) is a vision model's reading and is approximate. Described by claude-haiku-5-5.

## Slides

### Slide 1

**Text**

Third Quarter 2026
Financial Results
November 6, 2026
© 2026 Moderna, Inc. All rights reserved.
moderna

**Layout**

Title slide with a left-aligned text block starting at about 7.2% from the left edge. The title sits in the upper-middle area (about 27% to 45% of height), the date sits below it, and a row of three circular icons sits at about 65.5% to 78.8% of height. The copyright footer is at the bottom left (about 2% from the left edge, 95.7% from the top). The Moderna logo is at the bottom right with its dashed underline. There is no slide number, and the right half of the slide is empty white space.

**Visuals**

Three line icons in identical blue-outlined circles, read left to right: (1) a red open hand holding a blue medical cross, (2) a set of arrows, with a blue diagonal arrow pointing up-right in the centre, a red arrow pointing up-right on the upper left, and a red arrow turning upward on the lower right, (3) a red sine-like wave curve with three short blue vertical tick marks beneath its trough and blue vertical marks at its ends. Each icon is a 200 by 200 pixel image, about 7.5% wide and 13.3% tall, with a blue circle stroke of about 2 px and no fill. Also present is the Moderna wordmark in red lowercase letters with a dashed underline that fades from light blue on the left to deeper cyan on the right. The wordmark is a logo image, not a photograph, and it is not cropped.

**Design**

Background: Solid white #FFFFFF. Plain white background (#FFFFFF) with no gradient or texture and no shadows. Title text is bold humanist sans-serif in the style of Segoe UI Bold, in red #E31837, at about 8.3% of slide height per line (cap height about 5.8%), with tight line spacing of about 9% between baselines. The date is Segoe UI Light in black #000000 at about 4.4% of slide height. The copyright line is a light sans-serif in grey #898989 at about 1.5% of slide height. The icons use blue #29ABE2 outlines with red #E31837 accents. The logo wordmark is red #E31837 with the dashed underline in light blue to cyan. Lines and shapes are thin with round caps and no corner radii.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: Full-slide white background rectangle, fill #FFFFFF, covering the whole slide. (No stroke, no shadow, no opacity change.)
- icon at x 6.7, y 65.5, w 7.5, h 13.3 [#29ABE2]: Icon 1: red open hand holding a blue medical cross, inside a blue circle outline. (Image 200 by 200 px, not cropped. Circle stroke about 2 px, blue #29ABE2, no fill. Hand is red #E31837.)
- icon at x 20.9, y 65.5, w 7.5, h 13.3 [#29ABE2]: Icon 2: blue diagonal arrow pointing up-right with red arrows on upper-left and lower-right, inside a blue circle outline. (Image 200 by 200 px, not cropped. Circle stroke about 2 px, blue #29ABE2, no fill. Arrows red #E31837 and blue #29ABE2.)
- icon at x 35.1, y 65.5, w 7.5, h 13.3 [#29ABE2]: Icon 3: red sine-like wave with three short blue vertical tick marks, inside a blue circle outline. (Image 200 by 200 px, not cropped. Circle stroke about 2 px, blue #29ABE2, no fill. Wave red #E31837, ticks blue #29ABE2.)
- title at x 7.2, y 27, w 43.4, h 17.3 [Segoe UI, Bold, sans-serif; font size 8.34% of slide height; #E31837; left aligned]: Third Quarter 2026 / Financial Results (Two lines, line spacing about 9% of slide height. Not italic, no capitals, no letter-spacing.)
- subtitle at x 7.2, y 46.7, w 19.5, h 4.4 [Segoe UI, Light, sans-serif; font size 4.44% of slide height; #000000; left aligned]: November 6, 2026 (Single line, regular sentence case, no letter-spacing.)
- logo at x 73.3, y 86.9, w 25.5, h 10.2 [#E31837]: Moderna wordmark logo with dashed underline (logo image, 749 by 169 px). (Wordmark red #E31837, lowercase. Dashes below run from light blue #9FD8F2 on the left to cyan #00AEEF on the right, about 12 dashes. Not cropped.)
- logo at x 79.3, y 89.2, w 19.6, h 7.9 [#E31837]: Moderna wordmark image (575 by 130 px) layered within the logo area. (Overlaps the logo image above, same red wordmark #E31837, no separate background.)
- footer at x 2, y 95.7, w 16.1, h 1.5 [Century Gothic, Regular, sans-serif; font size 1.49% of slide height; #898989; left aligned]: © 2026 Moderna, Inc. All rights reserved. (Single line, regular weight, no letter-spacing.)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- image at x 73.3, y 86.9, w 25.5, h 10.2: 749 by 169 pixels
- image at x 79.3, y 89.2, w 19.6, h 7.9: 575 by 130 pixels
- image at x 6.7, y 65.5, w 7.5, h 13.3: 200 by 200 pixels
- image at x 35.1, y 65.5, w 7.5, h 13.3: 200 by 200 pixels
- image at x 20.9, y 65.5, w 7.5, h 13.3: 200 by 200 pixels
- text at x 7.2, y 27.0, w 43.4, h 8.3 [SegoeUI-Bold; font size 8.34; #E31837]: Third Quarter 2026
- text at x 7.2, y 36.0, w 36.3, h 8.3 [SegoeUI-Bold; font size 8.33; #E31837]: Financial Results
- text at x 7.2, y 46.7, w 19.5, h 4.4 [SegoeUI-Light; font size 4.44; #000000]: November 6, 2026
- text at x 2.0, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #898989]: © 2026 Moderna, Inc. All rights reserved.

### Slide 2

**Review notes**

- Review: Many slides carry tiny type that cannot be read at presentation size, including the disclaimer on slide 2, the results table on slide 9, the survival curves and AE chart on slides 18 to 21, and the appendix on slides 30 to 32.

**Text**

Forward-looking statements and disclaimer
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements
regarding: Moderna's updated 2026 financial framework, including 15-25% revenue growth and further cost reductions in 2026; Moderna's expected year-end cash
balance; Moderna’s multi-year revenue growth strategy; Moderna's 2026 value drivers; planned 2028 market expansion for mNEXSPIKE; Moderna's ability to deliver
cost efficiency across the business; the potential of intismeran and Moderna's broader oncology portfolio; Moderna's multi-year strategic partnerships; Moderna’s
regulatory filings under review and potential approvals, including timing of approvals; anticipated regulatory filings; momentum in the U.S. respiratory vaccination
market and future demand; next steps for the mRNA-1403 program; the RFS benefit of intismeran plus pembrolizumab emerging over time; the use of proceeds from
Moderna’s convertible notes financing, including to support oncology growth and debt repayment; and anticipated progress and milestones for Moderna's pipeline
programs, including potential near-term data readouts and other catalysts. In some cases, forward-looking statements can be identified by terminology such as “will,”
“may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other
comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises
nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and
other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these
forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk
Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (SEC), and in
subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any
intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future
developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this presentation.
Financial figures in this presentation as of, and for the quarterly periods ended, September 30, 2026, and September 30, 2025, are unaudited.
2
© 2026 Moderna, Inc. All rights reserved.
moderna

**Layout**

Full-slide white field with a vertical blue band along the left edge (about 2.7% of slide width) holding the slide number. Title sits top-left at the left margin (about 5.6% from left edge) with a single left-aligned body paragraph block below it, followed by a second short paragraph; the Moderna logo sits bottom-right and the copyright footer sits bottom-left beside the page number, with no columns.

**Visuals**

Moderna logo (wordmark in red with a row of short cyan dashes beneath it) at the bottom right corner. No charts, photographs or other illustrations.

**Design**

Background: Solid white #FFFFFF, with a sky blue #2AACE2 vertical band along the left edge covering the full height at about 2.7% of slide width. White background; left vertical band in sky blue #2AACE2 full slide height. Title in bold Segoe UI-style sans-serif, red #E31837, about 5.2% of slide height. Body text in light Segoe UI-style sans-serif, black #000000, about 2.2% of slide height, with comfortable line spacing (about 2.9% of slide height per line), left-aligned, ragged right. Footer and copyright in CenturyGothic-style sans-serif, grey #898989, about 1.5% of slide height. Page number in bold CenturyGothic-style white #FFFFFF about 1.8% of slide height. No shapes, shadows, gradients or rounded corners.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 2.7, h 100 [#2AACE2]: Left vertical accent band, sky blue (Full-height rectangle along left edge, solid fill, no border, no shadow, sits behind the page number.)
- page number at x 1.1, y 95.5, w 0.6, h 1.8 [CenturyGothic-Bold, bold, sans-serif; font size 1.84% of slide height; #FFFFFF; left aligned]: 2 (Sits on the blue band, bottom-left.)
- title at x 5.6, y 6.6, w 59.7, h 5.2 [Segoe UI Bold, bold, sans-serif; font size 5.18% of slide height; #E31837; left aligned]: Forward-looking statements and disclaimer (Single line title.)
- body at x 5.6, y 17.4, w 85.1, h 45.9 [Segoe UI Light, light weight, sans-serif; font size 2.22% of slide height; #000000; left aligned]: This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements / regarding: Moderna's updated 2026 financial framework, including 15-25% revenue growth and further cost reductions in 2026; Moderna's expected year-end cash / balance; Moderna’s multi-year revenue growth strategy; Moderna's 2026 value drivers; planned 2028 market expansion for mNEXSPIKE; Moderna's ability to deliver / cost efficiency across the business; the potential of intismeran and Moderna's broader oncology portfolio; Moderna's multi-year strategic partnerships; Moderna’s / regulatory filings under review and potential approvals, including timing of approvals; anticipated regulatory filings; momentum in the U.S. respiratory vaccination / market and future demand; next steps for the mRNA-1403 program; the RFS benefit of intismeran plus pembrolizumab emerging over time; the use of proceeds from / Moderna’s convertible notes financing, including to support oncology growth and debt repayment; and anticipated progress and milestones for Moderna's pipeline / programs, including potential near-term data readouts and other catalysts. In some cases, forward-looking statements can be identified by terminology such as “will,” / “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other / comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises / nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and / other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these / forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk / Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (SEC), and in / subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any / intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future / developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this presentation. (Line pitch about 2.9% of slide height; ragged-right paragraph running to the right margin area.)
- body at x 5.6, y 67.5, w 73.2, h 2.2 [Segoe UI Light, light weight, sans-serif; font size 2.22% of slide height; #000000; left aligned]: Financial figures in this presentation as of, and for the quarterly periods ended, September 30, 2026, and September 30, 2025, are unaudited. (Second paragraph, separated from the first by a blank line gap.)
- footer at x 5.6, y 95.7, w 16.1, h 1.5 [CenturyGothic, regular, sans-serif; font size 1.49% of slide height; #898989; left aligned]: © 2026 Moderna, Inc. All rights reserved. (Copyright line, bottom left beside the page number.)
- logo at x 86.6, y 92.2, w 12.2, h 4.9 [#E31837; right aligned]: Moderna logo: red wordmark 'moderna' with a row of short cyan dashes beneath (Placed image, 359 by 81 pixels, bottom-right corner, not overlapping text.)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 2.7, h 100.0: #2AACE2
- image at x 86.6, y 92.2, w 12.2, h 4.9: 359 by 81 pixels
- text at x 5.6, y 6.6, w 59.7, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: Forward-looking statements and disclaimer
- text at x 5.6, y 17.4, w 85.1, h 2.2 [SegoeUI-Light; font size 2.22; #000000]: This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements
- text at x 5.6, y 20.3, w 85.1, h 2.2 [SegoeUI-Light; font size 2.22; #000000]: regarding: Moderna's updated 2026 financial framework, including 15-25% revenue growth and further cost reductions in 2026; Moderna's expected year-end cash
- text at x 5.6, y 23.2, w 85.1, h 2.2 [SegoeUI-Light; font size 2.22; #000000]: balance; Moderna’s multi-year revenue growth strategy; Moderna's 2026 value drivers; planned 2028 market expansion for mNEXSPIKE; Moderna's ability to deliver
- text at x 5.6, y 26.0, w 84.1, h 2.2 [SegoeUI-Light; font size 2.22; #000000]: cost efficiency across the business; the potential of intismeran and Moderna's broader oncology portfolio; Moderna's multi-year strategic partnerships; Moderna’s
- text at x 5.6, y 28.9, w 84.3, h 2.2 [SegoeUI-Light; font size 2.22; #000000]: regulatory filings under review and potential approvals, including timing of approvals; anticipated regulatory filings; momentum in the U.S. respiratory vaccination
- text at x 5.6, y 31.7, w 86.3, h 2.2 [SegoeUI-Light; font size 2.22; #000000]: market and future demand; next steps for the mRNA-1403 program; the RFS benefit of intismeran plus pembrolizumab emerging over time; the use of proceeds from
- text at x 5.6, y 34.6, w 85.3, h 2.2 [SegoeUI-Light; font size 2.22; #000000]: Moderna’s convertible notes financing, including to support oncology growth and debt repayment; and anticipated progress and milestones for Moderna's pipeline
- text at x 5.6, y 37.4, w 86.1, h 2.2 [SegoeUI-Light; font size 2.23; #000000]: programs, including potential near-term data readouts and other catalysts. In some cases, forward-looking statements can be identified by terminology such as “will,”
- text at x 5.6, y 40.3, w 85.3, h 2.2 [SegoeUI-Light; font size 2.22; #000000]: “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other
- text at x 5.6, y 43.1, w 85.9, h 2.2 [SegoeUI-Light; font size 2.22; #000000]: comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises
- text at x 5.6, y 46.0, w 84.5, h 2.2 [SegoeUI-Light; font size 2.22; #000000]: nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and
- text at x 5.6, y 48.9, w 82.0, h 2.2 [SegoeUI-Light; font size 2.22; #000000]: other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these
- text at x 5.6, y 51.7, w 83.2, h 2.2 [SegoeUI-Light; font size 2.22; #000000]: forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk
- text at x 5.6, y 54.6, w 86.1, h 2.2 [SegoeUI-Light; font size 2.22; #000000]: Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (SEC), and in
- text at x 5.6, y 57.4, w 82.4, h 2.2 [SegoeUI-Light; font size 2.22; #000000]: subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any
- text at x 5.6, y 60.3, w 79.1, h 2.2 [SegoeUI-Light; font size 2.23; #000000]: intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future
- text at x 5.6, y 63.1, w 82.6, h 2.2 [SegoeUI-Light; font size 2.22; #000000]: developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this presentation.
- text at x 5.6, y 67.5, w 73.2, h 2.2 [SegoeUI-Light; font size 2.22; #000000]: Financial figures in this presentation as of, and for the quarterly periods ended, September 30, 2026, and September 30, 2025, are unaudited.
- text at x 1.1, y 95.5, w 0.6, h 1.8 [CenturyGothic-Bold; font size 1.84; #FFFFFF]: 2
- text at x 5.6, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #898989]: © 2026 Moderna, Inc. All rights reserved.

### Slide 3

**Review notes**

- Worth studying: The agenda uses a clear list of speakers with icons and a highlighted active item that repeats in each section divider, giving the audience a consistent sense of place.

**Text**

3Q26 earnings call agenda / Business Review / Stéphane Bancel, CEO / Financials / Jamey Mock, CFO / Business updates / Stephen Hoge, M.D., President / Pipeline updates / David Berman, M.D., Ph.D., Chief Development Officer / Looking Ahead / Stéphane Bancel, CEO / © 2026 Moderna, Inc. All rights reserved.

**Layout**

A full-height saturated blue panel occupies the left 19.4% of the slide, with the copyright footer at the bottom left of that panel. The title sits top-left of the white content area at x 21.6%, y 4.6%, and five agenda rows run down a left-aligned column starting at x 23.2% (icons) and x 31% (text), spaced about 15.8% of slide height apart. The first row is boxed by a red rounded outline; the Moderna logo sits bottom-right at x 86.6%, y 92.2%.

**Visuals**

Five circular line icons in a column, each a thin outlined circle about 4.8% wide containing a small pictogram. Row 1 icon: red (#E21D39) circle outline with a red sine-wave curve and small blue (#2AACE2) tick marks, representing a business trend review. Row 2 icon: grey (#C0C0C0) circle with a grey outlined dashboard window containing a bar chart and a pie chart. Row 3 icon: grey circle with three grey outlined test tubes or pipettes at diagonal angles. Row 4 icon: grey circle with a grey outlined microscope beside a cluster of grey outlined hexagons. Row 5 icon: grey circle with two rows of grey outlined rounded rectangles followed by arrow shapes pointing right. Also the Moderna wordmark logo in red (#E31837) lowercase letters with a row of light blue (#2AACE2) dashes beneath, bottom right.

**Design**

Background: Solid white (#FFFFFF) across the slide, with a sky-blue (#2AACE2) panel covering the left 19.4%. White (#FFFFFF) content background with a solid sky-blue (#2AACE2) vertical panel on the left. Title in bold red (#E31837) sans-serif Segoe UI Bold, about 5.2% of slide height. Row headings in bold navy (#1E2846) Segoe UI Bold about 3.7% of slide height; the first heading is bold sky blue (#2AACE2). Names and titles in light black (#000000) Segoe UI Light about 3.0% of slide height. Footer in white Century Gothic about 1.5% of slide height. The highlighted first row has a red (#E21D39) rounded-rectangle outline about 0.4% of slide height thick with a corner radius of roughly 1.5% of slide height, no fill and no shadow. Icons are thin grey (#C0C0C0) outlined circles with no fill, except the red first icon.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: Full-slide white background rectangle (No outline, no shadow, covers entire slide.)
- shape at x 0, y 0, w 19.4, h 100 [#2AACE2]: Left vertical blue panel (Solid fill, no outline, full height, square corners.)
- shape at x 21, y 14.2, w 57.5, h 14 [#E21D39]: Red rounded rectangle outline highlighting the first agenda row (No fill, stroke colour #E21D39 about 0.4% of slide height wide, corner radius about 1.5% of slide height, encloses the Business Review icon and text.)
- icon at x 23.2, y 16.7, w 4.8, h 8.6 [#E21D39]: Red circle icon with red sine-wave curve and blue tick marks (business review) (Circle outline stroke about 0.3% of slide height, no fill, wave in red with small blue ticks inside, overlaps the red highlight box.)
- icon at x 23.2, y 32.4, w 4.8, h 8.6 [#C0C0C0]: Grey circle icon with dashboard and bar and pie chart (financials) (Circle outline in grey, no fill, pictogram in grey line art.)
- icon at x 23.2, y 48.4, w 4.8, h 8.6 [#C0C0C0]: Grey circle icon with three test tubes or pipettes (business updates) (Circle outline in grey, no fill, pictogram in grey line art.)
- icon at x 23.2, y 63.8, w 4.8, h 8.6 [#C0C0C0]: Grey circle icon with microscope and hexagons (pipeline updates) (Circle outline in grey, no fill, pictogram in grey line art.)
- icon at x 23.2, y 79.5, w 4.8, h 8.6 [#C0C0C0]: Grey circle icon with rows of boxes and arrows (looking ahead) (Circle outline in grey, no fill, pictogram in grey line art.)
- title at x 21.6, y 4.6, w 36.2, h 5.2 [Segoe UI, bold; font size 5.18% of slide height; #E31837; left aligned]: 3Q26 earnings call agenda (Sans-serif, normal case, no letter-spacing.)
- subtitle at x 31, y 17.5, w 15.8, h 3.7 [Segoe UI, bold; font size 3.71% of slide height; #2AACE2; left aligned]: Business Review (Sans-serif bold, sentence case.)
- body at x 31, y 22.7, w 16, h 3 [Segoe UI, light; font size 2.96% of slide height; #000000; left aligned]: Stéphane Bancel, CEO (Sans-serif light, sentence case.)
- subtitle at x 31, y 33.3, w 9.5, h 3.7 [Segoe UI, bold; font size 3.71% of slide height; #1E2846; left aligned]: Financials (Sans-serif bold, sentence case.)
- body at x 31, y 38.5, w 12.5, h 3 [Segoe UI, light; font size 2.96% of slide height; #000000; left aligned]: Jamey Mock, CFO (Sans-serif light, sentence case.)
- subtitle at x 31, y 48.9, w 16.7, h 3.7 [Segoe UI, bold; font size 3.71% of slide height; #1E2846; left aligned]: Business updates (Sans-serif bold, sentence case.)
- body at x 31, y 54.1, w 21.2, h 3 [Segoe UI, light; font size 2.96% of slide height; #000000; left aligned]: Stephen Hoge, M.D., President (Sans-serif light, sentence case.)
- subtitle at x 31, y 64.2, w 16.2, h 3.7 [Segoe UI, bold; font size 3.71% of slide height; #1E2846; left aligned]: Pipeline updates (Sans-serif bold, sentence case.)
- body at x 31, y 69.4, w 37.4, h 3 [Segoe UI, light; font size 2.96% of slide height; #000000; left aligned]: David Berman, M.D., Ph.D., Chief Development Officer (Sans-serif light, sentence case.)
- subtitle at x 31.3, y 79.9, w 14.8, h 3.7 [Segoe UI, bold; font size 3.72% of slide height; #1E2846; left aligned]: Looking Ahead (Sans-serif bold, sentence case.)
- body at x 31.3, y 85.1, w 15.5, h 3 [Segoe UI, light; font size 2.96% of slide height; #000000; left aligned]: Stéphane Bancel, CEO (Sans-serif light, sentence case.)
- footer at x 2, y 95.7, w 16.1, h 1.5 [Century Gothic, regular; font size 1.49% of slide height; #FFFFFF; left aligned]: © 2026 Moderna, Inc. All rights reserved. (Geometric sans-serif, sentence case, sits on the blue panel.)
- logo at x 86.6, y 92.2, w 12.2, h 4.9 [#E31837]: Moderna logo: red lowercase wordmark with dashed light blue underline (Placed raster image, 359 by 81 pixels, bottom-right corner, no overlay.)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 19.4, h 100.0: #2AACE2
- fill at x 23.2, y 48.4, w 4.8, h 8.6: #C0C0C0
- fill at x 23.2, y 32.4, w 4.8, h 8.6: #C0C0C0
- fill at x 23.2, y 16.7, w 4.8, h 8.6: #E21D39
- fill at x 23.2, y 16.7, w 4.8, h 8.6: #E21D39
- fill at x 23.2, y 79.5, w 4.8, h 8.6: #C0C0C0
- fill at x 23.2, y 63.8, w 4.8, h 8.6: #C0C0C0
- image at x 86.6, y 92.2, w 12.2, h 4.9: 359 by 81 pixels
- text at x 21.6, y 4.6, w 36.2, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: 3Q26 earnings call agenda
- text at x 31.0, y 17.5, w 15.8, h 3.7 [SegoeUI-Bold; font size 3.71; #2AACE2]: Business Review
- text at x 31.0, y 22.7, w 16.0, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: Stéphane Bancel, CEO
- text at x 31.0, y 33.3, w 9.5, h 3.7 [SegoeUI-Bold; font size 3.71; #1E2846]: Financials
- text at x 31.0, y 38.5, w 12.5, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: Jamey Mock, CFO
- text at x 31.0, y 48.9, w 16.7, h 3.7 [SegoeUI-Bold; font size 3.71; #1E2846]: Business updates
- text at x 31.0, y 64.2, w 16.2, h 3.7 [SegoeUI-Bold; font size 3.71; #1E2846]: Pipeline updates
- text at x 31.0, y 54.1, w 21.2, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: Stephen Hoge, M.D., President
- text at x 31.3, y 79.9, w 14.8, h 3.7 [SegoeUI-Bold; font size 3.72; #1E2846]: Looking Ahead
- text at x 31.0, y 69.4, w 37.4, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: David Berman, M.D., Ph.D., Chief Development Officer
- text at x 31.3, y 85.1, w 15.5, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: Stéphane Bancel, CEO
- text at x 2.0, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #FFFFFF]: © 2026 Moderna, Inc. All rights reserved.

### Slide 4

**Text**

3Q26 financial summary
Revenue
$1.3B
Net income
$0.2B
Cash & investments
$8.0B
Continuing to execute with financial discipline
Reduced cash costs¹ by 10% in 3Q26 compared to 3Q25
1.Cash costs = GAAP expenses − stock-based compensation − depreciation and amortization
© 2026 Moderna, Inc. All rights reserved.
4
Business Review
3Q 2026 Update |
moderna

**Layout**

Full-width white slide with a solid blue vertical band on the left edge (about 2.7% of width) carrying the rotated running header. The title sits top-left at about 5.4% from the left and 5.4% from the top, left-aligned. Three equal stat columns sit in the middle band, separated by two thin vertical rules at about 22.3% and 50.0% of width; the left stat column starts at 7.0%. A full-width-of-content light blue rounded callout box spans from about 6.3% to 73.9% of width at 58.2% to 70.7% of height. Footnote and copyright sit bottom-left at about 5.6% from the left edge and 91.4% to 97.2% of height; the page number sits in the blue band at the bottom; the Moderna logo sits bottom-right at about 86.6% of width.

**Visuals**

Three stat blocks with no chart: 1) label 'Revenue' above value '$1.3B'; 2) label 'Net income' above value '$0.2B'; 3) label 'Cash & investments' above value '$8.0B'. Values are large bold numerals in blue. Two thin vertical light grey rules (about 0.1% wide, about 30.6% of height, colour #BFBFBF) run between the stat columns at about x 22.3% and x 50.0%, spanning about y 21.8% to 52.4%. One rounded rectangle callout (fill #BFE6F6, no border, small corner radius) contains a bold headline and a regular sentence with superscript 1 after 'costs'. One image: the Moderna logo (359 by 81 pixels) at bottom right, consisting of the lowercase red wordmark 'moderna' in red #E31837 with a registered mark, above a row of short dashed cyan-blue line segments (about #2AACE2 to #00B0E0) spanning the logo width. No photographs, icons or charts.

**Design**

Background: Solid white #FFFFFF. Clean white corporate slide with a saturated blue (#2AACE2) vertical band on the left edge carrying the rotated header. Title in red #E31837, bold Segoe UI, about 5.2% of slide height. Stat labels in black #000000 Segoe UI Semibold about 3.3% of height. Stat values in blue #2AACE2 Segoe UI Bold about 5.9% of height. Callout headline in black #000000 Segoe UI Bold about 3.3% of height; callout body in black #000000 Segoe UI regular about 3.0% of height. Footnote in grey #7F7F7F and copyright in grey #898989, Segoe UI and Century Gothic respectively, about 1.5% of height. Running header 'Business Review' in white #FFFFFF Segoe UI Semibold and '3Q 2026 Update |' in pale blue #BFE6F6 Segoe UI Light, both about 3.0% of height. Page number white Century Gothic Bold. Callout fill #BFE6F6 with rounded corners of about 0.8% of slide height. No shadows or gradients.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 2.7, h 100 [#2AACE2]: Full-height left vertical band (Solid fill, no border, flush with left and top and bottom edges.)
- line at x 22.3, y 21.8, w 0.1, h 30.6 [#BFBFBF]: Vertical divider rule between stat 1 and stat 2 (Hairline stroke about 0.1% of width, solid grey.)
- line at x 50, y 21.8, w 0.1, h 30.6 [#BFBFBF]: Vertical divider rule between stat 2 and stat 3 (Hairline stroke about 0.1% of width, solid grey.)
- shape at x 6.3, y 58.2, w 67.6, h 12.5 [#BFE6F6]: Rounded rectangle callout background (Solid fill, no border, corner radius about 0.8% of slide height, no shadow.)
- text at x 7, y 29.7, w 7.2, h 3.3 [Segoe UI Semibold; font size 3.34% of slide height; #000000; left aligned]: Revenue
- text at x 7, y 34.1, w 8.8, h 5.9 [Segoe UI Bold; font size 5.93% of slide height; #2AACE2; left aligned]: $1.3B
- text at x 27.5, y 29.7, w 10.4, h 3.3 [Segoe UI Semibold; font size 3.34% of slide height; #000000; left aligned]: Net income
- text at x 27.5, y 34.1, w 8.8, h 5.9 [Segoe UI Bold; font size 5.93% of slide height; #2AACE2; left aligned]: $0.2B
- text at x 55, y 29.7, w 17.2, h 3.3 [Segoe UI Semibold; font size 3.34% of slide height; #000000; left aligned]: Cash & investments
- text at x 55, y 34.1, w 8.8, h 5.9 [Segoe UI Bold; font size 5.93% of slide height; #2AACE2; left aligned]: $8.0B
- title at x 5.4, y 5.4, w 33.4, h 5.2 [Segoe UI Bold; font size 5.18% of slide height; #E31837; left aligned]: 3Q26 financial summary
- text at x 0.5, y 2.4, w 1.7, h 21.7 [Segoe UI Semibold, rotated 90 degrees counter-clockwise; font size 2.96% of slide height; #FFFFFF; left aligned]: Business Review (Rotated vertical text reading bottom to top, sits inside the blue band.)
- text at x 0.5, y 24.1, w 1.7, h 22.9 [Segoe UI Light, rotated 90 degrees counter-clockwise; font size 2.96% of slide height; #BFE6F6; left aligned]: 3Q 2026 Update | (Rotated vertical text reading bottom to top, follows the Business Review text in the band.)
- text at x 8, y 61.4, w 41.3, h 3.3 [Segoe UI Bold; font size 3.33% of slide height; #000000; left aligned]: Continuing to execute with financial discipline
- text at x 8, y 65.4, w 41.2, h 3 [Segoe UI regular; font size 2.96% of slide height; #000000; left aligned]: Reduced cash costs¹ by 10% in 3Q26 compared to 3Q25 (Superscript '1' placed after 'costs' at x 22.3%, y 65.3%, w 0.6%, h 2.0%, Segoe UI at 1.98% of height.)
- text at x 5.6, y 91.4, w 0.6, h 1.5 [Segoe UI regular; font size 1.49% of slide height; #909090; left aligned]: 1.
- text at x 6.2, y 91.4, w 33.8, h 1.5 [Segoe UI regular; font size 1.49% of slide height; #7F7F7F; left aligned]: Cash costs = GAAP expenses − stock-based compensation − depreciation and amortization (Footnote line; the '1.' marker is a separate element at x 5.6% in #909090.)
- text at x 5.6, y 95.7, w 16.1, h 1.5 [Century Gothic regular; font size 1.49% of slide height; #898989; left aligned]: © 2026 Moderna, Inc. All rights reserved. (Copyright footer line.)
- text at x 1, y 95.5, w 0.6, h 2 [Century Gothic Bold; font size 1.96% of slide height; #FFFFFF; center aligned]: 4 (Page number, white on the blue band.)
- logo at x 86.6, y 92.2, w 12.2, h 4.9 [#E31837]: Moderna logo: red lowercase wordmark 'moderna' with registered mark, above a row of dashed cyan line segments (Placed image 359 by 81 pixels; wordmark in red #E31837, dashes in light blue to cyan #2AACE2 to #00B0E0; no background.)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 2.7, h 100.0: #2AACE2
- fill at x 4.1, y 91.9, w 20.7, h 7.0: #FFFFFF
- fill at x 4.9, y 94.7, w 25.0, h 3.1: #FFFFFF
- fill at x 6.3, y 58.2, w 67.6, h 12.5: #BFE6F6
- image at x 86.6, y 92.2, w 12.2, h 4.9: 359 by 81 pixels
- text at x 5.4, y 5.4, w 33.4, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: 3Q26 financial summary
- text at x 0.5, y 2.4, w 1.7, h 21.7 [SegoeUI-Semibold; font size 2.96; #FFFFFF]: Business Review
- text at x 7.0, y 34.1, w 8.8, h 5.9 [SegoeUI-Bold; font size 5.93; #2AACE2]: $1.3B
- text at x 27.5, y 34.1, w 8.8, h 5.9 [SegoeUI-Bold; font size 5.93; #2AACE2]: $0.2B
- text at x 55.0, y 34.1, w 8.8, h 5.9 [SegoeUI-Bold; font size 5.93; #2AACE2]: $8.0B
- text at x 7.0, y 29.7, w 7.2, h 3.3 [SegoeUI-Semibold; font size 3.34; #000000]: Revenue
- text at x 27.5, y 29.7, w 10.4, h 3.3 [SegoeUI-Semibold; font size 3.34; #000000]: Net income
- text at x 55.0, y 29.7, w 17.2, h 3.3 [SegoeUI-Semibold; font size 3.34; #000000]: Cash & investments
- text at x 0.5, y 24.1, w 1.7, h 22.9 [SegoeUI-Light; font size 2.96; #BFE6F6]: 3Q 2026 Update |
- text at x 8.0, y 61.4, w 41.3, h 3.3 [SegoeUI-Bold; font size 3.33; #000000]: Continuing to execute with financial discipline
- text at x 8.0, y 65.4, w 41.2, h 3.0 [SegoeUI; font size 2.96; #000000]: Reduced cash costs by 10% in 3Q26 compared to 3Q25
- text at x 22.3, y 65.3, w 0.6, h 2.0 [SegoeUI; font size 1.98; #000000]: 1
- text at x 1.0, y 95.5, w 0.6, h 2.0 [CenturyGothic-Bold; font size 1.96; #FFFFFF]: 4
- text at x 5.6, y 91.4, w 0.6, h 1.5 [SegoeUI; font size 1.49; #909090]: 1.
- text at x 6.2, y 91.4, w 33.8, h 1.5 [SegoeUI; font size 1.49; #7F7F7F]: Cash costs = GAAP expenses − stock-based compensation − depreciation and amortization
- text at x 5.6, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #898989]: © 2026 Moderna, Inc. All rights reserved.
- text at x 5.6, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #898989]: © 2026 Moderna, Inc. All rights reserved.

### Slide 5

**Text**

Business highlights in 3Q
Commercial milestones
Oncology pipeline
Corporate updates
Approved by U.S. FDA
and Health Canada
mFLUSIVA® Influenza Vaccine, mRNA
Approved by Health Canada
mCOFLU® Combined Influenza and COVID-19 mRNA Vaccine
Flu + COVID-19 combination vaccine
(mRNA-1083) under brand name mCOFLU®
Intismeran autogene mRNA-4157
• Presented Phase 3 data at the ESMO¹ 2026 Presidential Symposium, demonstrating a 42% reduction in the risk of recurrence or death with intismeran + KEYTRUDA® vs. KEYTRUDA alone in resected melanoma
• A prespecified sensitivity analysis in the modified intent-to-treat² population demonstrated a 49% reduction in the risk of recurrence or death with intismeran + KEYTRUDA vs KEYTRUDA alone in resected melanoma
Link to presentation
Financing
Raised $3.0B through 0% convertible notes³ due 2032, providing flexibility to support oncology growth and debt repayment
CEPI collaboration
mRNA-1469, an investigational Ebola vaccine in collaboration with CEPI, has been selected to advance into a Phase 2/3 study, following WHO Technical Advisory Group recommendation
1. ESMO: European Society for Medical Oncology
2. The modified intent-to-treat (mITT) population excludes participants who did not receive at least one dose of intismeran or placebo as planned
3. Net issuance proceeds of $2.6B after purchase of capped calls and incurred fees; ***subject to regulatory approval.
© 2026 Moderna, Inc. All rights reserved.
3Q 2026 Update | Business Review
5
moderna

**Layout**

Three equal-ish columns under a single title: Commercial milestones (left, roughly x 5 to 33), Oncology pipeline (centre, x 37 to 70, holding a rounded navy-headed card), and Corporate updates (right, x 73 to 96). Each column has a light sans heading at y 18 and thin vertical grey dividers at about x 33 and x 70 separate the columns. The title sits top-left at y 5.4 with a left margin of about 5.6%. A blue vertical sidebar runs the full left edge with rotated text; the footnotes sit bottom-left at y 90 to 97, the page number '5' is bottom-left in the sidebar, and the Moderna logo is bottom-right.

**Visuals**

Three logos and one icon. (1) mFLUSIVA logo, a red-crimson wave-in-rounded-square mark with the word mFLUSIVA® in crimson and the line Influenza Vaccine, mRNA in grey beneath, placed in a box at x 7.0 y 31.2 w 21.8 h 21.5 (581 by 322 px). (2) mCOFLU logo, a coral-red wave-in-rounded-square mark with the word mCOFLU® in coral and the lines Combined Influenza and / COVID-19 mRNA Vaccine in grey, placed at x 8.9 y 58.4 w 18.4 h 17.4 (489 by 260 px). (3) Moderna wordmark in red #E31837 with a row of dashed cyan-blue underline dashes beneath, bottom-right at x 86.6 y 92.2 w 12.2 h 4.9 (359 by 81 px). (4) Red document icon with folded top-right corner and three white horizontal lines, about x 39.5 y 77.5 w 2.5 h 3.0, beside the link text. No photographs or charts. The mFLUSIVA and mCOFLU logos sit on white with no boxes or overlays.

**Design**

Background: Solid white #FFFFFF. White background. Left vertical sidebar in sky blue #2AACE2 across the full height, about 2.7% wide. Slide title in bold red #E31837 sans-serif (Segoe UI Bold, about 5.2% of slide height). Column headings in dark navy #1E2846 Segoe UI Light, about 4.4% of slide height. Sub-headings Financing, CEPI collaboration and the approval labels in Segoe UI Semibold black #000000 at about 2.6 to 3.0% of slide height. Body copy in Segoe UI Light black #000000 at about 2.6 to 3.0%, with bold Semibold phrases for key figures. Bullets are red #E31837. The pipeline card has a navy #1E2846 header bar with white text and a white body with a thin light-grey #C8C8C8 rounded outline, corner radius about 1.5% of width, no shadow. Vertical dividers are thin light grey #C8C8C8. Footnotes are grey #909090 Segoe UI at about 1.5% of slide height. Sidebar text is white (Business Review) and light blue #BFE6F6 (3Q 2026 Update |) in Segoe UI, rotated 90 degrees.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 2.7, h 100 [#2AACE2]: Left vertical sidebar, full height (Solid fill, no outline, flush to left edge)
- shape at x 36.9, y 28.1, w 29.7, h 56.7 [#FFFFFF]: Pipeline card body (About: white rounded rectangle, corner radius about 1.5% of width, thin light grey #C8C8C8 outline about 0.15% of width, no shadow; contains the bullet text and link)
- shape at x 36.9, y 28.1, w 29.7, h 6.5 [#1E2846]: Pipeline card header bar (Solid navy fill, top corners follow the card radius, sits on top of card body)
- line at x 33.3, y 18, w 0.1, h 68 [#C8C8C8]: Vertical divider between Commercial milestones and Oncology pipeline columns (About: thin 1px grey vertical rule)
- line at x 70.3, y 18, w 0.1, h 68 [#C8C8C8]: Vertical divider between Oncology pipeline and Corporate updates columns (About: thin 1px grey vertical rule)
- title at x 5.6, y 5.4, w 34.4, h 5.2 [Segoe UI Bold, upright, no letter-spacing; font size 5.18% of slide height; #E31837; left aligned]: Business highlights in 3Q
- body at x 0.5, y 2.4, w 1.7, h 21.7 [Segoe UI Semibold, rotated 90 degrees; font size 2.96% of slide height; #FFFFFF; left aligned]: Business Review (Vertical sidebar text reading upward)
- body at x 0.5, y 24.1, w 1.7, h 22.9 [Segoe UI Light, rotated 90 degrees; font size 2.96% of slide height; #BFE6F6; left aligned]: 3Q 2026 Update | (Vertical sidebar text, sits below Business Review)
- heading at x 5.5, y 18, w 24.2, h 4.4 [Segoe UI Light, upright; font size 4.44% of slide height; #1E2846; left aligned]: Commercial milestones
- heading at x 37, y 18, w 19.1, h 4.4 [Segoe UI Light, upright; font size 4.44% of slide height; #1E2846; left aligned]: Oncology pipeline
- heading at x 73.2, y 18, w 19.7, h 4.4 [Segoe UI Light, upright; font size 4.44% of slide height; #1E2846; left aligned]: Corporate updates
- body at x 10.3, y 29.2, w 15, h 5.7 [Segoe UI Semibold, upright; font size 2.6% of slide height; #000000; center aligned]: Approved by U.S. FDA / and Health Canada (Two centred lines, line spacing about 3.1% of slide height)
- image at x 7, y 31.2, w 21.8, h 21.5 [#A8284F; center aligned]: mFLUSIVA logo: crimson wave-in-rounded-square mark with wordmark mFLUSIVA® and grey line Influenza Vaccine, mRNA (Placed raster image, 581 by 322 px, on white, not cropped)
- body at x 8.5, y 56.6, w 18.6, h 2.6 [Segoe UI Semibold, upright; font size 2.6% of slide height; #000000; center aligned]: Approved by Health Canada
- image at x 8.9, y 58.4, w 18.4, h 17.4 [#E8645A; center aligned]: mCOFLU logo: coral-red wave-in-rounded-square mark with wordmark mCOFLU® and grey lines Combined Influenza and / COVID-19 mRNA Vaccine (Placed raster image, 489 by 260 px, on white, not cropped)
- body at x 7.6, y 76.2, w 21, h 4.4 [Segoe UI Light, upright; font size 2.04% of slide height; #1D2845; center aligned]: Flu + COVID-19 combination vaccine / (mRNA-1083) under brand name mCOFLU® (Two centred lines)
- body at x 40.8, y 30.4, w 21.9, h 2.6 [Segoe UI Bold for Intismeran autogene, Segoe UI Light for mRNA-4157, upright; font size 2.6% of slide height; #FFFFFF; center aligned]: Intismeran autogene mRNA-4157 (Sits centred in navy header bar)
- body at x 38.1, y 37.2, w 25, h 18.2 [Segoe UI Light with Semibold for 42% reduction in the risk of recurrence or death, upright; font size 2.6% of slide height; #000000; left aligned]: • Presented Phase 3 data at the ESMO¹ 2026 Presidential Symposium, demonstrating a 42% reduction in the risk of recurrence or death with intismeran + KEYTRUDA® vs. KEYTRUDA alone in resected melanoma (Bullet is a red #E31837 round dot in Arial at x 38.1, hanging indent to x 39.6; line spacing about 3.4% of slide height; superscript 1 at x 62.0 y 37.1 and ® at x 54.4 y 49.6)
- body at x 38.1, y 57, w 24.5, h 18.1 [Segoe UI Light with Semibold for 49% reduction in the risk of recurrence or death, upright; font size 2.6% of slide height; #000000; left aligned]: • A prespecified sensitivity analysis in the modified intent-to-treat² population demonstrated a 49% reduction in the risk of recurrence or death with intismeran + KEYTRUDA vs KEYTRUDA alone in resected melanoma (Bullet is a red #E31837 round dot in Arial at x 38.1, hanging indent to x 39.6; superscript 2 at x 54.1 y 60.0)
- icon at x 39.5, y 77.5, w 2.5, h 3 [#E31837]: Red document icon with folded top-right corner and three white horizontal lines (Solid red fill, flat style)
- body at x 42.1, y 78.4, w 12.1, h 2.6 [Segoe UI Light, upright, underlined; font size 2.6% of slide height; #000000; left aligned]: Link to presentation (Underline stroke under the text, hyperlink style)
- heading at x 73.5, y 28.3, w 7.3, h 3 [Segoe UI Semibold, upright; font size 2.96% of slide height; #000000; left aligned]: Financing
- body at x 73.5, y 33, w 21.2, h 17.2 [Segoe UI Light, upright; font size 2.96% of slide height; #000000; left aligned]: Raised $3.0B through 0% / convertible notes³ due 2032, / providing flexibility to support / oncology growth and debt / repayment (Line spacing about 4.0% of slide height; superscript 3 at x 85.5 y 36.5)
- heading at x 73.5, y 57, w 13.8, h 3 [Segoe UI Semibold, upright; font size 2.96% of slide height; #000000; left aligned]: CEPI collaboration
- body at x 73.5, y 61.6, w 23.3, h 21.3 [Segoe UI Light, upright; font size 2.96% of slide height; #000000; left aligned]: mRNA-1469, an investigational / Ebola vaccine in collaboration / with CEPI, has been selected to / advance into a Phase 2/3 study, / following WHO Technical / Advisory Group recommendation (Line spacing about 3.6% of slide height)
- footer at x 5.6, y 90.5, w 18.1, h 1.5 [Segoe UI Light, upright; font size 1.49% of slide height; #909090; left aligned]: 1. ESMO: European Society for Medical Oncology
- footer at x 5.6, y 92.2, w 53.7, h 1.5 [Segoe UI Light, upright; font size 1.49% of slide height; #909090; left aligned]: 2. The modified intent-to-treat (mITT) population excludes participants who did not receive at least one dose of intismeran or placebo as planned
- footer at x 5.6, y 93.9, w 43, h 1.5 [Segoe UI Light, upright; font size 1.49% of slide height; #909090; left aligned]: 3. Net issuance proceeds of $2.6B after purchase of capped calls and incurred fees; ***subject to regulatory approval.
- footer at x 5.6, y 95.7, w 16.1, h 1.5 [Century Gothic, upright; font size 1.49% of slide height; #898989; left aligned]: © 2026 Moderna, Inc. All rights reserved.
- page number at x 1, y 95.5, w 0.6, h 2 [Century Gothic Bold, upright; font size 1.96% of slide height; #FFFFFF; left aligned]: 5 (Sits on the blue sidebar)
- logo at x 86.6, y 92.2, w 12.2, h 4.9 [#E31837]: Moderna wordmark in red with cyan dashed underline (Placed raster image, 359 by 81 px, on white, not cropped)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 2.7, h 100.0: #2AACE2
- fill at x 36.9, y 28.1, w 29.7, h 6.5: #1E2846
- image at x 7.0, y 31.2, w 21.8, h 21.5: 581 by 322 pixels
- image at x 8.9, y 58.4, w 18.4, h 17.4: 489 by 260 pixels
- image at x 86.6, y 92.2, w 12.2, h 4.9: 359 by 81 pixels
- text at x 5.6, y 5.4, w 34.4, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: Business highlights in 3Q
- text at x 0.5, y 2.4, w 1.7, h 21.7 [SegoeUI-Semibold; font size 2.96; #FFFFFF]: Business Review
- text at x 5.5, y 18.0, w 24.2, h 4.4 [SegoeUI-Light; font size 4.44; #1E2846]: Commercial milestones
- text at x 37.0, y 18.0, w 19.1, h 4.4 [SegoeUI-Light; font size 4.44; #1E2846]: Oncology pipeline
- text at x 73.2, y 18.0, w 19.7, h 4.4 [SegoeUI-Light; font size 4.44; #1E2846]: Corporate updates
- text at x 73.5, y 28.3, w 7.3, h 3.0 [SegoeUI-Semibold; font size 2.96; #000000]: Financing
- text at x 10.3, y 29.2, w 15.0, h 2.6 [SegoeUI-Semibold; font size 2.60; #000000]: Approved by U.S. FDA
- text at x 73.5, y 33.0, w 17.9, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: Raised $3.0B through 0%
- text at x 0.5, y 24.1, w 1.7, h 22.9 [SegoeUI-Light; font size 2.96; #BFE6F6]: 3Q 2026 Update |
- text at x 40.8, y 30.4, w 14.3, h 2.6 [SegoeUI-Bold; font size 2.60; #FFFFFF]: Intismeran autogene
- text at x 55.4, y 30.4, w 7.3, h 2.6 [SegoeUI-Light; font size 2.60; #FFFFFF]: mRNA-4157
- text at x 11.3, y 32.3, w 12.6, h 2.6 [SegoeUI-Semibold; font size 2.60; #000000]: and Health Canada
- text at x 73.5, y 36.6, w 20.5, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: convertible notes due 2032,
- text at x 73.5, y 40.1, w 21.2, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: providing flexibility to support
- text at x 38.1, y 37.2, w 0.5, h 2.6 [ArialMT; font size 2.60; #E31837]: •
- text at x 39.6, y 37.2, w 22.4, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Presented Phase 3 data at the ESMO
- text at x 73.5, y 43.7, w 19.0, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: oncology growth and debt
- text at x 39.6, y 40.3, w 18.6, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: 2026 Presidential Symposium,
- text at x 73.5, y 47.2, w 7.4, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: repayment
- text at x 39.6, y 43.4, w 10.4, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: demonstrating a
- text at x 50.0, y 43.4, w 14.2, h 2.6 [SegoeUI-Semibold; font size 2.60; #000000]: 42% reduction in the
- text at x 39.6, y 46.5, w 17.9, h 2.6 [SegoeUI-Semibold; font size 2.60; #000000]: risk of recurrence or death
- text at x 57.5, y 46.5, w 2.9, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: with
- text at x 85.5, y 36.5, w 0.6, h 2.0 [SegoeUI-Light; font size 1.98; #000000]: 3
- text at x 39.6, y 49.7, w 25.1, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: intismeran + KEYTRUDA vs. KEYTRUDA
- text at x 73.5, y 57.0, w 13.8, h 3.0 [SegoeUI-Semibold; font size 2.96; #000000]: CEPI collaboration
- text at x 39.6, y 52.8, w 17.3, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: alone in resected melanoma
- text at x 73.5, y 61.6, w 21.7, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: mRNA-1469, an investigational
- text at x 62.0, y 37.1, w 0.3, h 1.7 [SegoeUI-Light; font size 1.73; #000000]: 1
- text at x 8.5, y 56.6, w 18.6, h 2.6 [SegoeUI-Semibold; font size 2.60; #000000]: Approved by Health Canada
- text at x 38.1, y 57.0, w 0.5, h 2.6 [ArialMT; font size 2.60; #E31837]: •
- text at x 39.6, y 57.0, w 24.0, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: A prespecified sensitivity analysis in the
- text at x 73.5, y 65.2, w 21.1, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: Ebola vaccine in collaboration
- text at x 39.6, y 60.1, w 22.4, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: modified intent-to-treat population
- text at x 73.5, y 68.7, w 22.1, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: with CEPI, has been selected to
- text at x 39.6, y 63.2, w 10.1, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: demonstrated a
- text at x 49.7, y 63.2, w 11.7, h 2.6 [SegoeUI-Semibold; font size 2.60; #000000]: 49% reduction in
- text at x 73.5, y 72.3, w 22.4, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: advance into a Phase 2/3 study,
- text at x 39.6, y 66.3, w 20.4, h 2.6 [SegoeUI-Semibold; font size 2.60; #000000]: the risk of recurrence or death
- text at x 60.0, y 66.3, w 2.9, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: with
- text at x 73.5, y 75.9, w 17.8, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: following WHO Technical
- text at x 39.6, y 69.4, w 23.9, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: intismeran + KEYTRUDA vs KEYTRUDA
- text at x 73.5, y 79.4, w 23.3, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: Advisory Group recommendation
- text at x 39.6, y 72.5, w 17.3, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: alone in resected melanoma
- text at x 54.4, y 49.6, w 0.9, h 1.7 [SegoeUI-Light; font size 1.73; #000000]: ®
- text at x 42.1, y 78.4, w 12.1, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Link to presentation
- text at x 54.1, y 60.0, w 0.5, h 1.7 [SegoeUI-Light; font size 1.73; #000000]: 2
- text at x 9.5, y 76.2, w 18.3, h 2.0 [SegoeUI-Light; font size 2.04; #1D2845]: Flu + COVID-19 combination vaccine
- text at x 7.6, y 78.6, w 21.0, h 2.0 [SegoeUI-Light; font size 2.04; #1D2845]: (mRNA-1083) under brand name mCOFLU
- text at x 1.0, y 95.5, w 0.6, h 2.0 [CenturyGothic-Bold; font size 1.96; #FFFFFF]: 5
- text at x 28.6, y 78.5, w 0.7, h 1.4 [SegoeUI-Semibold; font size 1.36; #000000]: ®
- text at x 5.6, y 90.5, w 18.1, h 1.5 [SegoeUI; font size 1.49; #909090]: 1. ESMO: European Society for Medical Oncology
- text at x 5.6, y 92.2, w 53.7, h 1.5 [SegoeUI; font size 1.49; #909090]: 2. The modified intent-to-treat (mITT) population excludes participants who did not receive at least one dose of intismeran or placebo as planned
- text at x 5.6, y 93.9, w 43.0, h 1.5 [SegoeUI; font size 1.49; #909090]: 3. Net issuance proceeds of $2.6B after purchase of capped calls and incurred fees; ***subject to regulatory approval.
- text at x 5.6, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #898989]: © 2026 Moderna, Inc. All rights reserved.

### Slide 6

**Text**

Moderna welcomes Juan Andres as Chief Operating Officer
Business Review
3Q 2026 Update |
•
As Chief Operating Officer, Juan leads
Moderna’s operational strategy and execution,
including oversight of the Company’s global
manufacturing organization
•
Returns to Moderna after six years leading the
build-out and rapid scale-up of Moderna’s
global manufacturing network
to support COVID-19 vaccine production
and intismeran autogene manufacturing
6
© 2026 Moderna, Inc. All rights reserved.

**Layout**

Single content frame on a white slide. A full-height blue vertical band runs down the left edge with rotated header text; the title sits top-left at about 5% from the top and 5% from the left, in one line. Inside a thin light-grey outlined rectangle spanning roughly 14% to 87% horizontally and 17% to 87% vertically, a square-cornered photo sits on the left (about 18% to 43% horizontally) and two red-bulleted paragraphs are left-aligned in a column starting at about 47% horizontally and vertically centred against the photo. The footer has a page number at bottom-left inside the blue band and a copyright line at bottom-left of the content area at about 5.6% from the left; the Moderna logo sits bottom-right at about 87% from the left.

**Visuals**

Photograph: a smiling middle-aged man with short greying dark hair, seen from the chest up, turned slightly to his left (viewer's left) with his head tilted, mouth open in a laugh. He wears a brown wool jacket with a blue-grey windowpane check and an open-collared white shirt. The background is a pale light-blue plain wall, softly lit. Lighting is soft and even from the front, with no hard shadows. Composition is a portrait crop: head and shoulders fill the frame, cropped at the bottom edge of the jacket and at the sides of the photo. The photo is a rectangle with very slightly rounded corners, not full-bleed, boxed within a light grey (#EDEDED) backing rectangle, with no overlay or tint. Logo: the Moderna wordmark in lowercase red letters (#E31837) with a row of short cyan (#2AACE2) dashes beneath it, bottom-right. No charts, tables or diagrams.

**Design**

Background: Solid white #FFFFFF. White background (#FFFFFF). A full-height vertical sky-blue band (#2AACE2) on the left edge, about 2.7% of slide width, carrying rotated white bold text 'Business Review' and rotated light pale-blue text '3Q 2026 Update |'. Title in Segoe UI Bold, red #E31837, single line, about 5.2% of slide height, sentence case, no letter-spacing change. Body text in Segoe UI Light, black #000000, about 3.3% of slide height, line spacing about 4% of slide height between lines and a larger gap between the two bullets. Bullet markers are red #E31837 round dots (Wingdings). Footer copyright in Century Gothic regular grey #898989 about 1.5% of height; page number in Century Gothic Bold white about 1.8% of height on the blue band. Outline frame is a thin light-grey (#D0D0D0-like) 1 px line with square corners and no fill, no shadow. Photo corners are very slightly rounded. No gradients or shadows.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: Full-slide background fill (Covers the whole slide, no outline.)
- shape at x 0, y 0, w 2.7, h 100 [#2AACE2]: Vertical left band (Solid fill, no outline, square corners, full slide height.)
- shape at x 14.1, y 17.3, w 72.9, h 69.8: Content frame outline (Rectangle with no fill and a thin light grey (#D0D0D0-like) stroke about 1 px, square corners, no shadow.)
- shape at x 17.8, y 24.3, w 25.2, h 56.1 [#EDEDED]: Photo backing rectangle (Solid light grey fill sitting directly behind the photo, fully covered by it.)
- photo at x 17.8, y 24.3, w 25.2, h 56.1: Smiling man in brown checked blazer and open white shirt against pale blue wall, head and shoulders portrait (Placed image 502 by 628 px, portrait crop, very slightly rounded corners, not full-bleed, no overlay or tint.)
- title at x 5.1, y 5.5, w 80.9, h 5.2 [Segoe UI Bold, regular capitalisation, no letter-spacing; font size 5.18% of slide height; #E31837; left aligned]: Moderna welcomes Juan Andres as Chief Operating Officer
- footer at x 0.5, y 2.4, w 1.7, h 21.7 [Segoe UI Semibold, rotated 90 degrees reading upward; font size 2.96% of slide height; #FFFFFF; left aligned]: Business Review (Vertical rotated text inside the blue band.)
- footer at x 0.5, y 24.1, w 1.7, h 22.9 [Segoe UI Light, rotated 90 degrees reading upward; font size 2.96% of slide height; #BFE6F6; left aligned]: 3Q 2026 Update | (Vertical rotated text inside the blue band, directly below Business Review.)
- shape at x 45.7, y 33.4, w 0.9, h 3.3 [Wingdings; font size 3.33% of slide height; #E31837; left aligned]: Bullet marker 1 (Round red dot bullet glyph aligned to first line of bullet 1.)
- body at x 47.2, y 33.4, w 36.8, h 15.3 [Segoe UI Light, regular weight, not italic, no capitals, no letter-spacing; font size 3.33% of slide height; #000000; left aligned]: As Chief Operating Officer, Juan leads / Moderna’s operational strategy and execution, / including oversight of the Company’s global / manufacturing organization (Line spacing about 4% of slide height; first bullet paragraph.)
- shape at x 45.7, y 54.1, w 0.9, h 3.3 [Wingdings; font size 3.33% of slide height; #E31837; left aligned]: Bullet marker 2 (Round red dot bullet glyph aligned to first line of bullet 2.)
- body at x 47.2, y 54.1, w 36.8, h 19.3 [Segoe UI Light, regular weight, not italic, no capitals, no letter-spacing; font size 3.33% of slide height; #000000; left aligned]: Returns to Moderna after six years leading the / build-out and rapid scale-up of Moderna’s / global manufacturing network / to support COVID-19 vaccine production / and intismeran autogene manufacturing (Line spacing about 4% of slide height; second bullet paragraph.)
- footer at x 1.1, y 95.5, w 0.6, h 1.8 [Century Gothic Bold; font size 1.84% of slide height; #FFFFFF; left aligned]: 6 (Page number on the blue band.)
- footer at x 5.6, y 95.7, w 16.1, h 1.5 [Century Gothic regular, no capitals, no letter-spacing; font size 1.49% of slide height; #898989; left aligned]: © 2026 Moderna, Inc. All rights reserved.
- logo at x 86.6, y 92.2, w 12.2, h 4.9 [#E31837]: Moderna wordmark logo with cyan dashed underline (Lowercase red wordmark 'moderna' with a row of short cyan (#2AACE2) dashes beneath, bottom-right corner, 359 by 81 px image.)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 2.7, h 100.0: #2AACE2
- fill at x 17.8, y 24.3, w 25.2, h 56.1: #EDEDED
- image at x 17.8, y 24.3, w 25.2, h 56.1: 502 by 628 pixels
- image at x 86.6, y 92.2, w 12.2, h 4.9: 359 by 81 pixels
- text at x 5.1, y 5.5, w 80.9, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: Moderna welcomes Juan Andres as Chief Operating Officer
- text at x 0.5, y 2.4, w 1.7, h 21.7 [SegoeUI-Semibold; font size 2.96; #FFFFFF]: Business Review
- text at x 45.7, y 33.4, w 0.9, h 3.3 [Wingdings-Regular; font size 3.33; #E31837]: 
- text at x 47.2, y 33.4, w 30.0, h 3.3 [SegoeUI-Light; font size 3.33; #000000]: As Chief Operating Officer, Juan leads
- text at x 47.2, y 37.4, w 36.8, h 3.3 [SegoeUI-Light; font size 3.33; #000000]: Moderna’s operational strategy and execution,
- text at x 0.5, y 24.1, w 1.7, h 22.9 [SegoeUI-Light; font size 2.96; #BFE6F6]: 3Q 2026 Update |
- text at x 47.2, y 41.4, w 34.8, h 3.3 [SegoeUI-Light; font size 3.33; #000000]: including oversight of the Company’s global
- text at x 47.2, y 45.4, w 21.7, h 3.3 [SegoeUI-Light; font size 3.34; #000000]: manufacturing organization
- text at x 45.7, y 54.1, w 0.9, h 3.3 [Wingdings-Regular; font size 3.33; #E31837]: 
- text at x 47.2, y 54.1, w 36.7, h 3.3 [SegoeUI-Light; font size 3.33; #000000]: Returns to Moderna after six years leading the
- text at x 47.2, y 58.1, w 33.6, h 3.3 [SegoeUI-Light; font size 3.33; #000000]: build-out and rapid scale-up of Moderna’s
- text at x 47.2, y 62.1, w 24.1, h 3.3 [SegoeUI-Light; font size 3.33; #000000]: global manufacturing network
- text at x 47.2, y 66.1, w 32.4, h 3.3 [SegoeUI-Light; font size 3.34; #000000]: to support COVID-19 vaccine production
- text at x 47.2, y 70.1, w 31.5, h 3.3 [SegoeUI-Light; font size 3.33; #000000]: and intismeran autogene manufacturing
- text at x 1.1, y 95.5, w 0.6, h 1.8 [CenturyGothic-Bold; font size 1.84; #FFFFFF]: 6
- text at x 5.6, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #898989]: © 2026 Moderna, Inc. All rights reserved.

### Slide 7

**Text**

3Q26 earnings call agenda
Business Review
Stéphane Bancel, CEO
Financials
Jamey Mock, CFO
Business updates
Stephen Hoge, M.D., President
Pipeline updates
David Berman, M.D., Ph.D., Chief Development Officer
Looking Ahead
Stéphane Bancel, CEO
© 2026 Moderna, Inc. All rights reserved.

**Layout**

A full-height blue sidebar occupies the left 19.4% of the slide and carries only the copyright footer at its bottom. The content column starts at about x 21.6% and holds the title at top left, followed by five agenda rows stacked vertically at roughly 15% intervals, each an icon at x 23.2% followed by a bold heading and a light light-weight name line at x 31%. The Financials row is enclosed in a red rounded outline. The Moderna logo sits bottom right, with no slide number visible.

**Visuals**

Six line icons in a column at x 23.2%, each about 4.8% wide by 8.6% high, inside outlined circles. 1) Business Review (y 16.7%): grey circle outline with a grey wave or curve glyph with tick marks. 2) Financials (y 32.4%): red #E21D39 circle outline containing a blue and red presentation board with a bar chart (two red bars, two blue bars) and a blue pie chart. 3) Business updates (y 48.4%): grey circle outline with three diagonal grey test tubes in a rack. 4) Pipeline updates (y 63.8%): grey circle outline with a grey microscope beside grey hexagon molecule shapes. 5) Looking Ahead (y 79.5%): grey circle outline with two rows of grey rounded rectangles each ending in a grey arrow. One rounded red outline rectangle surrounds the Financials row, spanning about x 21.0% to 78.5% and y 30.0% to 44.0%. One Moderna logo: red #E21D39 lowercase wordmark 'moderna' with a dashed cyan underline, about 12.2% wide, bottom right.

**Design**

Background: Solid #FFFFFF white with a #2AACE2 blue band from left edge to x 19.4%. White #FFFFFF background with a solid #2AACE2 sky-blue sidebar on the left. The slide title is bold red #E31837. Agenda headings are bold dark navy #1E2846, except the highlighted Financials heading which is #2AACE2. Names and roles are light-weight black #000000. Typefaces are Segoe UI Bold for headings and title and Segoe UI Light for names; the footer is Century Gothic in white. Title is about 5.2% of slide height, headings about 3.7%, names about 3.0%, footer about 1.5%. The highlight is a rounded rectangle with a red #E21D39 stroke of roughly 0.4% width, no fill and corner radius of about 1% of slide height. Icons use thin grey #C0C0C0 strokes. No shadows or gradients.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 19.4, h 100 [#2AACE2]: Blue sidebar, full height, left edge (Solid fill, no stroke, no shadow.)
- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: Background white panel covering the slide (Solid fill, no stroke.)
- shape at x 21, y 30, w 57.5, h 14 [#E21D39]: Rounded rectangle highlighting the Financials row (No fill, red #E21D39 stroke about 0.4% of slide height, corner radius about 1% of slide height, no shadow; encloses the Financials icon and text.)
- icon at x 23.2, y 16.7, w 4.8, h 8.6 [#C0C0C0]: Business Review icon: grey wave or curve glyph inside a grey circle outline (Circle outline stroke grey #C0C0C0, about 0.3% width; no fill.)
- icon at x 23.2, y 32.4, w 4.8, h 8.6 [#E21D39]: Financials icon: blue and red presentation board with bar chart and pie chart inside a red circle (Circle outline red #E21D39; glyph uses blue #2AACE2 and red #E21D39 strokes.)
- icon at x 23.2, y 48.4, w 4.8, h 8.6 [#C0C0C0]: Business updates icon: three diagonal grey test tubes in a rack inside a grey circle (Circle outline and glyph grey #C0C0C0.)
- icon at x 23.2, y 63.8, w 4.8, h 8.6 [#C0C0C0]: Pipeline updates icon: grey microscope beside hexagon molecules inside a grey circle (Circle outline and glyph grey #C0C0C0.)
- icon at x 23.2, y 79.5, w 4.8, h 8.6 [#C0C0C0]: Looking Ahead icon: two rows of grey rounded rectangles ending in arrows inside a grey circle (Circle outline and glyph grey #C0C0C0.)
- title at x 21.6, y 4.6, w 36.2, h 5.2 [Segoe UI, bold; font size 5.18% of slide height; #E31837; left aligned]: 3Q26 earnings call agenda
- body at x 31, y 17.5, w 15.8, h 3.7 [Segoe UI, bold; font size 3.71% of slide height; #1E2846; left aligned]: Business Review
- body at x 31, y 22.7, w 16, h 3 [Segoe UI, light; font size 2.96% of slide height; #000000; left aligned]: Stéphane Bancel, CEO
- body at x 31, y 33.3, w 9.5, h 3.7 [Segoe UI, bold; font size 3.71% of slide height; #2AACE2; left aligned]: Financials
- body at x 31, y 38.5, w 12.5, h 3 [Segoe UI, light; font size 2.96% of slide height; #000000; left aligned]: Jamey Mock, CFO
- body at x 31, y 48.9, w 16.7, h 3.7 [Segoe UI, bold; font size 3.71% of slide height; #1E2846; left aligned]: Business updates
- body at x 31, y 54.1, w 21.2, h 3 [Segoe UI, light; font size 2.96% of slide height; #000000; left aligned]: Stephen Hoge, M.D., President
- body at x 31, y 64.2, w 16.2, h 3.7 [Segoe UI, bold; font size 3.71% of slide height; #1E2846; left aligned]: Pipeline updates
- body at x 31, y 69.4, w 37.4, h 3 [Segoe UI, light; font size 2.96% of slide height; #000000; left aligned]: David Berman, M.D., Ph.D., Chief Development Officer
- body at x 31.3, y 79.9, w 14.8, h 3.7 [Segoe UI, bold; font size 3.72% of slide height; #1E2846; left aligned]: Looking Ahead
- body at x 31.3, y 85.1, w 15.5, h 3 [Segoe UI, light; font size 2.96% of slide height; #000000; left aligned]: Stéphane Bancel, CEO
- footer at x 2, y 95.7, w 16.1, h 1.5 [Century Gothic, regular; font size 1.49% of slide height; #FFFFFF; left aligned]: © 2026 Moderna, Inc. All rights reserved. (Sits on the blue sidebar.)
- logo at x 86.6, y 92.2, w 12.2, h 4.9 [#E21D39]: Moderna logo: red wordmark 'moderna' with dashed cyan underline (Image 359 by 81 pixels, bottom right corner.)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 19.4, h 100.0: #2AACE2
- fill at x 23.2, y 16.7, w 4.8, h 8.6: #C0C0C0
- fill at x 23.2, y 16.7, w 4.8, h 8.6: #C0C0C0
- fill at x 23.2, y 32.4, w 4.8, h 8.6: #E21D39
- fill at x 23.2, y 79.5, w 4.8, h 8.6: #C0C0C0
- fill at x 23.2, y 63.8, w 4.8, h 8.6: #C0C0C0
- fill at x 23.2, y 48.4, w 4.8, h 8.6: #C0C0C0
- image at x 86.6, y 92.2, w 12.2, h 4.9: 359 by 81 pixels
- text at x 21.6, y 4.6, w 36.2, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: 3Q26 earnings call agenda
- text at x 31.0, y 17.5, w 15.8, h 3.7 [SegoeUI-Bold; font size 3.71; #1E2846]: Business Review
- text at x 31.0, y 22.7, w 16.0, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: Stéphane Bancel, CEO
- text at x 31.0, y 33.3, w 9.5, h 3.7 [SegoeUI-Bold; font size 3.71; #2AACE2]: Financials
- text at x 31.0, y 38.5, w 12.5, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: Jamey Mock, CFO
- text at x 31.0, y 48.9, w 16.7, h 3.7 [SegoeUI-Bold; font size 3.71; #1E2846]: Business updates
- text at x 31.0, y 64.2, w 16.2, h 3.7 [SegoeUI-Bold; font size 3.71; #1E2846]: Pipeline updates
- text at x 31.0, y 54.1, w 21.2, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: Stephen Hoge, M.D., President
- text at x 31.3, y 79.9, w 14.8, h 3.7 [SegoeUI-Bold; font size 3.72; #1E2846]: Looking Ahead
- text at x 31.0, y 69.4, w 37.4, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: David Berman, M.D., Ph.D., Chief Development Officer
- text at x 31.3, y 85.1, w 15.5, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: Stéphane Bancel, CEO
- text at x 2.0, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #FFFFFF]: © 2026 Moderna, Inc. All rights reserved.

### Slide 8

**Review notes**

- Worth studying: A stacked bar chart of revenue by quarter with one short takeaway column beside it makes the key number readable at a glance.
- Review: The detailed slides are well made: slide 8 has a clean stacked chart with a takeaway title and three short bullets, and slide 14 has a clear paired-bar chart with a highlighted +3% total.
- Review: Slide 8 also reads oddly because the 3Q26 bar floats in a waterfall-like layout with no visible connection to the YTD bar.
- Worth keeping: Keep the section-tag system, the highlighted agenda dividers, and the takeaway headlines with chart plus short commentary as on slides 8 and 14.

**Text**

3Q26 revenue of $1.3B, 1Q-3Q total of $1.8B
Revenue through 3Q26
$1.3B
$1.8B
$0.5B
International
U.S.
0.5
0.8
0.4
0.9
0.9
0.2
1H26
3Q26
YTD
Strength in 3Q driven by increased
demand, operational execution, and
timing of shipments between 3Q and 4Q
Increased 2026 revenue outlook to
15-25% growth, exceeding prior
expectation of up to 10% growth
Continue to expect approximately even
split between U.S. and International
revenue for 2026
Values rounded to nearest $0.1B; totals may differ due to rounding
8
© 2026 Moderna, Inc. All rights reserved.
Financial Review
3Q 2026 Update |

**Layout**

Full-bleed white slide divided into a narrow vertical blue sidebar on the left edge carrying rotated section labels, and a main area with a red title across the top. Below the title, a stacked-column chart sits in the left half (about x 7 to 55) and a vertical thin grey divider at x 57.8 separates it from a three-bullet text column on the right (starting x 61.7). The footnote is centred under the chart, the page number and copyright sit in the bottom-left margin, and the moderna logo is bottom-right. Title is left-aligned at x 5.3 with its top at y 5.3; the chart title is centred over the chart at about x 20.8 to 41.1; the bullet column is left-aligned with bullets hanging at x 61.7.

**Visuals**

One chart, a stacked column chart reproduced as a picture, titled 'Revenue through 3Q26' (bold black, centred above the chart at y 22.6). Three columns on a shared baseline with no y-axis, no gridlines and no numeric axis labels; category labels beneath the baseline read '1H26', '3Q26' and 'YTD' in large light sans-serif. Series: International (navy #1F2A44 segments, labels in white) and U.S. (light blue #2AACE2 segments, labels in white). Values printed in segments: 1H26 International 0.4, U.S. 0.2, total $0.5B; 3Q26 International 0.5, U.S. 0.8, total $1.3B; YTD International 0.9, U.S. 0.9, total $1.8B. Totals are printed above each column in bold red #E31837 (about 3.3% of slide height). Legend at top-left of the chart: a navy square labelled 'International' and a light-blue square labelled 'U.S.'. Thin grey connector lines (#A6A6A6, about 0.1% of slide height) run horizontally from the top of the 1H26 column at the $0.5B level to the 3Q26 column, and from the top of the 3Q26 column at $1.3B to the top of the YTD column. Small grey tick marks sit on the baseline between columns. No value is highlighted beyond the red totals. The moderna logo is a red (#E31837) wordmark with a row of short light-blue (#2AACE2) dashes beneath it, placed bottom-right, unboxed.

**Design**

Background: Solid white #FFFFFF, with a full-slide background image layer of plain white. White background. Titles and accent in Moderna red #E31837. Body text is black #000000 in Segoe UI Light, about 3.3% of slide height, with red #E31837 bullets (CenturyGothic). Title is Segoe UI Bold, about 5.2% of slide height, red. Chart title is Segoe UI Bold black. Left sidebar is a solid blue #2AACE2 strip with white rotated 'Financial Review' in Segoe UI Semibold and pale blue #BFE6F6 rotated '3Q 2026 Update |' in Segoe UI Light. Footnote in Segoe UI, grey #A6A6A6, about 1.8% of slide height. Copyright in Century Gothic grey #898989, about 1.5%. Page number Century Gothic Bold white on the blue sidebar. Shapes are flat with no shadows, gradients or rounded corners. The divider is a thin grey vertical line.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- photo at x 0, y 0, w 100, h 100: Full-slide background image layer, plain white, covering the whole slide (2000 by 1125 px), full-bleed, no visible content (Opaque white, sits at back)
- shape at x 0, y 0, w 2.7, h 100 [#2AACE2]: Left vertical sidebar strip (Solid fill, no outline, full slide height)
- shape at x 94.2, y 0, w 5.8, h 48.8 [#FFFFFF]: Top-right white rectangle masking area (Solid white fill, no outline)
- line at x 57.7, y 22.9, w 0.1, h 57.5 [#A6A6A6]: Vertical thin divider between chart and bullet column (Stroke grey about 1px, no arrowheads)
- title at x 20.8, y 22.6, w 20.3, h 3.3 [Segoe UI Bold, sans-serif, normal italics, no capitals; font size 3.33% of slide height; #000000; center aligned]: Revenue through 3Q26
- chart at x 7.4, y 31.8, w 47.2, h 47 [#2AACE2]: Stacked column chart 'Revenue through 3Q26' with columns 1H26 ($0.5B: International 0.4, U.S. 0.2), 3Q26 ($1.3B: International 0.5, U.S. 0.8), YTD ($1.8B: International 0.9, U.S. 0.9); legend International (navy) and U.S. (light blue); connector lines at $0.5B and $1.3B levels (Placed picture 1258 by 705 px, no crop, no border, no overlay. Navy #1F2A44 International segments and light blue #2AACE2 U.S. segments; bar totals in red #E31837 above bars; white segment labels; category labels in large light sans-serif below baseline; grey baseline and connector lines)
- caption at x 15.9, y 81.5, w 30.7, h 1.8 [Segoe UI, sans-serif, regular, no italics, no capitals; font size 1.84% of slide height; #A6A6A6; center aligned]: Values rounded to nearest $0.1B; totals may differ due to rounding
- bullet list at x 61.7, y 28.9, w 32, h 45.3 [Segoe UI Light, sans-serif, normal weight, no italics, no capitals; font size 3.33% of slide height; #000000; left aligned]: Strength in 3Q driven by increased / demand, operational execution, and / timing of shipments between 3Q and 4Q / Increased 2026 revenue outlook to / 15-25% growth, exceeding prior / expectation of up to 10% growth / Continue to expect approximately even / split between U.S. and International / revenue for 2026 (Three bullets separated by blank lines; bullet glyph is a filled red #E31837 dot (CenturyGothic) at x 61.7 hanging; line spacing about 4.0% of slide height between wrapped lines; paragraph gap about 6.6%)
- title at x 5.3, y 5.3, w 61.2, h 5.2 [Segoe UI Bold, sans-serif, normal italics, no capitals; font size 5.18% of slide height; #E31837; left aligned]: 3Q26 revenue of $1.3B, 1Q-3Q total of $1.8B
- body at x 0.5, y 2.4, w 1.7, h 22 [Segoe UI Semibold, sans-serif, normal, no italics, no capitals; font size 2.96% of slide height; #FFFFFF; left aligned]: Financial Review (Rotated 270 degrees, reads bottom to top, on the blue sidebar)
- body at x 0.5, y 24.4, w 1.7, h 22.9 [Segoe UI Light, sans-serif, normal, no italics, no capitals; font size 2.96% of slide height; #BFE6F6; left aligned]: 3Q 2026 Update | (Rotated 270 degrees, reads bottom to top, on the blue sidebar, directly below Financial Review)
- logo at x 86.6, y 92.2, w 12.2, h 4.9 [#E31837]: moderna logo: red wordmark with a row of short light-blue dashes underneath (Placed picture 359 by 81 px, unboxed, bottom-right corner)
- footer at x 5.6, y 95.7, w 16.1, h 1.5 [Century Gothic, sans-serif, regular, no italics, no capitals; font size 1.49% of slide height; #898989; left aligned]: © 2026 Moderna, Inc. All rights reserved.
- page number at x 1.1, y 95.5, w 0.6, h 2 [Century Gothic, sans-serif, bold, no italics, no capitals; font size 1.96% of slide height; #FFFFFF; left aligned]: 8 (Sits on the blue sidebar)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 2.7, h 100.0: #2AACE2
- fill at x 0.0, y 0.0, w 2.7, h 100.0: #2AACE2
- fill at x 94.2, y 0.0, w 5.8, h 48.8: #FFFFFF
- image at x 0.0, y 0.0, w 100.0, h 100.0: 2000 by 1125 pixels (covers the slide)
- image at x 7.4, y 31.8, w 47.2, h 47.0: 1258 by 705 pixels
- image at x 86.6, y 92.2, w 12.2, h 4.9: 359 by 81 pixels
- text at x 5.3, y 5.3, w 61.2, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: 3Q26 revenue of $1.3B, 1Q-3Q total of $1.8B
- text at x 0.5, y 2.4, w 1.7, h 22.0 [SegoeUI-Semibold; font size 2.96; #FFFFFF]: Financial Review
- text at x 20.8, y 22.6, w 20.3, h 3.3 [SegoeUI-Bold; font size 3.33; #000000]: Revenue through 3Q26
- text at x 61.7, y 28.9, w 1.1, h 3.3 [CenturyGothic; font size 3.33; #E31837]: •
- text at x 63.6, y 28.9, w 27.7, h 3.3 [SegoeUI-Light; font size 3.33; #000000]: Strength in 3Q driven by increased
- text at x 63.6, y 32.9, w 28.8, h 3.3 [SegoeUI-Light; font size 3.33; #000000]: demand, operational execution, and
- text at x 63.6, y 36.9, w 32.0, h 3.3 [SegoeUI-Light; font size 3.33; #000000]: timing of shipments between 3Q and 4Q
- text at x 0.5, y 24.4, w 1.7, h 22.9 [SegoeUI-Light; font size 2.96; #BFE6F6]: 3Q 2026 Update |
- text at x 61.7, y 47.5, w 1.1, h 3.3 [CenturyGothic; font size 3.33; #E31837]: •
- text at x 63.6, y 47.5, w 27.7, h 3.3 [SegoeUI-Light; font size 3.33; #000000]: Increased 2026 revenue outlook to
- text at x 63.6, y 51.5, w 25.5, h 3.3 [SegoeUI-Light; font size 3.33; #000000]: 15-25% growth, exceeding prior
- text at x 63.6, y 55.5, w 25.4, h 3.3 [SegoeUI-Light; font size 3.33; #000000]: expectation of up to 10% growth
- text at x 61.7, y 66.2, w 1.1, h 3.3 [CenturyGothic; font size 3.33; #E31837]: •
- text at x 63.6, y 66.2, w 31.2, h 3.3 [SegoeUI-Light; font size 3.33; #000000]: Continue to expect approximately even
- text at x 63.6, y 70.2, w 28.1, h 3.3 [SegoeUI-Light; font size 3.33; #000000]: split between U.S. and International
- text at x 63.6, y 74.2, w 13.4, h 3.3 [SegoeUI-Light; font size 3.33; #000000]: revenue for 2026
- text at x 15.9, y 81.5, w 30.7, h 1.8 [SegoeUI; font size 1.84; #A6A6A6]: Values rounded to nearest $0.1B; totals may differ due to rounding
- text at x 1.1, y 95.5, w 0.6, h 2.0 [CenturyGothic-Bold; font size 1.96; #FFFFFF]: 8
- text at x 5.6, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #898989]: © 2026 Moderna, Inc. All rights reserved.

### Slide 9

**Review notes**

- Review: Many slides carry tiny type that cannot be read at presentation size, including the disclaimer on slide 2, the results table on slide 9, the survival curves and AE chart on slides 18 to 21, and the appendix on slides 30 to 32.
- Suggested repair: Enlarge or crop the unreadable tables and charts on slides 9, 19 to 21 and 30 to 32, and fill or merge the near-empty slides such as 23 and 32.

**Text**

3Q 2026 financial results
Financial Review
3Q 2026 Update |
In $ millions, except per share amounts
3Q 2026
3Q 2025
Change
(3Q'26 vs. 3Q'25)
Net product sales / $ 1,273 / $ 973 / $ 300 / 31 % / Other revenue1 / 40 / 43 / (3) / (7) % / Total revenue / 1,313 / 1,016 / 297 / 29 % / Cost of sales / 318 / 207 / 111 / 54 % / Research and development / 583 / 801 / (218) / (27) % / Selling, general and administrative / 282 / 268 / 14 / 5 % / Total operating expenses / 1,183 / 1,276 / (93) / (7)% / Income (loss) from operations / 130 / (260) / 390 / 150 % / Other income, net / 41 / 73 / (32) / (44) % / Provision for income taxes / 9 / 13 / (4) / (31) % / Net income (loss) / $ 162 / $ (200) / $ 362 / 181 % / Earnings (loss) per share – Diluted / $ 0.38 / $ (0.51) / $ 0.89 / 175 % / Weighted average shares – Diluted2 / 430 / 390 / 40 / 10 % / Weighted average shares – Basic2 / 401 / 390 / 11 / 3 % / Effective tax rate / 5 % / (7)%
1Includes grant, collaboration, licensing and royalty, and stand-ready manufacturing revenue
2We generated a net loss in the prior period presented, therefore the basic and diluted calculation was the same in 3Q 2025
In $ billions
9/30/2026
6/30/2026
Change
(9/30 vs. 6/30)
Cash, cash equivalents and investments / $ 8.0 / $ 6.9 / $ 1.1 / 16 %
© 2026 Moderna, Inc. All rights reserved.
9

**Layout**

Two-part layout on a white slide: a full-height vertical blue sidebar runs down the left edge (about 2.7% of the width) carrying the rotated section label and the page number at the bottom. The title sits top-left at about x 5.2%, y 4.3%, left-aligned, above a single financial table occupying the centre-left from x 5.5% to 87.2%, with the table's header row starting at y 14.5% and the bottom cash table beginning at y 79.4%. Two footnotes sit under the main table at x 6.1%. The copyright line sits bottom-left beside the sidebar at y 95.7%, and the moderna logo sits bottom-right at x 86.6%, y 92.2%. Table text is left-aligned for labels and right-aligned for figures; the Change column is wide and right-aligned.

**Visuals**

One table, no chart or photograph. Main table columns: row label; 3Q 2026; 3Q 2025; Change (3Q'26 vs. 3Q'25) in dollars; Change in percent. Rows in order: Net product sales $1,273 / $973 / $300 / 31 %; Other revenue1 40 / 43 / (3) / (7) %; Total revenue 1,313 / 1,016 / 297 / 29 %, shaded row; Cost of sales 318 / 207 / 111 / 54 %; Research and development 583 / 801 / (218) / (27) %; Selling, general and administrative 282 / 268 / 14 / 5 %; Total operating expenses 1,183 / 1,276 / (93) / (7)%, shaded row; blank spacer row; Income (loss) from operations 130 / (260) / 390 / 150 %, shaded row; Other income, net 41 / 73 / (32) / (44) %; Provision for income taxes 9 / 13 / (4) / (31) %; Net income (loss) $162 / $(200) / $362 / 181 %, shaded row; Earnings (loss) per share – Diluted $0.38 / $(0.51) / $0.89 / 175 %; Weighted average shares – Diluted2 430 / 390 / 40 / 10 %; Weighted average shares – Basic2 401 / 390 / 11 / 3 %; Effective tax rate 5 % / (7)% with no change entries. Shaded rows (light grey #F2F2F2 bands) are Total revenue, Total operating expenses, Income (loss) from operations and Net income (loss). Second table: header cells 9/30/2026, 6/30/2026 and Change (9/30 vs. 6/30) in dark blue; one data row Cash, cash equivalents and investments $8.0 / $6.9 / $1.1 / 16 %. No chart, legend or highlighted points. Logo: moderna wordmark in red with a row of short cyan dashes beneath it.

**Design**

Background: Solid white #FFFFFF. White background. Title in bold red #E31837 sans-serif (Segoe UI Bold), about 5.2% of slide height. Table header cells filled dark blue #114E82 with white bold Century Gothic text. Body text black #000000 in Century Gothic regular, about 2.0% of slide height; totals and labels in bold. Accent colours: sky blue sidebar #2AACE2 with white Segoe UI Semibold section name and pale blue #BFE6F6 Segoe UI Light '3Q 2026 Update |'. Footnote text about 1.7% of slide height. Copyright in grey #898989. Shaded table rows #F2F2F2 with no borders, square corners, no shadows or gradients.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: Full-slide background image, white (no visible content beyond the slide background)
- shape at x 0, y 0, w 2.7, h 100 [#2AACE2]: Left vertical sidebar, solid bar (Full height, square corners, no shadow)
- shape at x 94.2, y 0, w 5.8, h 48.8 [#FFFFFF]: Top-right white rectangle masking area (Plain white fill, no border)
- shape at x 46, y 14.5, w 9.9, h 5.6 [#114E82]: Table header cell fill 3Q 2026 (Square corners, no border)
- shape at x 56.8, y 14.5, w 9.9, h 5.6 [#114E82]: Table header cell fill 3Q 2025 (Square corners, no border)
- shape at x 67.6, y 14.5, w 19.6, h 5.6 [#114E82]: Table header cell fill Change (3Q'26 vs. 3Q'25) (Square corners, no border)
- shape at x 5.5, y 26.5, w 39.7, h 3.2 [#F2F2F2]: Shaded row band Total revenue (Behind row label and figures, no border)
- shape at x 5.5, y 39.2, w 39.7, h 3.2 [#F2F2F2]: Shaded row band Total operating expenses (Behind row label and figures, no border)
- shape at x 5.5, y 45.6, w 39.7, h 3.2 [#F2F2F2]: Shaded row band Income (loss) from operations (Behind row label and figures, no border)
- shape at x 5.5, y 55.2, w 39.7, h 3.2 [#F2F2F2]: Shaded row band Net income (loss) (Behind row label and figures, no border)
- shape at x 45.9, y 79.4, w 9.9, h 5 [#114E82]: Bottom table header cell fill 9/30/2026 (Square corners, no border)
- shape at x 56.5, y 79.4, w 9.9, h 5 [#114E82]: Bottom table header cell fill 6/30/2026 (Square corners, no border)
- shape at x 67.2, y 79.4, w 19.9, h 5 [#114E82]: Bottom table header cell fill Change (9/30 vs. 6/30) (Square corners, no border)
- title at x 5.2, y 4.3, w 33.7, h 5.2 [Segoe UI Bold, sans-serif, normal weight, no italics, no capitals, normal letter-spacing; font size 5.18% of slide height; #E31837; left aligned]: 3Q 2026 financial results
- text at x 0.5, y 2.4, w 1.7, h 22 [Segoe UI Semibold, sans-serif, rotated 90 degrees reading upward, no italics; font size 2.96% of slide height; #FFFFFF; left aligned]: Financial Review (Vertical text on the sidebar)
- text at x 0.5, y 24.4, w 1.7, h 22.9 [Segoe UI Light, sans-serif, rotated 90 degrees reading upward; font size 2.96% of slide height; #BFE6F6; left aligned]: 3Q 2026 Update | (Vertical text on the sidebar, below Financial Review)
- text at x 1.1, y 95.5, w 0.6, h 2 [Century Gothic Bold, sans-serif, normal weight; font size 1.96% of slide height; #FFFFFF; center aligned]: 1 (Page number on the sidebar)
- text at x 5.7, y 16.4, w 21.4, h 2 [Century Gothic Italic, sans-serif, italic, no capitals; font size 2.04% of slide height; #000000; left aligned]: In $ millions, except per share amounts
- text at x 48.7, y 16.4, w 4.5, h 2 [Century Gothic Bold, sans-serif, normal weight; font size 2.04% of slide height; #FFFFFF; center aligned]: 3Q 2026
- text at x 59.5, y 16.4, w 4.5, h 2 [Century Gothic Bold, sans-serif, normal weight; font size 2.04% of slide height; #FFFFFF; center aligned]: 3Q 2025
- text at x 72.8, y 15.2, w 9.3, h 4 [Century Gothic Bold, sans-serif, normal weight; font size 2.04% of slide height; #FFFFFF; center aligned]: Change / (3Q'26 vs. 3Q'25)
- table at x 5.5, y 20.5, w 82, h 51 [Century Gothic, sans-serif, regular weight; labels bold for Total revenue, Total operating expenses, Income (loss) from operations, Net income (loss); figures right-aligned; font size 2.04% of slide height; #000000; left aligned]: Net product sales | $ 1,273 | $ 973 | $ 300 | 31 % / Other revenue1 | 40 | 43 | (3) | (7) % / Total revenue | 1,313 | 1,016 | 297 | 29 % / Cost of sales | 318 | 207 | 111 | 54 % / Research and development | 583 | 801 | (218) | (27) % / Selling, general and administrative | 282 | 268 | 14 | 5 % / Total operating expenses | 1,183 | 1,276 | (93) | (7)% / Income (loss) from operations | 130 | (260) | 390 | 150 % / Other income, net | 41 | 73 | (32) | (44) % / Provision for income taxes | 9 | 13 | (4) | (31) % / Net income (loss) | $ 162 | $ (200) | $ 362 | 181 % / Earnings (loss) per share – Diluted | $ 0.38 | $ (0.51) | $ 0.89 | 175 % / Weighted average shares – Diluted2 | 430 | 390 | 40 | 10 % / Weighted average shares – Basic2 | 401 | 390 | 11 | 3 % / Effective tax rate | 5 % | (7)% (Row labels left-aligned, numeric columns right-aligned; line spacing about 3.2% of slide height between rows; no visible gridlines; shaded rows #F2F2F2 behind Total revenue, Total operating expenses, Income (loss) from operations and Net income (loss); blank spacer row between Total operating expenses and Income (loss) from operations)
- text at x 6.1, y 73, w 42.1, h 1.7 [Century Gothic, sans-serif, regular weight; font size 1.67% of slide height; #000000; left aligned]: 1Includes grant, collaboration, licensing and royalty, and stand-ready manufacturing revenue (Footnote; superscript 1 at x 5.7 y 72.9)
- text at x 6.1, y 75.6, w 55.8, h 1.7 [Century Gothic, sans-serif, regular weight; font size 1.67% of slide height; #000000; left aligned]: 2We generated a net loss in the prior period presented, therefore the basic and diluted calculation was the same in 3Q 2025 (Footnote; superscript 2 at x 5.7 y 75.5)
- text at x 5.7, y 82.1, w 5.9, h 2 [Century Gothic Italic, sans-serif, italic; font size 2.04% of slide height; #000000; left aligned]: In $ billions
- text at x 48.1, y 81.1, w 5.6, h 2 [Century Gothic Bold, sans-serif, normal weight; font size 2.04% of slide height; #FFFFFF; center aligned]: 9/30/2026
- text at x 58.7, y 81.1, w 5.6, h 2 [Century Gothic Bold, sans-serif, normal weight; font size 2.04% of slide height; #FFFFFF; center aligned]: 6/30/2026
- text at x 73.2, y 79.8, w 7.9, h 4 [Century Gothic Bold, sans-serif, normal weight; font size 2.04% of slide height; #FFFFFF; center aligned]: Change / (9/30 vs. 6/30)
- table at x 5.7, y 85.3, w 80, h 2 [Century Gothic, sans-serif, regular weight; label bold; font size 2.04% of slide height; #000000; left aligned]: Cash, cash equivalents and investments | $ 8.0 | $ 6.9 | $ 1.1 | 16 % (Single data row, figures right-aligned, no fill)
- logo at x 86.6, y 92.2, w 12.2, h 4.9 [#E31837]: moderna logo: red lowercase wordmark with a row of short cyan dashes beneath it (Corner logo bottom right, unboxed)
- footer at x 5.6, y 95.7, w 16.1, h 1.5 [Century Gothic, sans-serif, regular weight; font size 1.49% of slide height; #898989; left aligned]: © 2026 Moderna, Inc. All rights reserved.

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 2.7, h 100.0: #2AACE2
- fill at x 0.0, y 0.0, w 2.7, h 100.0: #2AACE2
- fill at x 94.2, y 0.0, w 5.8, h 48.8: #FFFFFF
- fill at x 46.0, y 14.5, w 9.9, h 5.6: #114E82
- fill at x 56.8, y 14.5, w 9.9, h 5.6: #114E82
- fill at x 67.6, y 14.5, w 19.6, h 5.6: #114E82
- fill at x 5.5, y 26.5, w 39.7, h 3.2: #F2F2F2
- fill at x 5.5, y 39.2, w 39.7, h 3.2: #F2F2F2
- fill at x 5.5, y 45.6, w 39.7, h 3.2: #F2F2F2
- fill at x 5.5, y 55.2, w 39.7, h 3.2: #F2F2F2
- fill at x 45.9, y 79.4, w 9.9, h 5.0: #114E82
- fill at x 56.5, y 79.4, w 9.9, h 5.0: #114E82
- fill at x 67.2, y 79.4, w 19.9, h 5.0: #114E82
- image at x 0.0, y 0.0, w 100.0, h 100.0: 2000 by 1125 pixels (covers the slide)
- image at x 86.6, y 92.2, w 12.2, h 4.9: 359 by 81 pixels
- text at x 5.2, y 4.3, w 33.7, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: 3Q 2026 financial results
- text at x 0.5, y 2.4, w 1.7, h 22.0 [SegoeUI-Semibold; font size 2.96; #FFFFFF]: Financial Review
- text at x 75.1, y 15.2, w 4.5, h 2.0 [CenturyGothic-Bold; font size 2.04; #FFFFFF]: Change
- text at x 5.7, y 16.4, w 21.4, h 2.0 [CenturyGothic-Italic; font size 2.04; #000000]: In $ millions, except per share amounts
- text at x 48.7, y 16.4, w 4.5, h 2.0 [CenturyGothic-Bold; font size 2.04; #FFFFFF]: 3Q 2026
- text at x 59.5, y 16.4, w 4.5, h 2.0 [CenturyGothic-Bold; font size 2.04; #FFFFFF]: 3Q 2025
- text at x 72.8, y 17.7, w 9.3, h 2.0 [CenturyGothic-Bold; font size 2.04; #FFFFFF]: (3Q'26 vs. 3Q'25)
- text at x 7.0, y 20.9, w 9.7, h 2.0 [CenturyGothic-Bold; font size 2.04; #000000]: Net product sales
- text at x 46.3, y 20.9, w 0.6, h 2.0 [CenturyGothic-Bold; font size 2.04; #000000]: $
- text at x 51.7, y 20.9, w 2.9, h 2.0 [CenturyGothic-Bold; font size 2.04; #000000]: 1,273
- text at x 57.1, y 20.9, w 0.6, h 2.0 [CenturyGothic-Bold; font size 2.04; #000000]: $
- text at x 63.5, y 20.9, w 1.9, h 2.0 [CenturyGothic-Bold; font size 2.04; #000000]: 973
- text at x 67.9, y 20.9, w 0.6, h 2.0 [CenturyGothic-Bold; font size 2.04; #000000]: $
- text at x 74.5, y 20.9, w 1.9, h 2.0 [CenturyGothic-Bold; font size 2.04; #000000]: 300
- text at x 84.3, y 20.9, w 2.8, h 2.0 [CenturyGothic-Bold; font size 2.04; #000000]: 31 %
- text at x 0.5, y 24.4, w 1.7, h 22.9 [SegoeUI-Light; font size 2.96; #BFE6F6]: 3Q 2026 Update |
- text at x 7.0, y 24.1, w 8.1, h 2.0 [CenturyGothic; font size 2.04; #000000]: Other revenue
- text at x 53.3, y 24.1, w 1.3, h 2.0 [CenturyGothic; font size 2.04; #000000]: 40
- text at x 64.1, y 24.1, w 1.3, h 2.0 [CenturyGothic; font size 2.04; #000000]: 43
- text at x 75.4, y 24.1, w 1.5, h 2.0 [CenturyGothic; font size 2.04; #000000]: (3)
- text at x 84.5, y 24.1, w 2.6, h 2.0 [CenturyGothic; font size 2.04; #000000]: (7) %
- text at x 5.7, y 27.3, w 7.5, h 2.0 [CenturyGothic-Bold; font size 2.05; #000000]: Total revenue
- text at x 51.7, y 27.3, w 2.9, h 2.0 [CenturyGothic-Bold; font size 2.05; #000000]: 1,313
- text at x 62.5, y 27.3, w 2.9, h 2.0 [CenturyGothic-Bold; font size 2.05; #000000]: 1,016
- text at x 74.5, y 27.3, w 1.9, h 2.0 [CenturyGothic-Bold; font size 2.05; #000000]: 297
- text at x 84.3, y 27.3, w 2.8, h 2.0 [CenturyGothic-Bold; font size 2.05; #000000]: 29 %
- text at x 7.0, y 30.5, w 6.9, h 2.0 [CenturyGothic; font size 2.04; #000000]: Cost of sales
- text at x 52.7, y 30.5, w 1.9, h 2.0 [CenturyGothic; font size 2.04; #000000]: 318
- text at x 63.5, y 30.5, w 1.9, h 2.0 [CenturyGothic; font size 2.04; #000000]: 207
- text at x 74.6, y 30.5, w 1.9, h 2.0 [CenturyGothic; font size 2.04; #000000]: 111
- text at x 84.3, y 30.5, w 2.8, h 2.0 [CenturyGothic; font size 2.04; #000000]: 54 %
- text at x 7.0, y 33.7, w 15.7, h 2.0 [CenturyGothic; font size 2.04; #000000]: Research and development
- text at x 52.7, y 33.7, w 1.9, h 2.0 [CenturyGothic; font size 2.04; #000000]: 583
- text at x 63.5, y 33.7, w 1.9, h 2.0 [CenturyGothic; font size 2.04; #000000]: 801
- text at x 74.1, y 33.7, w 2.7, h 2.0 [CenturyGothic; font size 2.04; #000000]: (218)
- text at x 83.9, y 33.7, w 3.2, h 2.0 [CenturyGothic; font size 2.04; #000000]: (27) %
- text at x 15.1, y 24.1, w 0.4, h 1.4 [CenturyGothic; font size 1.36; #000000]: 1
- text at x 7.0, y 36.9, w 19.1, h 2.0 [CenturyGothic; font size 2.04; #000000]: Selling, general and administrative
- text at x 52.7, y 36.9, w 1.9, h 2.0 [CenturyGothic; font size 2.04; #000000]: 282
- text at x 63.5, y 36.9, w 1.9, h 2.0 [CenturyGothic; font size 2.04; #000000]: 268
- text at x 75.2, y 36.9, w 1.3, h 2.0 [CenturyGothic; font size 2.04; #000000]: 14
- text at x 85.0, y 36.9, w 2.2, h 2.0 [CenturyGothic; font size 2.04; #000000]: 5 %
- text at x 5.7, y 40.1, w 13.9, h 2.0 [CenturyGothic-Bold; font size 2.04; #000000]: Total operating expenses
- text at x 51.7, y 40.1, w 2.9, h 2.0 [CenturyGothic-Bold; font size 2.04; #000000]: 1,183
- text at x 62.5, y 40.1, w 2.9, h 2.0 [CenturyGothic-Bold; font size 2.04; #000000]: 1,276
- text at x 74.7, y 40.1, w 2.2, h 2.0 [CenturyGothic-Bold; font size 2.04; #000000]: (93)
- text at x 84.5, y 40.1, w 2.6, h 2.0 [CenturyGothic-Bold; font size 2.04; #000000]: (7)%
- text at x 5.7, y 46.5, w 16.5, h 2.0 [CenturyGothic-Bold; font size 2.04; #000000]: Income (loss) from operations
- text at x 52.7, y 46.5, w 1.9, h 2.0 [CenturyGothic-Bold; font size 2.04; #000000]: 130
- text at x 63.0, y 46.5, w 2.8, h 2.0 [CenturyGothic-Bold; font size 2.04; #000000]: (260)
- text at x 74.5, y 46.5, w 1.9, h 2.0 [CenturyGothic-Bold; font size 2.04; #000000]: 390
- text at x 83.7, y 46.5, w 3.5, h 2.0 [CenturyGothic-Bold; font size 2.04; #000000]: 150 %
- text at x 7.0, y 49.7, w 10.2, h 2.0 [CenturyGothic; font size 2.04; #000000]: Other income, net
- text at x 53.3, y 49.7, w 1.3, h 2.0 [CenturyGothic; font size 2.04; #000000]: 41
- text at x 64.1, y 49.7, w 1.3, h 2.0 [CenturyGothic; font size 2.04; #000000]: 73
- text at x 74.7, y 49.7, w 2.1, h 2.0 [CenturyGothic; font size 2.04; #000000]: (32)
- text at x 83.9, y 49.7, w 3.2, h 2.0 [CenturyGothic; font size 2.04; #000000]: (44) %
- text at x 7.0, y 52.9, w 14.4, h 2.0 [CenturyGothic; font size 2.04; #000000]: Provision for income taxes
- text at x 53.9, y 52.9, w 0.6, h 2.0 [CenturyGothic; font size 2.04; #000000]: 9
- text at x 64.1, y 52.9, w 1.3, h 2.0 [CenturyGothic; font size 2.04; #000000]: 13
- text at x 75.4, y 52.9, w 1.5, h 2.0 [CenturyGothic; font size 2.04; #000000]: (4)
- text at x 83.9, y 52.9, w 3.2, h 2.0 [CenturyGothic; font size 2.04; #000000]: (31) %
- text at x 5.7, y 56.1, w 10.0, h 2.0 [CenturyGothic-Bold; font size 2.04; #000000]: Net income (loss)
- text at x 46.3, y 56.1, w 0.6, h 2.0 [CenturyGothic-Bold; font size 2.04; #000000]: $
- text at x 52.7, y 56.1, w 1.9, h 2.0 [CenturyGothic-Bold; font size 2.04; #000000]: 162
- text at x 57.1, y 56.1, w 0.6, h 2.0 [CenturyGothic-Bold; font size 2.04; #000000]: $
- text at x 63.0, y 56.1, w 2.8, h 2.0 [CenturyGothic-Bold; font size 2.04; #000000]: (200)
- text at x 67.9, y 56.1, w 0.6, h 2.0 [CenturyGothic-Bold; font size 2.04; #000000]: $
- text at x 74.5, y 56.1, w 1.9, h 2.0 [CenturyGothic-Bold; font size 2.04; #000000]: 362
- text at x 83.7, y 56.1, w 3.5, h 2.0 [CenturyGothic-Bold; font size 2.04; #000000]: 181 %
- text at x 7.0, y 59.3, w 18.3, h 2.0 [CenturyGothic; font size 2.04; #000000]: Earnings (loss) per share – Diluted
- text at x 46.3, y 59.3, w 0.6, h 2.0 [CenturyGothic; font size 2.04; #000000]: $
- text at x 52.4, y 59.3, w 2.2, h 2.0 [CenturyGothic; font size 2.04; #000000]: 0.38
- text at x 57.1, y 59.3, w 0.6, h 2.0 [CenturyGothic; font size 2.04; #000000]: $
- text at x 62.7, y 59.3, w 3.0, h 2.0 [CenturyGothic; font size 2.04; #000000]: (0.51)
- text at x 67.9, y 59.3, w 0.6, h 2.0 [CenturyGothic; font size 2.04; #000000]: $
- text at x 74.2, y 59.3, w 2.2, h 2.0 [CenturyGothic; font size 2.04; #000000]: 0.89
- text at x 83.7, y 59.3, w 3.4, h 2.0 [CenturyGothic; font size 2.04; #000000]: 175 %
- text at x 7.0, y 62.5, w 19.5, h 2.0 [CenturyGothic; font size 2.04; #000000]: Weighted average shares – Diluted
- text at x 52.7, y 62.5, w 1.9, h 2.0 [CenturyGothic; font size 2.04; #000000]: 430
- text at x 63.5, y 62.5, w 1.9, h 2.0 [CenturyGothic; font size 2.04; #000000]: 390
- text at x 75.2, y 62.5, w 1.3, h 2.0 [CenturyGothic; font size 2.04; #000000]: 40
- text at x 84.3, y 62.5, w 2.8, h 2.0 [CenturyGothic; font size 2.04; #000000]: 10 %
- text at x 7.0, y 65.7, w 18.4, h 2.0 [CenturyGothic; font size 2.04; #000000]: Weighted average shares – Basic
- text at x 52.7, y 65.7, w 1.9, h 2.0 [CenturyGothic; font size 2.04; #000000]: 401
- text at x 63.5, y 65.7, w 1.9, h 2.0 [CenturyGothic; font size 2.04; #000000]: 390
- text at x 75.2, y 65.7, w 1.3, h 2.0 [CenturyGothic; font size 2.04; #000000]: 11
- text at x 85.0, y 65.7, w 2.2, h 2.0 [CenturyGothic; font size 2.04; #000000]: 3 %
- text at x 7.0, y 68.9, w 9.4, h 2.0 [CenturyGothic; font size 2.04; #000000]: Effective tax rate
- text at x 53.8, y 68.9, w 2.1, h 2.0 [CenturyGothic; font size 2.04; #000000]: 5 %
- text at x 64.2, y 68.9, w 2.5, h 2.0 [CenturyGothic; font size 2.04; #000000]: (7)%
- text at x 74.8, y 79.8, w 4.5, h 2.0 [CenturyGothic-Bold; font size 2.04; #FFFFFF]: Change
- text at x 48.1, y 81.1, w 5.6, h 2.0 [CenturyGothic-Bold; font size 2.04; #FFFFFF]: 9/30/2026
- text at x 58.7, y 81.1, w 5.6, h 2.0 [CenturyGothic-Bold; font size 2.04; #FFFFFF]: 6/30/2026
- text at x 5.7, y 82.1, w 5.9, h 2.0 [CenturyGothic-Italic; font size 2.04; #000000]: In $ billions
- text at x 73.2, y 82.3, w 7.9, h 2.0 [CenturyGothic-Bold; font size 2.04; #FFFFFF]: (9/30 vs. 6/30)
- text at x 5.7, y 85.3, w 22.3, h 2.0 [CenturyGothic-Bold; font size 2.04; #000000]: Cash, cash equivalents and investments
- text at x 46.2, y 85.3, w 0.6, h 2.0 [CenturyGothic; font size 2.04; #000000]: $
- text at x 53.8, y 85.3, w 1.6, h 2.0 [CenturyGothic; font size 2.04; #000000]: 8.0
- text at x 56.8, y 85.3, w 0.6, h 2.0 [CenturyGothic; font size 2.04; #000000]: $
- text at x 64.4, y 85.3, w 1.6, h 2.0 [CenturyGothic; font size 2.04; #000000]: 6.9
- text at x 67.4, y 85.3, w 0.6, h 2.0 [CenturyGothic; font size 2.04; #000000]: $
- text at x 74.7, y 85.3, w 1.6, h 2.0 [CenturyGothic; font size 2.04; #000000]: 1.1
- text at x 84.3, y 85.3, w 2.7, h 2.0 [CenturyGothic; font size 2.04; #000000]: 16 %
- text at x 6.1, y 73.0, w 42.1, h 1.7 [CenturyGothic; font size 1.67; #000000]: Includes grant, collaboration, licensing and royalty, and stand-ready manufacturing revenue
- text at x 6.1, y 75.6, w 55.8, h 1.7 [CenturyGothic; font size 1.67; #000000]: We generated a net loss in the prior period presented, therefore the basic and diluted calculation was the same in 3Q 2025
- text at x 26.4, y 62.4, w 0.4, h 1.4 [CenturyGothic; font size 1.36; #000000]: 2
- text at x 25.4, y 65.6, w 0.4, h 1.4 [CenturyGothic; font size 1.36; #000000]: 2
- text at x 1.1, y 95.5, w 0.6, h 2.0 [CenturyGothic-Bold; font size 1.96; #FFFFFF]: 9
- text at x 5.6, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #898989]: © 2026 Moderna, Inc. All rights reserved.
- text at x 5.7, y 72.9, w 0.3, h 1.1 [CenturyGothic; font size 1.11; #000000]: 1
- text at x 5.7, y 75.5, w 0.3, h 1.1 [CenturyGothic; font size 1.11; #000000]: 2

### Slide 10

**Text**

Updated 2026 GAAP financial framework / UPDATED FRAMEWORK / CHANGE FROM PREVIOUS / Total revenue / 15-25% growth from 2025 / (Expect 2026 revenue to be approximately even split between U.S. and International) / Increased from up to 10% growth from 2025 / (Expect 2026 revenue split of ~50% U.S. and ~50% International) / Cost of sales1 / ~$1.7B / Unchanged / ~$4.5B / GAAP expenses excluding $0.9B litigation settlement charge / R&D / ~$2.7B / Improved from $2.9B / ~$3.8B / adjusted cash costs2 excluding $0.9B litigation settlement charge / SG&A / ~$1.0B / Unchanged / Tax / Negligible / Unchanged / Capital expenditures / $0.2B / Improved to low end of prior $0.2–0.3B range / Cash and investments / 2026 year-end balance of $8.1-8.3B / (Excludes any further drawdowns from the Company’s remaining $0.9B available under its credit facility) / Increase driven by improved operational execution and net proceeds from convertible debt issuance / 1. Includes $0.9B litigation settlement charge / 2. Excluding $0.9B for litigation settlement charge. Cash costs = GAAP expenses − stock-based compensation − depreciation and amortization / 10 / © 2026 Moderna, Inc. All rights reserved. / 3Q 2026 Update | Financial Review

**Layout**

Full-width table-style grid on a white slide: a column of seven light-blue row labels at left (x 5.3%), a middle column of values starting at x 20.5%, a right column of changes starting at x 58.2%, separated by a thin dashed vertical divider at x 56.4%. Thin grey horizontal rules separate rows, spanning x 5.4% to 86%. The title sits top-left at x 5.4%, y 5.2%, with the column headings in bold caps just below it at y 14.8%. A vertical blue sidebar runs down the left edge with the section label rotated; the page number sits bottom-left, the footnotes and copyright bottom-left above the footer line, and the Moderna logo sits bottom-right.

**Visuals**

No charts, photographs or icons. Non-text elements: (1) a solid light-blue (#2AACE2) vertical sidebar along the left edge, 2.7% wide, full height. (2) Seven light-blue (#BFE6F6) rectangular label boxes behind the row labels Total revenue, Cost of sales, R&D, SG&A, Tax, Capital expenditures and Cash and investments, square corners, no outline. (3) Thin grey horizontal rules (about #BFBFBF, 1 px) between rows at about y 26%, 37.7%, 46.2%, 54.7%, 63.2% and 74.8%, spanning x 5.4% to 86%. (4) A dashed grey vertical divider (about #A6A6A6) at x 56.4% from y 13.8% to 86%. (5) A light-blue (#2AACE2) bracket line, about 1.5 px, from the top of the cost values (x 24.8%, y 31%) down to y 52.6% at x 27.8%, with a short horizontal tick from it to x 30% at y 41.7%, grouping Cost of sales, R&D and SG&A. (6) Moderna logo bottom-right: the red (#E31837) lowercase wordmark 'moderna' with a row of short dashed light-blue (#2AACE2) underline dashes beneath it.

**Design**

Background white (#FFFFFF). Title in bold red (#E31837) sans-serif, Segoe UI Bold, about 5.2% of slide height (cap height about 3.6%). Body text black (#000000) Segoe UI regular, about 2.6% of slide height; secondary explanatory lines in Segoe UI regular, about 2.0%. Row labels in Segoe UI Semibold, dark navy #1D2845, about 2.6%. Column headings in Segoe UI Bold caps, black, about 2.0%. Accent cost figures and their captions in bright blue #2AACE2: the bold figures ~$4.5B and ~$3.8B in Segoe UI Bold about 3.0%, captions in Segoe UI regular about 2.2%. Vertical sidebar label: 'Financial Review' in Segoe UI Semibold white and '3Q 2026 Update |' in Segoe UI Light pale blue #BFE6F6, about 3.0%. Footnotes in Century Gothic about 1.3% grey (#7F7F7F). Copyright in Century Gothic about 1.5% grey #898989. Page number in Century Gothic Bold white about 2.0% on the blue sidebar. Shapes have square corners, no shadows, no gradients.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 2.7, h 100 [#2AACE2]: Left vertical sidebar (Full-height rectangle, square corners, no outline.)
- shape at x 5.3, y 18.3, w 13.7, h 9.2 [#BFE6F6]: Label box behind Total revenue (Square corners, no outline.)
- shape at x 5.3, y 30.9, w 13.7, h 5.2 [#BFE6F6]: Label box behind Cost of sales (Square corners, no outline.)
- shape at x 5.3, y 39.4, w 13.7, h 5.2 [#BFE6F6]: Label box behind R&D (Square corners, no outline.)
- shape at x 5.3, y 48, w 13.7, h 5.2 [#BFE6F6]: Label box behind SG&A (Square corners, no outline.)
- shape at x 5.3, y 56.5, w 13.7, h 5.2 [#BFE6F6]: Label box behind Tax (Square corners, no outline.)
- shape at x 5.3, y 65.1, w 13.7, h 8.3 [#BFE6F6]: Label box behind Capital expenditures (Square corners, no outline.)
- shape at x 5.3, y 76.7, w 13.7, h 8.3 [#BFE6F6]: Label box behind Cash and investments (Square corners, no outline.)
- line at x 56.4, y 13.8, w 0.1, h 72.2 [#A6A6A6]: Dashed vertical column divider (1 px dashed grey line.)
- line at x 5.4, y 26, w 80.6, h 0.1 [#BFBFBF]: Horizontal row rule below Total revenue (1 px solid grey line.)
- line at x 5.4, y 37.7, w 80.6, h 0.1 [#BFBFBF]: Horizontal row rule below Cost of sales (1 px solid grey line.)
- line at x 5.4, y 46.2, w 80.6, h 0.1 [#BFBFBF]: Horizontal row rule below R&D (1 px solid grey line.)
- line at x 5.4, y 54.7, w 80.6, h 0.1 [#BFBFBF]: Horizontal row rule below SG&A (1 px solid grey line.)
- line at x 5.4, y 63.2, w 80.6, h 0.1 [#BFBFBF]: Horizontal row rule below Tax (1 px solid grey line.)
- line at x 5.4, y 74.8, w 80.6, h 0.1 [#BFBFBF]: Horizontal row rule below Capital expenditures (1 px solid grey line.)
- shape at x 24.8, y 31, w 3, h 21.6 [#2AACE2]: Bracket grouping Cost of sales, R&D and SG&A (Stroke about 1.5 px, square right-angle corners, open to the left; vertical spine at x 27.8% with horizontal ends to x 24.8%.)
- line at x 27.8, y 41.5, w 2.2, h 0.1 [#2AACE2]: Bracket tick to captions (About 1.5 px stroke.)
- title at x 5.4, y 5.2, w 56.4, h 5.2 [Segoe UI Bold; font size 5.18% of slide height; #E31837; left aligned]: Updated 2026 GAAP financial framework
- logo at x 86.6, y 92.2, w 12.2, h 4.9 [#E31837]: Moderna logo: red lowercase wordmark moderna with dashed light-blue underline (Raster image 359 by 81 pixels, bottom-right corner, no background box.)
- caption at x 0.5, y 2.4, w 1.7, h 22 [Segoe UI Semibold, rotated 270 degrees; font size 2.96% of slide height; #FFFFFF; left aligned]: Financial Review (Vertical text reading upward, sits on the blue sidebar.)
- caption at x 0.5, y 24.4, w 1.7, h 22.9 [Segoe UI Light, rotated 270 degrees; font size 2.96% of slide height; #BFE6F6; left aligned]: 3Q 2026 Update | (Vertical text reading upward, directly below Financial Review on the sidebar.)
- subtitle at x 20.5, y 14.8, w 12.4, h 2 [Segoe UI Bold, caps; font size 1.96% of slide height; #000000; left aligned]: UPDATED FRAMEWORK
- subtitle at x 58.2, y 14.8, w 13.6, h 2 [Segoe UI Bold, caps; font size 1.96% of slide height; #000000; left aligned]: CHANGE FROM PREVIOUS
- body at x 6.8, y 21.8, w 8.9, h 2.6 [Segoe UI Semibold; font size 2.6% of slide height; #1D2845; left aligned]: Total revenue
- body at x 20.5, y 19.7, w 20.6, h 8 [Segoe UI; font size 2.6% of slide height; #000000; left aligned]: 15-25% growth from 2025 / (Expect 2026 revenue to be approximately / even split between U.S. and International) (Line 1 at 2.6% size, Segoe UI regular black; lines 2 and 3 at 1.96% size, line spacing about 2.0%.)
- body at x 58.2, y 20.6, w 31.1, h 5 [Segoe UI; font size 2.6% of slide height; #000000; left aligned]: Increased from up to 10% growth from 2025 / (Expect 2026 revenue split of ~50% U.S. and ~50% International) (Line 1 at 2.6%; line 2 in parentheses at 1.96%.)
- body at x 6.8, y 32.4, w 8.3, h 2.6 [Segoe UI Semibold; font size 2.6% of slide height; #1D2845; left aligned]: Cost of sales1 (Superscript 1 at 1.73% size.)
- body at x 20.7, y 32.2, w 4.5, h 2.6 [Segoe UI; font size 2.6% of slide height; #000000; left aligned]: ~$1.7B
- body at x 58.2, y 32.4, w 7.4, h 2.6 [Segoe UI; font size 2.6% of slide height; #000000; left aligned]: Unchanged
- body at x 31.7, y 32.1, w 17.8, h 8 [Segoe UI Bold for ~$4.5B, Segoe UI regular for captions; font size 2.96% of slide height; #2AACE2; left aligned]: ~$4.5B / GAAP expenses excluding $0.9B / litigation settlement charge (Figure at 2.96% bold, captions at 2.22% regular in the same blue; line spacing about 2.6%.)
- body at x 6.8, y 40.9, w 3, h 2.6 [Segoe UI Semibold; font size 2.6% of slide height; #1D2845; left aligned]: R&D
- body at x 20.7, y 40.9, w 4.5, h 2.6 [Segoe UI; font size 2.6% of slide height; #000000; left aligned]: ~$2.7B
- body at x 58.2, y 41.2, w 13.5, h 2.6 [Segoe UI; font size 2.6% of slide height; #000000; left aligned]: Improved from $2.9B
- body at x 31.7, y 42.9, w 20.5, h 11 [Segoe UI Bold for ~$3.8B, Segoe UI regular for captions; font size 2.96% of slide height; #2AACE2; left aligned]: ~$3.8B / adjusted cash costs2 excluding $0.9B / litigation settlement charge (Figure at 2.96% bold; captions at 2.22% regular in blue.)
- body at x 6.8, y 49.5, w 3.8, h 2.6 [Segoe UI Semibold; font size 2.6% of slide height; #1D2845; left aligned]: SG&A
- body at x 20.7, y 49.3, w 4.5, h 2.6 [Segoe UI; font size 2.6% of slide height; #000000; left aligned]: ~$1.0B
- body at x 58.2, y 49.4, w 7.4, h 2.6 [Segoe UI; font size 2.6% of slide height; #000000; left aligned]: Unchanged
- body at x 20.7, y 58, w 6.6, h 2.6 [Segoe UI; font size 2.6% of slide height; #000000; left aligned]: Negligible
- body at x 6.8, y 58, w 2.2, h 2.6 [Segoe UI Semibold; font size 2.6% of slide height; #1D2845; left aligned]: Tax
- body at x 58.2, y 58, w 7.4, h 2.6 [Segoe UI; font size 2.6% of slide height; #000000; left aligned]: Unchanged
- body at x 6.8, y 66.6, w 8.6, h 5.2 [Segoe UI Semibold; font size 2.6% of slide height; #1D2845; left aligned]: Capital / expenditures
- body at x 20.7, y 68.2, w 3.5, h 2.6 [Segoe UI; font size 2.6% of slide height; #000000; left aligned]: $0.2B
- body at x 58.2, y 68.2, w 29.3, h 2.6 [Segoe UI; font size 2.6% of slide height; #000000; left aligned]: Improved to low end of prior $0.2–0.3B range
- body at x 6.8, y 78.2, w 8, h 5.2 [Segoe UI Semibold; font size 2.6% of slide height; #1D2845; left aligned]: Cash and / investments
- body at x 20.5, y 77.5, w 26.3, h 8 [Segoe UI; font size 2.6% of slide height; #000000; left aligned]: 2026 year-end balance of $8.1-8.3B / (Excludes any further drawdowns from the Company’s / remaining $0.9B available under its credit facility) (Line 1 at 2.6%; lines 2 and 3 in parentheses at 1.96%.)
- body at x 58.2, y 76.8, w 29.3, h 11 [Segoe UI; font size 2.6% of slide height; #000000; left aligned]: Increase driven by improved operational / execution and net proceeds from / convertible debt issuance (Three lines at 2.6% size, line spacing about 3.1%.)
- footer at x 5.4, y 91.2, w 50.1, h 2.8 [Century Gothic; font size 1.29% of slide height; #7F7F7F; left aligned]: 1. Includes $0.9B litigation settlement charge / 2. Excluding $0.9B for litigation settlement charge. Cash costs = GAAP expenses − stock-based compensation − depreciation and amortization
- footer at x 5.6, y 95.7, w 16.1, h 1.5 [Century Gothic; font size 1.49% of slide height; #898989; left aligned]: © 2026 Moderna, Inc. All rights reserved.
- page number at x 0.8, y 95.5, w 1.2, h 2 [Century Gothic Bold; font size 1.96% of slide height; #FFFFFF; left aligned]: 10 (White on the blue sidebar.)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 2.7, h 100.0: #2AACE2
- fill at x 0.0, y 0.0, w 2.7, h 100.0: #2AACE2
- fill at x 94.2, y 0.0, w 5.8, h 48.8: #FFFFFF
- fill at x 12.5, y 26.5, w 12.4, h 26.9: #FFFFFF
- fill at x 5.3, y 18.3, w 13.7, h 9.2: #BFE6F6
- fill at x 5.3, y 30.9, w 13.7, h 5.2: #BFE6F6
- fill at x 5.3, y 39.4, w 13.7, h 5.2: #BFE6F6
- fill at x 5.3, y 56.5, w 13.7, h 5.2: #BFE6F6
- fill at x 5.3, y 65.1, w 13.7, h 8.3: #BFE6F6
- fill at x 5.3, y 76.7, w 13.7, h 8.3: #BFE6F6
- fill at x 5.3, y 48.0, w 13.7, h 5.2: #BFE6F6
- image at x 0.0, y 0.0, w 100.0, h 100.0: 2000 by 1125 pixels (covers the slide)
- image at x 86.6, y 92.2, w 12.2, h 4.9: 359 by 81 pixels
- text at x 5.4, y 5.2, w 56.4, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: Updated 2026 GAAP financial framework
- text at x 0.5, y 2.4, w 1.7, h 22.0 [SegoeUI-Semibold; font size 2.96; #FFFFFF]: Financial Review
- text at x 20.5, y 19.7, w 1.6, h 2.6 [SegoeUI; font size 2.60; #000000]: 15
- text at x 20.5, y 14.8, w 12.4, h 2.0 [SegoeUI-Bold; font size 1.96; #000000]: UPDATED FRAMEWORK
- text at x 22.1, y 19.7, w 15.3, h 2.6 [SegoeUI; font size 2.60; #000000]: -25% growth from 2025
- text at x 58.2, y 14.8, w 13.6, h 2.0 [SegoeUI-Bold; font size 1.96; #000000]: CHANGE FROM PREVIOUS
- text at x 58.2, y 20.6, w 28.6, h 2.6 [SegoeUI; font size 2.60; #000000]: Increased from up to 10% growth from 2025
- text at x 6.8, y 21.8, w 8.9, h 2.6 [SegoeUI-Semibold; font size 2.60; #1D2845]: Total revenue
- text at x 31.7, y 32.1, w 6.0, h 3.0 [SegoeUI-Bold; font size 2.96; #2AACE2]: ~$4.5B
- text at x 0.5, y 24.4, w 1.7, h 22.9 [SegoeUI-Light; font size 2.96; #BFE6F6]: 3Q 2026 Update |
- text at x 20.5, y 22.7, w 20.6, h 2.0 [SegoeUI; font size 1.96; #000000]: (Expect 2026 revenue to be approximately
- text at x 58.2, y 23.6, w 31.1, h 2.0 [SegoeUI; font size 1.96; #000000]: (Expect 2026 revenue split of ~50% U.S. and ~50% International)
- text at x 6.8, y 32.4, w 8.3, h 2.6 [SegoeUI-Semibold; font size 2.60; #1D2845]: Cost of sales
- text at x 20.7, y 32.2, w 4.5, h 2.6 [SegoeUI; font size 2.60; #000000]: ~$1.7B
- text at x 58.2, y 32.4, w 7.4, h 2.6 [SegoeUI; font size 2.60; #000000]: Unchanged
- text at x 20.5, y 25.1, w 20.0, h 2.0 [SegoeUI; font size 1.96; #000000]: even split between U.S. and International)
- text at x 31.7, y 42.9, w 6.0, h 3.0 [SegoeUI-Bold; font size 2.96; #2AACE2]: ~$3.8B
- text at x 6.8, y 40.9, w 3.0, h 2.6 [SegoeUI-Semibold; font size 2.60; #1D2845]: R&D
- text at x 20.7, y 40.9, w 4.5, h 2.6 [SegoeUI; font size 2.60; #000000]: ~$2.7B
- text at x 31.7, y 35.5, w 17.8, h 2.2 [SegoeUI; font size 2.22; #2AACE2]: GAAP expenses excluding $0.9B
- text at x 58.2, y 41.2, w 13.5, h 2.6 [SegoeUI; font size 2.60; #000000]: Improved from $2.9B
- text at x 31.7, y 38.2, w 15.1, h 2.2 [SegoeUI; font size 2.22; #2AACE2]: litigation settlement charge
- text at x 15.1, y 32.3, w 0.4, h 1.7 [SegoeUI-Semibold; font size 1.73; #1D2845]: 1
- text at x 6.8, y 49.5, w 3.8, h 2.6 [SegoeUI-Semibold; font size 2.60; #1D2845]: SG&A
- text at x 20.7, y 49.3, w 4.5, h 2.6 [SegoeUI; font size 2.60; #000000]: ~$1.0B
- text at x 58.2, y 49.4, w 7.4, h 2.6 [SegoeUI; font size 2.60; #000000]: Unchanged
- text at x 31.7, y 47.1, w 20.5, h 2.2 [SegoeUI; font size 2.22; #2AACE2]: adjusted cash costs excluding $0.9B
- text at x 6.8, y 58.0, w 2.2, h 2.6 [SegoeUI-Semibold; font size 2.60; #1D2845]: Tax
- text at x 20.7, y 58.0, w 6.6, h 2.6 [SegoeUI; font size 2.60; #000000]: Negligible
- text at x 31.7, y 49.9, w 15.1, h 2.2 [SegoeUI; font size 2.22; #2AACE2]: litigation settlement charge
- text at x 58.2, y 58.0, w 7.4, h 2.6 [SegoeUI; font size 2.60; #000000]: Unchanged
- text at x 6.8, y 66.6, w 5.0, h 2.6 [SegoeUI-Semibold; font size 2.60; #1D2845]: Capital
- text at x 20.7, y 68.2, w 3.5, h 2.6 [SegoeUI; font size 2.60; #000000]: $0.2B
- text at x 58.2, y 68.2, w 29.3, h 2.6 [SegoeUI; font size 2.60; #000000]: Improved to low end of prior $0.2–0.3B range
- text at x 6.8, y 69.7, w 8.6, h 2.6 [SegoeUI-Semibold; font size 2.60; #1D2845]: expenditures
- text at x 58.2, y 76.8, w 26.4, h 2.6 [SegoeUI; font size 2.60; #000000]: Increase driven by improved operational
- text at x 6.8, y 78.2, w 6.4, h 2.6 [SegoeUI-Semibold; font size 2.60; #1D2845]: Cash and
- text at x 20.5, y 77.5, w 23.1, h 2.6 [SegoeUI; font size 2.60; #000000]: 2026 year-end balance of $8.1-8.3B
- text at x 58.2, y 80.0, w 21.7, h 2.6 [SegoeUI; font size 2.60; #000000]: execution and net proceeds from
- text at x 6.8, y 81.3, w 8.0, h 2.6 [SegoeUI-Semibold; font size 2.60; #1D2845]: investments
- text at x 42.5, y 47.0, w 0.5, h 1.5 [SegoeUI; font size 1.49; #2AACE2]: 2
- text at x 58.2, y 83.1, w 16.4, h 2.6 [SegoeUI; font size 2.60; #000000]: convertible debt issuance
- text at x 20.5, y 80.5, w 26.3, h 2.0 [SegoeUI; font size 1.96; #000000]: (Excludes any further drawdowns from the Company’s
- text at x 20.5, y 82.8, w 23.6, h 2.0 [SegoeUI; font size 1.96; #000000]: remaining $0.9B available under its credit facility)
- text at x 0.8, y 95.5, w 1.2, h 2.0 [CenturyGothic-Bold; font size 1.96; #FFFFFF]: 10
- text at x 5.6, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #898989]: © 2026 Moderna, Inc. All rights reserved.
- text at x 5.4, y 91.2, w 15.6, h 1.3 [CenturyGothic; font size 1.29; #7F7F7F]: 1. Includes $0.9B litigation settlement charge
- text at x 5.4, y 92.7, w 50.1, h 1.3 [CenturyGothic; font size 1.29; #7F7F7F]: 2. Excluding $0.9B for litigation settlement charge. Cash costs = GAAP expenses − stock-based compensation − depreciation and amortization

### Slide 11

**Text**

3Q26 earnings call agenda
Business Review
Stéphane Bancel, CEO
Financials
Jamey Mock, CFO
Business updates
Stephen Hoge, M.D., President
Pipeline updates
David Berman, M.D., Ph.D., Chief Development Officer
Looking Ahead
Stéphane Bancel, CEO
© 2026 Moderna, Inc. All rights reserved.

**Layout**

A full-height left vertical blue band occupies the leftmost 19.4% of the slide, with the copyright footer set in white at its bottom-left. To the right, on the white field, the red title sits top-left at about 4.6% from the top, left-aligned at x 21.6%. Five agenda rows follow in a single column, each with a grey outlined circular icon at x 23.2% and a bold heading with a light name line beside it starting at x 31%. The highlighted third row is boxed by a red rounded rectangle spanning roughly x 23.4% to 95.6%. The Moderna logo sits bottom-right at x 86.6%, y 92.2%.

**Visuals**

Five circular line icons, each about 4.8% wide, arranged in a vertical column at x 23.2%. Row 1 (y 16.7%): grey #C0C0C0 outline circle containing a stylised wave/curve line icon with small bars. Row 2 (y 32.4%): grey #C0C0C0 outline circle containing a presentation board with a bar chart and pie chart. Row 3 (y 48.4%): red #E31837 outline circle containing blue test-tube/vial icons with red caps, representing business updates; this row is highlighted. Row 4 (y 63.8%): grey #C0C0C0 outline circle containing a figure at a microscope beside hexagon molecule shapes. Row 5 (y 79.5%): grey #C0C0C0 outline circle containing two rows of rectangles with arrows pointing right, representing looking ahead. Plus one Moderna wordmark logo in red with a row of small cyan dashes beneath it, bottom-right. None of the icons are photographic.

**Design**

Background: White #FFFFFF with a left vertical band in blue #2AACE2.

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 19.4, h 100.0: #2AACE2
- fill at x 23.2, y 48.4, w 4.8, h 8.6: #E31837
- fill at x 23.2, y 32.4, w 4.8, h 8.6: #C0C0C0
- fill at x 23.2, y 16.7, w 4.8, h 8.6: #C0C0C0
- fill at x 23.2, y 16.7, w 4.8, h 8.6: #C0C0C0
- fill at x 23.2, y 79.5, w 4.8, h 8.6: #C0C0C0
- fill at x 23.2, y 63.8, w 4.8, h 8.6: #C0C0C0
- image at x 86.6, y 92.2, w 12.2, h 4.9: 359 by 81 pixels
- text at x 21.6, y 4.6, w 36.2, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: 3Q26 earnings call agenda
- text at x 31.0, y 17.5, w 15.8, h 3.7 [SegoeUI-Bold; font size 3.71; #1E2846]: Business Review
- text at x 31.0, y 22.7, w 16.0, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: Stéphane Bancel, CEO
- text at x 31.0, y 33.3, w 9.5, h 3.7 [SegoeUI-Bold; font size 3.71; #1E2846]: Financials
- text at x 31.0, y 38.5, w 12.5, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: Jamey Mock, CFO
- text at x 31.0, y 48.9, w 16.7, h 3.7 [SegoeUI-Bold; font size 3.71; #2AACE2]: Business updates
- text at x 31.0, y 64.2, w 16.2, h 3.7 [SegoeUI-Bold; font size 3.71; #1E2846]: Pipeline updates
- text at x 31.0, y 54.1, w 21.2, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: Stephen Hoge, M.D., President
- text at x 31.3, y 79.9, w 14.8, h 3.7 [SegoeUI-Bold; font size 3.72; #1E2846]: Looking Ahead
- text at x 31.0, y 69.4, w 37.4, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: David Berman, M.D., Ph.D., Chief Development Officer
- text at x 31.3, y 85.1, w 15.5, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: Stéphane Bancel, CEO
- text at x 2.0, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #FFFFFF]: © 2026 Moderna, Inc. All rights reserved.

### Slide 12

**Review notes**

- Worth studying: A rising timeline graphic with product bands across 2026 to 2028 turns the multi-year strategy into a single visual sequence.

**Text**

Advancing a multi-year revenue growth strategy
3Q 2026 Update |
Business updates
2026
2027
2028
Infectious disease vaccines
Geographic expansion
Oncology therapeutics
Rare disease therapeutics
PA
mRNA-4359
Intismeran
Norovirus
Flu + COVID
Flu
LATAM & APAC strategic agreements
EU market growth
mNEXSPIKE
UK, Can, Aus strategic partnerships
Executing our strategy
mFLUSIVA®: FDA approval for 50-64 years of age; accelerated approval for adults 65+; approved in Canada for adults 50+
mCOFLU®: Approved in Canada for adults 50+ (known as mCOMBRIAX® in the EU)
mNEXSPIKE®: Annual strain approvals secured in U.S., Canada, Japan, Taiwan
mRESVIA®: Continued progress in U.S. placement and ex-U.S. awards
Mexico: Signed 5-year agreement for COVID-19 vaccines with local manufacturer
Intismeran: Positive Phase 3 data in adjuvant melanoma study presented at ESMO
12
© 2026 Moderna, Inc. All rights reserved.
moderna

**Layout**

Two-column slide on white. The title sits top-left at about 5.4% from the left and top, in one line spanning roughly two-thirds of the width. The left column holds the roadmap graphic (image) from about 5% to 60% of the width and 15% to 91% of the height, with the year labels below it. A thin vertical grey divider at about 63% of the width separates it from the right column, which has the heading 'Executing our strategy' at about 18.7% from the top and a bulleted list below it. A blue vertical band runs down the left edge with the rotated section label, the slide number 12 sits at bottom-left on the band, the copyright line sits bottom-left beside it, and the moderna logo sits bottom-right.

**Visuals**

One roadmap illustration (diagram) occupying the left column. It shows three house-shaped outlined columns, one each for 2026, 2027 and 2028, rising in height from left to right, with a grey (#E6E6E6) rising band behind them and a dark navy (#1F2A44) diagonal line running from the left edge at about 65% of the image height up to the right edge at about 40% of the image height. Each column contains stacked rounded rectangles with labels. 2026 column (lowest): red 'mNEXSPIKE' box above a light blue 'UK, Can, Aus strategic partnerships' box. 2027 column: navy 'Intismeran' box at top, red 'Flu' box below it, then light blue 'LATAM & APAC strategic agreements' and light blue 'EU market growth' boxes. 2028 column (tallest): light steel blue 'PA' box at top, navy 'mRNA-4359' box below it, then red 'Norovirus' and red 'Flu + COVID' boxes. A legend at top-left of the graphic lists four colour swatches: red 'Infectious disease vaccines', light blue 'Geographic expansion', navy 'Oncology therapeutics', steel blue 'Rare disease therapeutics'. No values or axis scales are printed; the chart is not quantitative. The image is not cropped and is boxed on white with no overlay. The moderna logo is a red wordmark with a row of blue dashes beneath it, and there are no other icons.

**Design**

Background: Solid white #FFFFFF with a light blue #2AACE2 vertical band along the left edge. White background. Vertical blue band on the left edge in #2AACE2 with white text. Title in bold red #E31837 at about 5.2% of slide height, Segoe UI Bold, sans-serif. Heading 'Executing our strategy' in black #000000 Segoe UI Light at about 3.3% of height. Body bullets in black #000000 Segoe UI Light at about 2.6% of height, with bold Segoe UI Semibold lead-in labels and red #E31837 Wingdings bullet dots. Chart labels are white or black sans-serif. Accent colours: red #E31837, light blue #2AACE2, navy #1F2A44, steel blue #6391C4. The graphic's columns have thin light-grey outlines and subtle grey drop shadows; the grey band is #E6E6E6. Copyright text is grey #898989 Century Gothic at about 1.5% of height. Slide number is white bold Century Gothic at about 1.8%.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: Full-slide white background fill (Covers the whole slide.)
- shape at x 0, y 0, w 2.7, h 100 [#2AACE2]: Left vertical blue band (Full-height rectangle on the left edge, no border.)
- diagram at x 5.1, y 15.4, w 55.1, h 75.5: Roadmap illustration of 2026, 2027 and 2028 house-shaped columns with stacked coloured boxes, legend and rising grey band; navy diagonal line across the grey band. (Boxed image 1470 by 1132 pixels, not cropped, no overlay. Columns have thin light-grey outlines and soft shadows; grey band #E6E6E6; navy line #1F2A44 about 0.3% of height thick.)
- title at x 5.4, y 5.4, w 66.6, h 5.2 [Segoe UI Bold; font size 5.18% of slide height; #E31837; left aligned]: Advancing a multi-year revenue growth strategy (Single line, sentence case, no italics.)
- caption at x 0.4, y 2.4, w 1.7, h 22.9 [Segoe UI Semibold, rotated 90 degrees reading upward; font size 2.96% of slide height; #FFFFFF; left aligned]: Business updates (Vertical text on the blue band.)
- caption at x 0.4, y 25.4, w 1.7, h 22.9 [Segoe UI Light, rotated 90 degrees reading upward; font size 2.96% of slide height; #BFE6F6; left aligned]: 3Q 2026 Update | (Vertical text on the blue band, continuing from Business updates.)
- shape at x 63.2, y 17, w 0.2, h 67 [#D0D0D0]: Vertical divider line (Thin light-grey vertical rule, about 1 pixel wide.)
- title at x 65.7, y 18.7, w 18, h 3.3 [Segoe UI Light; font size 3.33% of slide height; #000000; left aligned]: Executing our strategy (Heading above the bullet list.)
- bullet list at x 65.7, y 27, w 25, h 54.8 [Segoe UI Light with Segoe UI Semibold bold lead-ins; font size 2.6% of slide height; #000000; left aligned]: Bullet 1: mFLUSIVA®: FDA approval for 50-64 years of age; accelerated approval for adults 65+; approved in Canada for adults 50+ / Bullet 2: mCOFLU®: Approved in Canada for adults 50+ (known as mCOMBRIAX® in the EU) / Bullet 3: mNEXSPIKE®: Annual strain approvals secured in U.S., Canada, Japan, Taiwan / Bullet 4: mRESVIA®: Continued progress in U.S. placement and ex-U.S. awards / Bullet 5: Mexico: Signed 5-year agreement for COVID-19 vaccines with local manufacturer / Bullet 6: Intismeran: Positive Phase 3 data in adjuvant melanoma study presented at ESMO (Red #E31837 round bullet dots at x 65.7; paragraphs separated by roughly one blank line; text lines spaced about 3.1% of height; superscript registered marks on product names.)
- caption at x 5.1, y 15.4, w 55.1, h 75.5: Legend: Infectious disease vaccines / Geographic expansion / Oncology therapeutics / Rare disease therapeutics (Legend is part of the roadmap image; listed here for completeness, not a separate element.)
- caption at x 11.5, y 95.5, w 10, h 3.5 [Arial-like sans-serif Regular; font size 3.5% of slide height; #000000; center aligned]: 2026 (Year label under the 2026 column, part of the image.)
- caption at x 29.5, y 95.5, w 10, h 3.5 [Arial-like sans-serif Regular; font size 3.5% of slide height; #000000; center aligned]: 2027 (Year label under the 2027 column, part of the image.)
- caption at x 47.8, y 95.5, w 10, h 3.5 [Arial-like sans-serif Regular; font size 3.5% of slide height; #000000; center aligned]: 2028 (Year label under the 2028 column, part of the image.)
- logo at x 86.6, y 92.2, w 12.2, h 4.9 [#E31837]: moderna wordmark logo with dashed blue underline (Placed image 359 by 81 pixels; red lowercase wordmark with a row of light blue dashes beneath.)
- page number at x 0.8, y 95.5, w 1.2, h 1.8 [Century Gothic Bold; font size 1.84% of slide height; #FFFFFF; left aligned]: 12 (Sits on the blue band.)
- footer at x 5.6, y 95.7, w 16.1, h 1.5 [Century Gothic Regular; font size 1.49% of slide height; #898989; left aligned]: © 2026 Moderna, Inc. All rights reserved. (Copyright line at the bottom-left.)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 2.7, h 100.0: #2AACE2
- image at x 5.1, y 15.4, w 55.1, h 75.5: 1470 by 1132 pixels
- image at x 86.6, y 92.2, w 12.2, h 4.9: 359 by 81 pixels
- text at x 5.4, y 5.4, w 66.6, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: Advancing a multi-year revenue growth strategy
- text at x 0.4, y 2.4, w 1.7, h 22.9 [SegoeUI-Semibold; font size 2.96; #FFFFFF]: Business updates
- text at x 65.7, y 18.7, w 18.0, h 3.3 [SegoeUI-Light; font size 3.33; #000000]: Executing our strategy
- text at x 65.7, y 27.0, w 0.7, h 2.6 [Wingdings-Regular; font size 2.60; #E31837]: 
- text at x 67.2, y 27.0, w 6.8, h 2.6 [SegoeUI-Semibold; font size 2.60; #000000]: mFLUSIVA
- text at x 74.9, y 27.0, w 0.8, h 2.6 [CenturyGothic; font size 2.60; #000000]: :
- text at x 75.7, y 27.0, w 20.0, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: FDA approval for 50-64 years of
- text at x 67.2, y 30.2, w 25.4, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: age; accelerated approval for adults 65+;
- text at x 0.4, y 25.4, w 1.7, h 22.9 [SegoeUI-Light; font size 2.96; #BFE6F6]: 3Q 2026 Update |
- text at x 67.2, y 33.3, w 21.4, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: approved in Canada for adults 50+
- text at x 65.7, y 40.1, w 0.7, h 2.6 [Wingdings-Regular; font size 2.60; #E31837]: 
- text at x 67.2, y 40.1, w 7.4, h 2.6 [SegoeUI-Semibold; font size 2.60; #000000]: mCOFLU :
- text at x 74.1, y 27.0, w 0.9, h 1.7 [SegoeUI-Semibold; font size 1.74; #000000]: ®
- text at x 74.6, y 40.1, w 22.0, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Approved in Canada for adults 50+
- text at x 67.2, y 43.2, w 21.8, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: (known as mCOMBRIAX in the EU)
- text at x 65.7, y 50.0, w 0.7, h 2.6 [Wingdings-Regular; font size 2.60; #E31837]: 
- text at x 67.2, y 50.0, w 7.8, h 2.6 [SegoeUI-Semibold; font size 2.60; #000000]: mNEXSPIKE
- text at x 75.9, y 50.0, w 0.4, h 2.6 [CenturyGothic-Bold; font size 2.60; #000000]: :
- text at x 76.7, y 50.0, w 19.8, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Annual strain approvals secured
- text at x 67.2, y 53.1, w 18.2, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: in U.S., Canada, Japan, Taiwan
- text at x 65.7, y 59.9, w 0.7, h 2.6 [Wingdings-Regular; font size 2.60; #E31837]: 
- text at x 67.2, y 59.9, w 6.1, h 2.6 [SegoeUI-Semibold; font size 2.60; #000000]: mRESVIA
- text at x 73.0, y 40.0, w 0.9, h 1.7 [SegoeUI-Semibold; font size 1.73; #000000]: ®
- text at x 74.2, y 59.9, w 0.8, h 2.6 [SegoeUI-Semibold; font size 2.60; #000000]: :
- text at x 75.0, y 59.9, w 16.6, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Continued progress in U.S.
- text at x 67.2, y 63.0, w 18.5, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: placement and ex-U.S. awards
- text at x 81.9, y 43.1, w 0.9, h 1.7 [SegoeUI-Semibold; font size 1.73; #000000]: ®
- text at x 65.7, y 69.8, w 0.7, h 2.6 [Wingdings-Regular; font size 2.60; #E31837]: 
- text at x 67.2, y 69.8, w 5.2, h 2.6 [SegoeUI-Semibold; font size 2.60; #000000]: Mexico:
- text at x 72.8, y 69.8, w 22.9, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Signed 5-year agreement for COVID-
- text at x 67.2, y 73.0, w 21.4, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: 19 vaccines with local manufacturer
- text at x 75.1, y 49.9, w 0.9, h 1.7 [SegoeUI-Semibold; font size 1.74; #000000]: ®
- text at x 65.7, y 78.3, w 0.7, h 2.6 [Wingdings-Regular; font size 2.60; #E31837]: 
- text at x 67.2, y 78.3, w 7.8, h 2.6 [SegoeUI-Semibold; font size 2.60; #000000]: Intismeran:
- text at x 75.0, y 78.3, w 20.3, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Positive Phase 3 data in adjuvant
- text at x 67.2, y 81.4, w 22.4, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: melanoma study presented at ESMO
- text at x 73.4, y 59.9, w 0.9, h 1.7 [SegoeUI-Semibold; font size 1.73; #000000]: ®
- text at x 0.8, y 95.5, w 1.2, h 1.8 [CenturyGothic-Bold; font size 1.84; #FFFFFF]: 12
- text at x 5.6, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #898989]: © 2026 Moderna, Inc. All rights reserved.

### Slide 13

**Text**

Infectious disease vaccines: approved products
Business updates
3Q 2026 Update |
Deliveries underway in
markets worldwide
XFG strain approved
in U.S., EU, Canada,
Japan, Taiwan for
2026/2027 season
Supplying U.S., Japan, Taiwan,
Spain with planned 2028
market expansion
XFG strain approved
in U.S., Canada,
Japan, Taiwan for
2026/2027 season
Additional filings
planned for 2H26
Approved in 44 countries
Clinical study: Safety
and immunogenicity
of revaccination
following a protein
subunit RSV vaccine1
Approved in
U.S., Canada
U.S. FDA approval for
adults 50-64 and
accelerated approval in
adults 65+
Recommended by
AAFP for adults 65+ as
an enhanced influenza
vaccine
Approved in Canada
for adults 50+
Under review in the EU,
Australia, and Taiwan
Approved in EU, Canada
Approved in Canada
for adults 50+ under
brand name mCOFLU®
Under review in
Japan, UK, Australia,
Switzerland
Awaiting further
guidance from FDA
on refiling in the U.S.
New update
1. https://www.sciencedirect.com/science/article/pii/S0264410X26008777
© 2026 Moderna, Inc. All rights reserved.
13

**Layout**

Five equal-width white cards in a row spanning the slide from about x 4% to x 97%, top edge at 14.7% and bottom at 88% of slide height, with about 1.3% gutters between cards. Title sits top-left at x 5.1%, y 4.2%, left-aligned, above the cards. A full-height blue vertical band runs along the left edge (0 to 2.7%) carrying rotated section text. Footer row at the bottom: a 'New update' tag at left (x 4.2%, y 89.5%), a footnote beside it, copyright line at bottom left, and the Moderna logo bottom right (x 86.6%, y 92.2%); slide number 13 sits bottom-left inside the blue band.

**Visuals**

Five product cards, each a white rounded rectangle with a thin light-grey outline and a coloured header tab along its top edge. Card 1 (spikevax): tab #085B81, logo spikevax with 'COVID-19 Vaccine, mRNA', subhead 'Deliveries underway in markets worldwide', one red arrow bullet. Card 2 (mNEXSPIKE): tab #00837B, logo mNEXSPIKE with 'COVID-19 Vaccine, mRNA' (teal hexagon with red wave), subhead 'Supplying U.S., Japan, Taiwan, Spain with planned 2028 market expansion', one red arrow bullet and one dot bullet. Card 3 (mRESVIA): tab #77A4D9, logo mRESVIA with '(Respiratory Syncytial Virus Vaccine)' (blue hexagon with red wave), subhead 'Approved in 44 countries', one red arrow bullet. Card 4 (mFLUSIVA): tab #B65379, logo mFLUSIVA with 'Influenza Vaccine, mRNA' (magenta ring with red wave), subhead 'Approved in U.S., Canada', three red arrow bullets and one dot bullet. Card 5 (mCOMBRIAX): tab #F37877, logo mCOMBRIAX with 'Influenza and COVID-19, mRNA Vaccine' (coral hexagon with wave), subhead 'Approved in EU, Canada', one red arrow bullet and two dot bullets. Footer: a 'New update' tag with a red arrow icon, and the Moderna wordmark in red.

**Design**

Background: Solid white #FFFFFF. Plain white background; title in red #E31837 Segoe UI Bold, about 5.2% of slide height; body in Segoe UI Light about 2.6% of slide height, colours #0D0D0D, #1D2845 and #000000; card subheads Segoe UI Semibold about 2.0% in each card's accent colour; accent colours #085B81, #00837B, #77A4D9, #B65379, #F37877; left band #2AACE2 with white Segoe UI Semibold section title and light-blue #BFE6F6 subtitle; card outlines about 1 px #E6E6E6 with rounded corners of about 1.5% of slide width and a faint shadow; bullets are red #E31837 arrow glyphs or black dot glyphs.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: Slide background, plain white fill
- shape at x 0, y 0, w 2.7, h 100 [#2AACE2]: Left vertical accent band (Full height, flush left edge, no border)
- shape at x 4.2, y 16.4, w 17.5, h 71.7 [#FFFFFF]: Card 1 body (spikevax column) (Rounded rectangle, outline about 1 px #E6E6E6, corner radius about 1.5% of width, faint shadow; top corners sit under the header tab)
- shape at x 4.2, y 14.9, w 17.3, h 5.1 [#085B81]: Card 1 header tab (Rounded top corners, flat bottom merging into card)
- shape at x 23, y 16.4, w 17.5, h 71.5 [#FFFFFF]: Card 2 body (mNEXSPIKE column) (Same card styling as card 1)
- shape at x 23, y 14.9, w 17.3, h 4.9 [#00837B]: Card 2 header tab (Rounded top corners)
- shape at x 41.9, y 16.4, w 17.5, h 71.7 [#FFFFFF]: Card 3 body (mRESVIA column) (Same card styling as card 1)
- shape at x 41.9, y 14.9, w 17.3, h 4.9 [#77A4D9]: Card 3 header tab (Rounded top corners)
- shape at x 60.7, y 16.4, w 17.6, h 71.5 [#FFFFFF]: Card 4 body (mFLUSIVA column) (Same card styling as card 1)
- shape at x 60.7, y 14.7, w 17.6, h 4.9 [#B65379]: Card 4 header tab (Rounded top corners)
- shape at x 79.6, y 16.4, w 17.6, h 71.5 [#FFFFFF]: Card 5 body (mCOMBRIAX column) (Same card styling as card 1)
- shape at x 79.6, y 14.7, w 17.6, h 4.9 [#F37877]: Card 5 header tab (Rounded top corners)
- shape at x 4.2, y 89.5, w 8.75, h 4.1 [#FFFFFF]: Footer 'New update' tag outline (White rounded rectangle, grey #A6A6A6 outline about 1 px, corner radius about 8% of its height, slight shadow)
- icon at x 5, y 90.6, w 1.5, h 2 [#E31837]: Red arrow icon inside the New update tag (Solid right-pointing arrow)
- title at x 5.1, y 4.2, w 64.1, h 5.2 [Segoe UI Bold; font size 5.18% of slide height; #E31837; left aligned]: Infectious disease vaccines: approved products
- caption at x 0.4, y 2.4, w 1.7, h 22.9 [Segoe UI Semibold, rotated 90 degrees counter-clockwise; font size 2.96% of slide height; #FFFFFF; left aligned]: Business updates
- caption at x 0.4, y 25.4, w 1.7, h 22.9 [Segoe UI Light, rotated 90 degrees counter-clockwise; font size 2.96% of slide height; #BFE6F6; left aligned]: 3Q 2026 Update |
- logo at x 5.2, y 19.1, w 15.7, h 8.7 [#2F4858]: spikevax logo with COVID-19 Vaccine, mRNA beneath (Hexagon with red wave icon; wordmark dark slate; tagline grey)
- logo at x 24.4, y 19.4, w 14.4, h 7.3 [#00837B]: mNEXSPIKE logo with COVID-19 Vaccine, mRNA beneath (Teal hexagon with red wave icon; wordmark teal; tagline grey; position estimated)
- logo at x 44.3, y 18.5, w 12.8, h 11.3 [#77A4D9]: mRESVIA logo with (Respiratory Syncytial Virus Vaccine) beneath (Light blue hexagon with red wave icon; wordmark light blue; tagline grey)
- logo at x 61.9, y 18.8, w 15.3, h 10 [#B65379]: mFLUSIVA logo with Influenza Vaccine, mRNA beneath (Magenta ring with red wave icon; wordmark magenta; tagline grey)
- logo at x 80.5, y 18.5, w 15.7, h 13.6 [#F37877]: mCOMBRIAX logo with Influenza and COVID-19, mRNA Vaccine beneath (Coral hexagon with wave icon; wordmark coral; tagline grey)
- subtitle at x 7, y 30.3, w 11, h 4.4 [Segoe UI Semibold; font size 2.04% of slide height; #136185; center aligned]: Deliveries underway in / markets worldwide (Two lines, centred in card 1)
- body at x 7.6, y 37.6, w 12.8, h 11 [Segoe UI Light; font size 2.6% of slide height; #0D0D0D; left aligned]: XFG strain approved / in U.S., EU, Canada, / Japan, Taiwan for / 2026/2027 season (Red #E31837 arrow bullet at x 6.2%; line spacing about 3.1% of height)
- subtitle at x 24.4, y 30.3, w 15, h 7 [Segoe UI Semibold; font size 2.04% of slide height; #00837B; center aligned]: Supplying U.S., Japan, Taiwan, / Spain with planned 2028 / market expansion (Three lines, centred in card 2)
- body at x 25.9, y 37.6, w 12.9, h 11 [Segoe UI Light; font size 2.6% of slide height; #0D0D0D; left aligned]: XFG strain approved / in U.S., Canada, / Japan, Taiwan for / 2026/2027 season (Red arrow bullet at x 24.4%)
- body at x 25.9, y 54.4, w 10.7, h 5.8 [Segoe UI Light; font size 2.6% of slide height; #0D0D0D; left aligned]: Additional filings / planned for 2H26 (Black dot bullet at x 24.4%, line spacing about 3.1% of height)
- subtitle at x 44.1, y 31.5, w 13.2, h 2 [Segoe UI Semibold; font size 2.04% of slide height; #6393C0; center aligned]: Approved in 44 countries
- body at x 44.8, y 37, w 12.9, h 14 [Segoe UI Light; font size 2.6% of slide height; #000000; left aligned]: Clinical study: Safety / and immunogenicity / of revaccination / following a protein / subunit RSV vaccine1 (Red arrow bullet at x 43.4%; superscript 1 is a footnote marker at x 57.0%, y 49.4%, size 1.73% of height)
- subtitle at x 63, y 31.5, w 13.1, h 2 [Segoe UI Semibold; font size 2.04% of slide height; #B65379; center aligned]: Approved in / U.S., Canada (Two lines, centred in card 4)
- body at x 63.6, y 36.6, w 13.9, h 8.5 [Segoe UI Light; font size 2.6% of slide height; #1D2845; left aligned]: U.S. FDA approval for / adults 50-64 and / accelerated approval in / adults 65+ (Red arrow bullet at x 62.1%)
- body at x 63.6, y 51.3, w 13.7, h 8.5 [Segoe UI Light; font size 2.6% of slide height; #1D2845; left aligned]: Recommended by / AAFP for adults 65+ as / an enhanced influenza / vaccine (Red arrow bullet at x 62.1%)
- body at x 63.6, y 66, w 12.4, h 5.7 [Segoe UI Light; font size 2.6% of slide height; #1D2845; left aligned]: Approved in Canada / for adults 50+ (Red arrow bullet at x 62.1%)
- body at x 63.6, y 74.4, w 14, h 5.7 [Segoe UI Light; font size 2.6% of slide height; #1D2845; left aligned]: Under review in the EU, / Australia, and Taiwan (Black dot bullet at x 62.1%)
- subtitle at x 82.2, y 31.6, w 12.9, h 2 [Segoe UI Semibold; font size 2.04% of slide height; #FF4B4B; center aligned]: Approved in EU, Canada
- body at x 82.8, y 36.6, w 12.4, h 8.5 [Segoe UI Light; font size 2.6% of slide height; #1D2845; left aligned]: Approved in Canada / for adults 50+ under / brand name mCOFLU® (Red arrow bullet at x 81.3%; ® is a superscript mark at x 95.5%, y 42.8%, size 1.73% of height)
- body at x 82.8, y 50.4, w 12.7, h 8.5 [Segoe UI Light; font size 2.6% of slide height; #000000; left aligned]: Under review in / Japan, UK, Australia, / Switzerland (Black dot bullet at x 81.3%)
- body at x 82.8, y 64.2, w 12.7, h 8.5 [Segoe UI Light; font size 2.6% of slide height; #000000; left aligned]: Awaiting further / guidance from FDA / on refiling in the U.S. (Black dot bullet at x 81.3%)
- shape at x 86.6, y 96.7, w 12.2, h 0.4 [#2AACE2]: Thin dashed line under Moderna wordmark (Row of short cyan dashes, light blue #2AACE2)
- logo at x 86.6, y 92.2, w 12.2, h 4.9 [#E31837]: moderna wordmark logo (Lowercase red wordmark, rounded geometric sans)
- footnote at x 13.9, y 91.7, w 26.9, h 1.5 [Segoe UI; font size 1.49% of slide height; #A6A6A6; left aligned]: 1. https://www.sciencedirect.com/science/article/pii/S0264410X26008777
- body at x 6.3, y 90.9, w 4.8, h 1.7 [Segoe UI Light; font size 1.67% of slide height; #000000; left aligned]: New update
- footer at x 5.6, y 95.7, w 16.1, h 1.5 [Century Gothic; font size 1.49% of slide height; #898989; left aligned]: © 2026 Moderna, Inc. All rights reserved.
- page number at x 0.8, y 95.5, w 1.2, h 1.8 [Century Gothic Bold; font size 1.84% of slide height; #FFFFFF; left aligned]: 13

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 2.7, h 100.0: #2AACE2
- fill at x 4.2, y 14.9, w 17.3, h 5.1: #085B81
- fill at x 4.2, y 16.4, w 17.5, h 71.7: #FFFFFF
- fill at x 23.0, y 14.9, w 17.3, h 4.9: #00837B
- fill at x 23.0, y 16.4, w 17.5, h 71.5: #FFFFFF
- fill at x 41.9, y 14.9, w 17.3, h 4.9: #77A4D9
- fill at x 41.9, y 16.4, w 17.5, h 71.7: #FFFFFF
- fill at x 79.6, y 14.7, w 17.6, h 4.9: #F37877
- fill at x 79.6, y 16.4, w 17.6, h 71.5: #FFFFFF
- fill at x 60.7, y 14.7, w 17.6, h 4.9: #B65379
- fill at x 60.7, y 16.4, w 17.6, h 71.5: #FFFFFF
- image at x 80.5, y 18.5, w 15.7, h 13.6: 419 by 204 pixels
- image at x 61.9, y 18.8, w 15.3, h 10.0: 408 by 150 pixels
- image at x 44.3, y 18.5, w 12.8, h 11.3: 383 by 189 pixels
- image at x 5.2, y 19.1, w 15.7, h 8.7: 418 by 131 pixels
- image at x 86.6, y 92.2, w 12.2, h 4.9: 359 by 81 pixels
- text at x 5.1, y 4.2, w 64.1, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: Infectious disease vaccines: approved products
- text at x 0.4, y 2.4, w 1.7, h 22.9 [SegoeUI-Semibold; font size 2.96; #FFFFFF]: Business updates
- text at x 0.4, y 25.4, w 1.7, h 22.9 [SegoeUI-Light; font size 2.96; #BFE6F6]: 3Q 2026 Update |
- text at x 43.4, y 37.0, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 44.8, y 37.0, w 12.7, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Clinical study: Safety
- text at x 62.1, y 36.6, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 63.6, y 36.6, w 12.8, h 2.6 [SegoeUI-Light; font size 2.60; #1D2845]: U.S. FDA approval for
- text at x 81.3, y 36.6, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 82.8, y 36.6, w 12.4, h 2.6 [SegoeUI-Light; font size 2.60; #1D2845]: Approved in Canada
- text at x 6.2, y 37.6, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 7.6, y 37.6, w 12.8, h 2.6 [SegoeUI-Light; font size 2.60; #0D0D0D]: XFG strain approved
- text at x 7.0, y 30.3, w 12.1, h 2.0 [SegoeUI-Semibold; font size 2.04; #136185]: Deliveries underway in
- text at x 24.4, y 30.3, w 15.0, h 2.0 [SegoeUI-Semibold; font size 2.04; #00837B]: Supplying U.S., Japan, Taiwan,
- text at x 7.6, y 40.7, w 12.4, h 2.6 [SegoeUI-Light; font size 2.60; #0D0D0D]: in U.S., EU, Canada,
- text at x 24.4, y 39.7, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 25.9, y 39.7, w 12.9, h 2.6 [SegoeUI-Light; font size 2.60; #0D0D0D]: XFG strain approved
- text at x 44.1, y 31.5, w 13.2, h 2.0 [SegoeUI-Semibold; font size 2.04; #6393C0]: Approved in 44 countries
- text at x 44.8, y 40.1, w 12.9, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: and immunogenicity
- text at x 63.0, y 31.5, w 6.8, h 2.0 [SegoeUI-Semibold; font size 2.04; #B65379]: Approved in
- text at x 63.6, y 39.7, w 10.2, h 2.6 [SegoeUI-Light; font size 2.60; #1D2845]: adults 50-64 and
- text at x 69.7, y 31.5, w 6.4, h 2.0 [SegoeUI-Semibold; font size 2.04; #B65379]: U.S., Canada
- text at x 82.2, y 31.6, w 12.9, h 2.0 [SegoeUI-Semibold; font size 2.04; #FF4B4B]: Approved in EU, Canada
- text at x 82.8, y 39.7, w 12.4, h 2.6 [SegoeUI-Light; font size 2.60; #1D2845]: for adults 50+ under
- text at x 7.9, y 32.7, w 9.9, h 2.0 [SegoeUI-Semibold; font size 2.04; #136185]: markets worldwide
- text at x 25.7, y 32.7, w 12.4, h 2.0 [SegoeUI-Semibold; font size 2.04; #00837B]: Spain with planned 2028
- text at x 25.9, y 42.8, w 10.0, h 2.6 [SegoeUI-Light; font size 2.60; #0D0D0D]: in U.S., Canada,
- text at x 44.8, y 43.2, w 10.0, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: of revaccination
- text at x 63.6, y 42.8, w 13.9, h 2.6 [SegoeUI-Light; font size 2.60; #1D2845]: accelerated approval in
- text at x 82.8, y 42.8, w 12.8, h 2.6 [SegoeUI-Light; font size 2.60; #1D2845]: brand name mCOFLU
- text at x 7.6, y 43.8, w 10.7, h 2.6 [SegoeUI-Light; font size 2.60; #0D0D0D]: Japan, Taiwan for
- text at x 27.4, y 35.2, w 8.8, h 2.0 [SegoeUI-Semibold; font size 2.04; #00837B]: market expansion
- text at x 25.9, y 45.9, w 10.7, h 2.6 [SegoeUI-Light; font size 2.60; #0D0D0D]: Japan, Taiwan for
- text at x 63.6, y 46.0, w 6.2, h 2.6 [SegoeUI-Light; font size 2.60; #1D2845]: adults 65+
- text at x 7.6, y 47.0, w 11.1, h 2.6 [SegoeUI-Light; font size 2.60; #0D0D0D]: 2026/2027 season
- text at x 44.8, y 46.4, w 11.8, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: following a protein
- text at x 25.9, y 49.0, w 11.6, h 2.6 [SegoeUI-Light; font size 2.60; #0D0D0D]: 2026/2027 season
- text at x 44.8, y 49.5, w 12.2, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: subunit RSV vaccine
- text at x 62.1, y 51.3, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 63.6, y 51.3, w 11.2, h 2.6 [SegoeUI-Light; font size 2.60; #1D2845]: Recommended by
- text at x 81.3, y 50.4, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 82.8, y 50.4, w 10.0, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Under review in
- text at x 82.8, y 53.5, w 12.7, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Japan, UK, Australia,
- text at x 24.4, y 54.4, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 25.9, y 54.4, w 10.5, h 2.6 [SegoeUI-Light; font size 2.60; #0D0D0D]: Additional filings
- text at x 63.6, y 54.4, w 13.7, h 2.6 [SegoeUI-Light; font size 2.60; #1D2845]: AAFP for adults 65+ as
- text at x 25.9, y 57.5, w 10.7, h 2.6 [SegoeUI-Light; font size 2.60; #0D0D0D]: planned for 2H26
- text at x 63.6, y 57.5, w 13.5, h 2.6 [SegoeUI-Light; font size 2.60; #1D2845]: an enhanced influenza
- text at x 82.8, y 56.6, w 7.0, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Switzerland
- text at x 63.6, y 60.6, w 4.3, h 2.6 [SegoeUI-Light; font size 2.60; #1D2845]: vaccine
- text at x 81.3, y 64.2, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 82.8, y 64.2, w 10.2, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Awaiting further
- text at x 95.5, y 42.8, w 0.9, h 1.7 [SegoeUI-Semibold; font size 1.73; #000000]: ®
- text at x 62.1, y 66.0, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 63.6, y 66.0, w 12.4, h 2.6 [SegoeUI-Light; font size 2.60; #1D2845]: Approved in Canada
- text at x 82.8, y 67.3, w 12.2, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: guidance from FDA
- text at x 63.6, y 69.1, w 8.1, h 2.6 [SegoeUI-Light; font size 2.60; #1D2845]: for adults 50+
- text at x 82.8, y 70.4, w 12.7, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: on refiling in the U.S.
- text at x 57.0, y 49.4, w 0.3, h 1.7 [SegoeUI-Light; font size 1.73; #000000]: 1
- text at x 62.1, y 74.4, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 63.6, y 74.4, w 14.0, h 2.6 [SegoeUI-Light; font size 2.60; #1D2845]: Under review in the EU,
- text at x 63.6, y 77.5, w 12.0, h 2.6 [SegoeUI-Light; font size 2.60; #1D2845]: Australia, and Taiwan
- text at x 0.8, y 95.5, w 1.2, h 1.8 [CenturyGothic-Bold; font size 1.84; #FFFFFF]: 13
- text at x 6.3, y 90.9, w 4.8, h 1.7 [SegoeUI-Light; font size 1.67; #000000]: New update
- text at x 13.9, y 91.7, w 26.9, h 1.5 [SegoeUI; font size 1.49; #A6A6A6]: 1. https://www.sciencedirect.com/science/article/pii/S0264410X26008777
- text at x 5.6, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #898989]: © 2026 Moderna, Inc. All rights reserved.

### Slide 14

**Review notes**

- Worth studying: Large figures for each vaccine category are paired with a small year-over-year comparison, so the market message is carried by the numbers themselves.
- Review: The detailed slides are well made: slide 8 has a clean stacked chart with a takeaway title and three short bullets, and slide 14 has a clear paired-bar chart with a highlighted +3% total.
- Worth keeping: Keep the section-tag system, the highlighted agenda dividers, and the takeaway headlines with chart plus short commentary as on slides 8 and 14.

**Text**

Business updates / 3Q 2026 Update | / U.S. respiratory vaccination demand remains resilient / U.S. retail + LTC respiratory vaccines market remains stable / Season-to-date through October 30, 2026 | Retail + LTC / Flu / 27.0M / 29.1M / COVID-19 / 14.5M / 14.0M / RSV / 1.3M / 1.0M / All / respiratory / vaccines / 42.9M / 44.1M / +3% / 2025/26 season as of 10/31/25* / 2026/27 season as of 10/30/26 / Totals may differ due to rounding / *Prior-year date assumes the corresponding reporting week / Strong momentum / Robust flu and COVID-19 activity / continues into late October, / bringing total respiratory / vaccinations closer to 2025/26 / season levels / Source: IQVIA, retail + LTC shots in arms, week ending October 30, 2026. Rounded values. / © 2026 Moderna, Inc. All rights reserved. / 14 / (Moderna logo)

**Layout**

Two-column layout on a white field: a left data column spanning roughly 5% to 59% of the width holding a grouped horizontal bar chart, and a right text column starting at about 68% of the width, separated by a thin vertical grey rule at about 64% of the width. The title sits top-left at about 4% from the top, left-aligned at about 5% from the left edge, with a narrow full-height blue band along the left edge (0 to 2.7% width) carrying the rotated section label 'Business updates' and '3Q 2026 Update |'. The footer (source line and copyright) is left-aligned at about 5.5% from the left, the slide number '14' sits in the blue band near the bottom, and the Moderna logo is bottom-right at about 87% from the left.

**Visuals**

Chart: grouped horizontal bar chart, titled 'U.S. retail + LTC respiratory vaccines market remains stable', season-to-date through October 30, 2026, Retail + LTC. Categories top to bottom: Flu, COVID-19, RSV, All respiratory vaccines. Two series per category: light blue bar = 2025/26 season as of 10/31/25* (#BDE5F3), dark blue bar = 2026/27 season as of 10/30/26 (#2AACE2). Printed values: Flu 27.0M (2025/26) and 29.1M (2026/27); COVID-19 14.5M and 14.0M; RSV 1.3M and 1.0M; All respiratory vaccines 42.9M and 44.1M. No axis, axis ticks or gridlines are printed; bar lengths are roughly proportional to values (about 1.1% of slide width per million). The All respiratory vaccines row is highlighted with a light grey band and shows a red callout '+3%' to its right. Horizontal dark grey rules separate Flu, COVID-19 and RSV rows; no rule under RSV. Legend below the chart: light blue square with '2025/26 season as of 10/31/25*' and dark blue square with '2026/27 season as of 10/30/26'. Logo: Moderna wordmark in red lowercase with a row of short cyan dashes beneath it.

**Design**

Background: Solid white #FFFFFF. Clean corporate white design. Background white #FFFFFF. Vertical blue band #2AACE2 along the left edge, full height. Title in bold red #E31837. Chart heading in semibold navy #1E2948. Subtitle and source in light grey-blue #687381. Chart row labels in cyan #2AACE2 (Flu, COVID-19, RSV) and navy #1E2948 (All respiratory vaccines). Chart values in semibold navy #1E2948 and black. Callout +3% in bold red #ED1237. Right-column heading 'Strong momentum' in semibold black #000000 and body in light black #000000. Typefaces: Segoe UI family (Bold for title, Semibold for headings and labels, Light for subtitle, body and source), sans-serif; slide-number and copyright in Century Gothic. Title size about 5.2% of slide height; chart heading about 3.3%; body and labels about 2.4 to 3.3%; footnotes about 1.7%. Thin grey rules #3A3A3A-like, 1 px. Square corners on bars and highlight band; no shadows or gradients.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: Full-slide white background rectangle (Covers the slide, no border)
- shape at x 0, y 0, w 2.7, h 100 [#2AACE2]: Left vertical blue band (Solid fill, no border, square corners)
- text at x 0.4, y 2.4, w 1.7, h 22.9 [Segoe UI Semibold, rotated 270 degrees, reading upward; font size 2.96% of slide height; #FFFFFF; center aligned]: Business updates
- text at x 0.4, y 25.4, w 1.7, h 22.9 [Segoe UI Light, rotated 270 degrees, reading upward; font size 2.96% of slide height; #BFE6F6; center aligned]: 3Q 2026 Update |
- text at x 0.8, y 95.5, w 1.2, h 1.8 [Century Gothic Bold; font size 1.84% of slide height; #FFFFFF; left aligned]: CenturyGothic-Bold page number
- text at x 0.8, y 95.5, w 1.2, h 1.8 [Century Gothic Bold; font size 1.84% of slide height; #FFFFFF; left aligned]: 14
- title at x 5.1, y 4.2, w 73.2, h 5.2 [Segoe UI Bold, regular case, no letter-spacing change; font size 5.18% of slide height; #E31837; left aligned]: U.S. respiratory vaccination demand remains resilient
- shape at x 5.5, y 61.3, w 52.9, h 11.7 [#EEEEF0]: Grey highlight band behind the All respiratory vaccines row (Solid fill, no border, square corners)
- line at x 5.5, y 29, w 52.9, h 0.1 [#3A3A3A]: Horizontal rule above Flu row (1 px dark grey stroke)
- line at x 5.5, y 39.6, w 52.9, h 0.1 [#3A3A3A]: Horizontal rule between Flu and COVID-19 rows (1 px dark grey stroke)
- line at x 5.5, y 50.3, w 52.9, h 0.1 [#3A3A3A]: Horizontal rule between COVID-19 and RSV rows (1 px dark grey stroke)
- line at x 64.2, y 18.8, w 0.1, h 64 [#BFBFBF]: Vertical divider between chart and right column (1 px light grey stroke)
- text at x 5.5, y 18.6, w 50, h 3.3 [Segoe UI Semibold; font size 3.33% of slide height; #1E2948; left aligned]: U.S. retail + LTC respiratory vaccines market remains stable
- text at x 5.5, y 23.4, w 28.1, h 2.1 [Segoe UI Light; font size 2.13% of slide height; #687381; left aligned]: Season-to-date through October 30, 2026 | Retail + LTC
- text at x 13.1, y 33.8, w 2.1, h 2.8 [Segoe UI Semibold; font size 2.78% of slide height; #2AACE2; right aligned]: Flu
- shape at x 17.1, y 32.5, w 18.6, h 1.8 [#BDE5F3]: Flu 2025/26 bar (27.0M) (Solid fill, square ends)
- shape at x 17.1, y 35.1, w 20, h 1.8 [#2AACE2]: Flu 2026/27 bar (29.1M) (Solid fill, square ends)
- text at x 36.3, y 32.6, w 3.8, h 2.4 [Segoe UI Semibold; font size 2.4% of slide height; #1E2948; left aligned]: 27.0M
- text at x 37.8, y 35.4, w 3.6, h 2.4 [Segoe UI Semibold; font size 2.4% of slide height; #1E2948; left aligned]: 29.1M
- text at x 8.4, y 44.2, w 6.8, h 2.8 [Segoe UI Semibold; font size 2.78% of slide height; #2AACE2; right aligned]: COVID-19
- shape at x 17.1, y 42.9, w 10, h 1.8 [#BDE5F3]: COVID-19 2025/26 bar (14.5M) (Solid fill, square ends)
- shape at x 17.1, y 45.8, w 9.6, h 1.8 [#2AACE2]: COVID-19 2026/27 bar (14.0M) (Solid fill, square ends)
- text at x 27.8, y 43, w 3.6, h 2.4 [Segoe UI Semibold; font size 2.4% of slide height; #1E2948; left aligned]: 14.5M
- text at x 27.4, y 45.8, w 3.6, h 2.4 [Segoe UI Semibold; font size 2.4% of slide height; #1E2948; left aligned]: 14.0M
- text at x 12.4, y 54.7, w 2.8, h 2.8 [Segoe UI Semibold; font size 2.78% of slide height; #2AACE2; right aligned]: RSV
- shape at x 17.1, y 53.8, w 0.9, h 1.8 [#BDE5F3]: RSV 2025/26 bar (1.3M) (Solid fill, square ends)
- shape at x 17.1, y 56.4, w 0.7, h 1.8 [#2AACE2]: RSV 2026/27 bar (1.0M) (Solid fill, square ends)
- text at x 18.4, y 53.6, w 2.9, h 2.4 [Segoe UI Semibold; font size 2.4% of slide height; #000000; left aligned]: 1.3M (Visible label. A second hidden text line reading 1.30M (color #1E2948, same position) sits under it in the file.)
- text at x 18.2, y 56.5, w 2.9, h 2.4 [Segoe UI Semibold; font size 2.4% of slide height; #000000; left aligned]: 1.0M (Visible label. A second hidden text line reading 1.00M (color #1E2948, same position) sits under it in the file.)
- text at x 13.4, y 63, w 2.3, h 2.8 [Segoe UI Semibold; font size 2.78% of slide height; #1E2948; right aligned]: All
- text at x 7.5, y 66, w 7.7, h 2.8 [Segoe UI Semibold; font size 2.78% of slide height; #1E2948; right aligned]: respiratory
- text at x 9.4, y 69, w 5.9, h 2.8 [Segoe UI Semibold; font size 2.78% of slide height; #1E2948; right aligned]: vaccines
- shape at x 17.1, y 65.1, w 29.5, h 2 [#BDE5F3]: All respiratory vaccines 2025/26 bar (42.9M) (Solid fill, square ends)
- shape at x 17.1, y 68, w 30.4, h 2 [#27AADE]: All respiratory vaccines 2026/27 bar (44.1M) (Solid fill, square ends)
- text at x 47.1, y 64.8, w 3.8, h 2.4 [Segoe UI Semibold; font size 2.4% of slide height; #000000; left aligned]: 42.9M
- text at x 47.4, y 67.9, w 3.7, h 2.4 [Segoe UI Semibold; font size 2.4% of slide height; #000000; left aligned]: 44.1M
- text at x 52.6, y 66, w 4.5, h 3.7 [Segoe UI Bold; font size 3.71% of slide height; #ED1237; left aligned]: +3%
- shape at x 5.5, y 75.1, w 1.2, h 1.2 [#BDE5F3]: Legend swatch, 2025/26 season (Solid square, no border)
- text at x 7.3, y 75.1, w 16, h 2 [Segoe UI Regular; font size 2.04% of slide height; #646464; left aligned]: 2025/26 season as of 10/31/25*
- shape at x 5.5, y 78.2, w 1.2, h 1.9 [#2AACE2]: Legend swatch, 2026/27 season (Solid square, no border)
- text at x 7.3, y 78.5, w 15.6, h 2 [Segoe UI Regular; font size 2.04% of slide height; #646464; left aligned]: 2026/27 season as of 10/30/26
- text at x 5.5, y 83.7, w 13.9, h 1.7 [Segoe UI Regular; font size 1.67% of slide height; #A6A6A6; left aligned]: Totals may differ due to rounding
- text at x 5.5, y 86.4, w 24.7, h 1.7 [Segoe UI Regular; font size 1.67% of slide height; #A6A6A6; left aligned]: *Prior-year date assumes the corresponding reporting week
- text at x 68.3, y 37.5, w 16.1, h 3.3 [Segoe UI Semibold; font size 3.33% of slide height; #000000; left aligned]: Strong momentum
- body at x 68.3, y 41.5, w 26, h 14 [Segoe UI Light; font size 3.33% of slide height; #000000; left aligned]: Robust flu and COVID-19 activity / continues into late October, / bringing total respiratory / vaccinations closer to 2025/26 / season levels (Line spacing about 1.2; five lines, each on its own line)
- text at x 5.5, y 93, w 35.3, h 1.7 [Segoe UI Light; font size 1.67% of slide height; #687381; left aligned]: Source: IQVIA, retail + LTC shots in arms, week ending October 30, 2026. Rounded values.
- footer at x 5.6, y 95.7, w 16.1, h 1.5 [Century Gothic Regular; font size 1.49% of slide height; #898989; left aligned]: © 2026 Moderna, Inc. All rights reserved.
- logo at x 86.6, y 92.2, w 12.2, h 4.9: Moderna wordmark logo in red with a row of cyan dashes beneath (Placed image, 359 by 81 pixels, no background box)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 2.7, h 100.0: #2AACE2
- fill at x 5.5, y 61.3, w 52.9, h 11.7: #EEEEF0
- fill at x 17.1, y 65.1, w 29.5, h 2.0: #BDE5F3
- fill at x 17.1, y 68.0, w 30.4, h 2.0: #27AADE
- fill at x 17.1, y 64.7, w 29.4, h 2.4: #BFE6F6
- fill at x 17.1, y 67.8, w 29.9, h 2.4: #2AACE2
- image at x 86.6, y 92.2, w 12.2, h 4.9: 359 by 81 pixels
- text at x 5.1, y 4.2, w 73.2, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: U.S. respiratory vaccination demand remains resilient
- text at x 0.4, y 2.4, w 1.7, h 22.9 [SegoeUI-Semibold; font size 2.96; #FFFFFF]: Business updates
- text at x 5.5, y 18.6, w 50.0, h 3.3 [SegoeUI-Semibold; font size 3.33; #1E2948]: U.S. retail + LTC respiratory vaccines market remains stable
- text at x 5.5, y 23.4, w 28.1, h 2.1 [SegoeUI-Light; font size 2.13; #687381]: Season-to-date through October 30, 2026 | Retail + LTC
- text at x 68.3, y 37.5, w 16.1, h 3.3 [SegoeUI-Semibold; font size 3.33; #000000]: Strong momentum
- text at x 0.4, y 25.4, w 1.7, h 22.9 [SegoeUI-Light; font size 2.96; #BFE6F6]: 3Q 2026 Update |
- text at x 13.1, y 33.8, w 2.1, h 2.8 [SegoeUI-Semibold; font size 2.78; #2AACE2]: Flu
- text at x 68.3, y 41.5, w 26.0, h 3.3 [SegoeUI-Light; font size 3.33; #000000]: Robust flu and COVID-19 activity
- text at x 36.3, y 32.6, w 3.8, h 2.4 [SegoeUI-Semibold; font size 2.40; #1E2948]: 27.0M
- text at x 68.3, y 45.5, w 22.1, h 3.3 [SegoeUI-Light; font size 3.34; #000000]: continues into late October,
- text at x 37.8, y 35.4, w 3.6, h 2.4 [SegoeUI-Semibold; font size 2.40; #1E2948]: 29.1M
- text at x 68.3, y 49.5, w 20.0, h 3.3 [SegoeUI-Light; font size 3.33; #000000]: bringing total respiratory
- text at x 8.4, y 44.2, w 6.8, h 2.8 [SegoeUI-Semibold; font size 2.78; #2AACE2]: COVID-19
- text at x 68.3, y 53.5, w 24.2, h 3.3 [SegoeUI-Light; font size 3.33; #000000]: vaccinations closer to 2025/26
- text at x 68.3, y 57.5, w 10.1, h 3.3 [SegoeUI-Light; font size 3.33; #000000]: season levels
- text at x 27.8, y 43.0, w 3.6, h 2.4 [SegoeUI-Semibold; font size 2.40; #1E2948]: 14.5M
- text at x 52.6, y 66.0, w 4.5, h 3.7 [SegoeUI-Bold; font size 3.71; #ED1237]: +3%
- text at x 27.4, y 45.8, w 3.6, h 2.4 [SegoeUI-Semibold; font size 2.40; #1E2948]: 14.0M
- text at x 12.4, y 54.7, w 2.8, h 2.8 [SegoeUI-Semibold; font size 2.78; #2AACE2]: RSV
- text at x 13.4, y 63.0, w 2.3, h 2.8 [SegoeUI-Semibold; font size 2.78; #1E2948]: All
- text at x 18.4, y 53.6, w 2.9, h 2.4 [SegoeUI-Semibold; font size 2.40; #000000]: 1.3M
- text at x 18.6, y 53.7, w 3.6, h 2.4 [SegoeUI-Semibold; font size 2.40; #1E2948]: 1.30M
- text at x 18.2, y 56.5, w 2.9, h 2.4 [SegoeUI-Semibold; font size 2.40; #000000]: 1.0M
- text at x 18.4, y 56.6, w 3.6, h 2.4 [SegoeUI-Semibold; font size 2.40; #1E2948]: 1.00M
- text at x 7.5, y 66.0, w 7.7, h 2.8 [SegoeUI-Semibold; font size 2.78; #1E2948]: respiratory
- text at x 9.4, y 69.0, w 5.9, h 2.8 [SegoeUI-Semibold; font size 2.78; #1E2948]: vaccines
- text at x 47.1, y 64.8, w 3.8, h 2.4 [SegoeUI-Semibold; font size 2.40; #000000]: 42.9M
- text at x 47.4, y 67.9, w 3.7, h 2.4 [SegoeUI-Semibold; font size 2.40; #000000]: 44.1M
- text at x 7.3, y 75.1, w 16.0, h 2.0 [SegoeUI; font size 2.04; #646464]: 2025/26 season as of 10/31/25*
- text at x 7.3, y 78.5, w 15.6, h 2.0 [SegoeUI; font size 2.04; #646464]: 2026/27 season as of 10/30/26
- text at x 5.5, y 83.7, w 13.9, h 1.7 [SegoeUI; font size 1.67; #A6A6A6]: Totals may differ due to rounding
- text at x 0.8, y 95.5, w 1.2, h 1.8 [CenturyGothic-Bold; font size 1.84; #FFFFFF]: 14
- text at x 5.5, y 86.4, w 24.7, h 1.7 [SegoeUI; font size 1.67; #A6A6A6]: *Prior-year date assumes the corresponding reporting week
- text at x 5.5, y 93.0, w 35.3, h 1.7 [SegoeUI-Light; font size 1.67; #687381]: Source: IQVIA, retail + LTC shots in arms, week ending October 30, 2026. Rounded values.
- text at x 5.6, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #898989]: © 2026 Moderna, Inc. All rights reserved.

### Slide 15

**Review notes**

- Review: Several pages are sparse or poorly filled, such as slide 23 with two near-empty cards, slide 15 and slide 32, and the agenda is repeated five times.

**Text**

Infectious disease vaccines: late-stage pipeline
Business updates
3Q 2026 Update |
Norovirus
mRNA-1403
In Phase 3
•
Phase 3 interim analysis
did not meet statistical
criteria for early success
Moderna has decided not
to enroll an additional
cohort this season
Company is engaging
Health Authorities to
determine next steps for
the program
New update
15
© 2026 Moderna, Inc. All rights reserved.
moderna

**Layout**

Single-column composition on a white slide with a full-height vertical blue band at the left edge (about 2.7% of slide width) carrying the rotated section label and page number. The title sits top-left at about 5% from the left edge and 4% from the top, left-aligned. A single white card with a red top cap is centred horizontally in the middle-right area (x 35.7% to 55.7%) and starts about 17% from the top, leaving the left and right thirds empty. The footer has a 'New update' tag at bottom-left, a copyright line beneath it, and the Moderna logo at bottom-right, with the page number in the blue band at bottom-left.

**Visuals**

No charts, tables or photographs. Three non-text graphic elements: (1) a card, a white rounded rectangle with a thin light-grey outline and a soft shadow, with a solid red #E31837 cap across its top edge; the card has a pale pink #FACED4 tag bar reading 'In Phase 3' and contains three bullet items. (2) Three red #E31837 right-pointing block arrow icons: two sit as bullet markers beside the second and third bullet items in the card, and one sits inside the 'New update' box at bottom-left. The first bullet item uses a plain black round bullet. (3) The Moderna logo at bottom-right: the lowercase red #E31837 wordmark 'moderna' with a small registered mark, above a row of short dashed cyan-blue (#2AACE2-like) line segments. The logo is a placed raster image, 359 by 81 pixels, not cropped.

**Design**

Background: Solid white #FFFFFF. Clean white background with a saturated sky-blue #2AACE2 vertical band on the left. Title text is red #E31837 in Segoe UI Bold, about 5.2% of slide height, sentence case. Body text is black #000000 in Segoe UI Light about 2.6% of slide height. Band text is white #FFFFFF Segoe UI Semibold for the section label and light blue #BFE6F6 Segoe UI Light for the second label line; page number is white CenturyGothic Bold. Accent colour is red #E31837 with pale pink #FACED4 tag fill. Card has rounded corners of roughly 3% of slide width, a red top cap, and a faint grey shadow. Footer copyright is grey #898989 CenturyGothic about 1.5% of slide height. No gradients.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: Full-slide white background fill (Covers the entire slide, no outline.)
- shape at x 0, y 0, w 2.7, h 100 [#2AACE2]: Vertical left band in sky blue (Full slide height, square corners, no outline; holds the rotated band text and the page number.)
- shape at x 35.7, y 17.3, w 20, h 5.1 [#E31837]: Card top cap in red (Rounded top corners matching the card, overlapping the top of the white card body beneath it.)
- shape at x 35.7, y 19, w 20, h 69.5 [#FFFFFF]: Card body, white rounded rectangle (Corner radius about 3% of slide width at the bottom and top, thin light-grey outline about 0.1% of slide width, faint soft drop shadow, opacity 100%.)
- shape at x 37.4, y 31, w 16.8, h 4 [#FACED4]: Tag bar behind 'In Phase 3' (Flat rectangle, square corners, no outline.)
- title at x 5.2, y 4.1, w 63.6, h 5.2 [Segoe UI Bold; font size 5.18% of slide height; #E31837; left aligned]: Infectious disease vaccines: late-stage pipeline (Single line, sentence case, normal tracking.)
- body at x 0.4, y 2.4, w 1.7, h 22.9 [Segoe UI Semibold; font size 2.96% of slide height; #FFFFFF; center aligned]: Business updates (Rotated 270 degrees so it reads bottom to top, sitting in the blue band.)
- body at x 0.4, y 25.4, w 1.7, h 22.9 [Segoe UI Light; font size 2.96% of slide height; #BFE6F6; center aligned]: 3Q 2026 Update | (Rotated 270 degrees so it reads bottom to top, placed directly below the first band label.)
- subtitle at x 40.4, y 21.5, w 10.7, h 4.1 [Segoe UI Bold; font size 4.07% of slide height; #E31837; center aligned]: Norovirus (Single line, centred on the card.)
- subtitle at x 42.1, y 26.2, w 7.4, h 2.6 [Segoe UI Light; font size 2.6% of slide height; #E31837; center aligned]: mRNA-1403 (Single line, centred on the card.)
- body at x 42.9, y 32, w 5.8, h 2.2 [Segoe UI Semibold; font size 2.22% of slide height; #E31837; center aligned]: In Phase 3 (Set on the pale pink tag bar.)
- icon at x 37.6, y 38.3, w 0.9, h 2.6 [CenturyGothic; font size 2.6% of slide height; #000000; left aligned]: Black round bullet marker for the first item (Bullet character, black, aligned with the first line of the first item.)
- bullet list at x 39, y 38.3, w 14.8, h 8.8 [Segoe UI Light; font size 2.6% of slide height; #000000; left aligned]: Phase 3 interim analysis / did not meet statistical / criteria for early success (Three lines with line spacing about 3.1% of slide height, first item of three bullets.)
- icon at x 37.3, y 50, w 1.6, h 1.8 [#E31837]: Red right-pointing block arrow marker for the second item (Solid filled block arrow, no outline.)
- bullet list at x 39, y 49.9, w 16.2, h 8.8 [Segoe UI Light; font size 2.6% of slide height; #000000; left aligned]: Moderna has decided not / to enroll an additional / cohort this season (Three lines with line spacing about 3.1% of slide height, second item.)
- icon at x 37.3, y 61.7, w 1.6, h 1.8 [#E31837]: Red right-pointing block arrow marker for the third item (Solid filled block arrow, no outline.)
- bullet list at x 39, y 61.4, w 15.2, h 12 [Segoe UI Light; font size 2.6% of slide height; #000000; left aligned]: Company is engaging / Health Authorities to / determine next steps for / the program (Four lines with line spacing about 3.1% of slide height, third item.)
- shape at x 6.2, y 89.5, w 8.2, h 4.1 [#FFFFFF]: New update tag box (White rounded rectangle, corner radius about 0.5% of slide width, thin grey #A6A6A6 outline about 0.1% of slide width.)
- icon at x 6.4, y 90.8, w 1, h 1.7 [#E31837]: Red right-pointing block arrow inside New update box (Solid filled block arrow, no outline.)
- caption at x 7.8, y 90.9, w 4.8, h 1.7 [Segoe UI Light; font size 1.67% of slide height; #000000; left aligned]: New update (Single line inside the tag box, to the right of the arrow icon.)
- page number at x 0.8, y 95.5, w 1.2, h 1.8 [CenturyGothic Bold; font size 1.84% of slide height; #FFFFFF; left aligned]: 15 (Sits on the sky-blue band at bottom-left.)
- footer at x 5.6, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49% of slide height; #898989; left aligned]: © 2026 Moderna, Inc. All rights reserved. (Single line below the New update tag.)
- logo at x 86.6, y 92.2, w 12.2, h 4.9 [#E31837]: Moderna logo: lowercase red wordmark moderna with a registered mark, above a row of short dashed cyan-blue line segments (Placed raster image 359 by 81 pixels, not cropped, no background box, bottom-right corner.)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 2.7, h 100.0: #2AACE2
- fill at x 35.7, y 17.3, w 20.0, h 5.1: #E31837
- fill at x 35.7, y 19.0, w 20.0, h 69.5: #FFFFFF
- fill at x 37.4, y 31.0, w 16.8, h 4.0: #FACED4
- image at x 86.6, y 92.2, w 12.2, h 4.9: 359 by 81 pixels
- text at x 5.2, y 4.1, w 63.6, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: Infectious disease vaccines: late-stage pipeline
- text at x 0.4, y 2.4, w 1.7, h 22.9 [SegoeUI-Semibold; font size 2.96; #FFFFFF]: Business updates
- text at x 40.4, y 21.5, w 10.7, h 4.1 [SegoeUI-Bold; font size 4.07; #E31837]: Norovirus
- text at x 42.1, y 26.2, w 7.4, h 2.6 [SegoeUI-Light; font size 2.60; #E31837]: mRNA-1403
- text at x 0.4, y 25.4, w 1.7, h 22.9 [SegoeUI-Light; font size 2.96; #BFE6F6]: 3Q 2026 Update |
- text at x 37.6, y 38.3, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 39.0, y 38.3, w 14.8, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Phase 3 interim analysis
- text at x 42.9, y 32.0, w 5.8, h 2.2 [SegoeUI-Semibold; font size 2.22; #E31837]: In Phase 3
- text at x 39.0, y 41.4, w 14.1, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: did not meet statistical
- text at x 39.0, y 44.5, w 14.4, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: criteria for early success
- text at x 37.6, y 49.9, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 39.0, y 49.9, w 16.2, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Moderna has decided not
- text at x 39.0, y 53.0, w 13.8, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: to enroll an additional
- text at x 39.0, y 56.1, w 11.1, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: cohort this season
- text at x 37.6, y 61.4, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 39.0, y 61.4, w 13.8, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Company is engaging
- text at x 39.0, y 64.5, w 13.0, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Health Authorities to
- text at x 39.0, y 67.6, w 15.2, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: determine next steps for
- text at x 39.0, y 70.8, w 7.7, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: the program
- text at x 0.8, y 95.5, w 1.2, h 1.8 [CenturyGothic-Bold; font size 1.84; #FFFFFF]: 15
- text at x 7.8, y 90.9, w 4.8, h 1.7 [SegoeUI-Light; font size 1.67; #000000]: New update
- text at x 5.6, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #898989]: © 2026 Moderna, Inc. All rights reserved.

### Slide 16

**Text**

3Q26 earnings call agenda / Business Review / Stéphane Bancel, CEO / Financials / Jamey Mock, CFO / Business updates / Stephen Hoge, M.D., President / Pipeline updates / David Berman, M.D., Ph.D., Chief Development Officer / Looking Ahead / Stéphane Bancel, CEO / © 2026 Moderna, Inc. All rights reserved.

**Layout**

A full-height saturated sky-blue sidebar occupies the left 19.4% of the slide, with the content area to its right on white. The title sits top-left of the content area at about 4.6% from the top, left-aligned at x 21.6%. Five agenda rows run down the content area as icon-plus-text pairs: each grey outlined circle icon sits at x about 23.2%, with a bold navy heading and a light black speaker line beside it at x about 31%. The fourth row (Pipeline updates) is boxed by a red rounded rectangle and its heading is set in sky blue. The copyright line sits bottom-left inside the sidebar, and the Moderna logo sits bottom-right near the edge; there is no slide number visible.

**Visuals**

Five grey outlined line icons in circles and one red-outlined icon in a circle. Icon 1 (Business Review): a grey circle containing a grey wavy curve with small tick marks, like a smoothed line trend. Icon 2 (Financials): a grey circle containing a grey dashboard window with a small bar chart and a pie-slice clock symbol. Icon 3 (Business updates): a grey circle containing three diagonal grey test tubes or pipettes stacked in parallel. Icon 4 (Pipeline updates): a red (#E21D39) circle outline containing a sky-blue microscope with a red hexagonal molecule cluster to its right and a blue stage base. Icon 5 (Looking Ahead): a grey circle containing two rows of rounded boxes each followed by an outlined right-pointing arrow. Circles are about 4.8% of slide width and have a light grey (#C0C0C0) stroke, no fill. The Pipeline row is outlined by a red (#E21D39) rounded rectangle stroke about 0.5% of slide height thick with a transparent interior. The Moderna logo is a red (#E31837) lowercase wordmark 'moderna' with a registered mark, above a row of short sky-blue dashes.

**Design**

Background: Solid white #FFFFFF with a sky-blue #2AACE2 vertical band covering the left 19.4% of the slide. Plain white background with a sky-blue (#2AACE2) left sidebar. Title is Segoe UI Bold in red #E31837, about 5.2% of slide height. Headings are Segoe UI Bold in navy #1E2846 at about 3.7% of slide height; the highlighted heading is sky blue #2AACE2. Speaker lines are Segoe UI Light in black #000000 at about 3.0% of slide height. Footer copyright is Century Gothic in white #FFFFFF at about 1.5% of slide height. Lines are thin light-grey circle strokes; the red highlight box has rounded corners of roughly 1.5% of slide height radius, a solid red stroke, no fill and no shadow. No gradients or shadows.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 19.4, h 100 [#2AACE2]: Left sidebar filled rectangle, full height, covering the left edge of the slide (Solid fill, no outline, no shadow, square corners)
- shape at x 21, y 61, w 57.5, h 14 [#E21D39]: Red highlight rounded rectangle around the Pipeline updates row (No fill, solid stroke #E21D39 about 0.5% of slide height wide, corner radius about 1.5% of slide height, overlaps the fourth icon and heading)
- icon at x 23.2, y 16.7, w 4.8, h 8.6 [#C0C0C0]: Business Review icon: grey wavy curve with tick marks inside a circle (Circle outline stroke #C0C0C0 about 0.2% of slide height, no fill; line icon inside)
- icon at x 23.2, y 32.4, w 4.8, h 8.6 [#C0C0C0]: Financials icon: grey dashboard window with bar chart and pie clock symbol inside a circle (Circle outline stroke #C0C0C0, no fill; line icon inside)
- icon at x 23.2, y 48.4, w 4.8, h 8.6 [#C0C0C0]: Business updates icon: three diagonal grey test tubes inside a circle (Circle outline stroke #C0C0C0, no fill; line icon inside)
- icon at x 23.2, y 63.8, w 4.8, h 8.6 [#E21D39]: Pipeline updates icon: sky-blue microscope with red hexagon molecules inside a red circle (Circle outline stroke #E21D39, no fill; microscope in #2AACE2 and hexagons in #E21D39)
- icon at x 23.2, y 79.5, w 4.8, h 8.6 [#C0C0C0]: Looking Ahead icon: two rows of boxes each followed by an arrow inside a circle (Circle outline stroke #C0C0C0, no fill; line icon inside)
- title at x 21.6, y 4.6, w 36.2, h 5.2 [Segoe UI, Bold; font size 5.18% of slide height; #E31837; left aligned]: 3Q26 earnings call agenda (Sentence case, no letter-spacing, single line)
- body at x 31, y 17.5, w 15.8, h 3.7 [Segoe UI, Bold; font size 3.71% of slide height; #1E2846; left aligned]: Business Review (Heading for agenda item 1)
- body at x 31, y 22.7, w 16, h 3 [Segoe UI, Light; font size 2.96% of slide height; #000000; left aligned]: Stéphane Bancel, CEO (Speaker line for agenda item 1)
- body at x 31, y 33.3, w 9.5, h 3.7 [Segoe UI, Bold; font size 3.71% of slide height; #1E2846; left aligned]: Financials (Heading for agenda item 2)
- body at x 31, y 38.5, w 12.5, h 3 [Segoe UI, Light; font size 2.96% of slide height; #000000; left aligned]: Jamey Mock, CFO (Speaker line for agenda item 2)
- body at x 31, y 48.9, w 16.7, h 3.7 [Segoe UI, Bold; font size 3.71% of slide height; #1E2846; left aligned]: Business updates (Heading for agenda item 3)
- body at x 31, y 54.1, w 21.2, h 3 [Segoe UI, Light; font size 2.96% of slide height; #000000; left aligned]: Stephen Hoge, M.D., President (Speaker line for agenda item 3)
- body at x 31, y 64.2, w 16.2, h 3.7 [Segoe UI, Bold; font size 3.71% of slide height; #2AACE2; left aligned]: Pipeline updates (Heading for agenda item 4, highlighted in sky blue)
- body at x 31, y 69.4, w 37.4, h 3 [Segoe UI, Light; font size 2.96% of slide height; #000000; left aligned]: David Berman, M.D., Ph.D., Chief Development Officer (Speaker line for agenda item 4)
- body at x 31.3, y 79.9, w 14.8, h 3.7 [Segoe UI, Bold; font size 3.72% of slide height; #1E2846; left aligned]: Looking Ahead (Heading for agenda item 5)
- body at x 31.3, y 85.1, w 15.5, h 3 [Segoe UI, Light; font size 2.96% of slide height; #000000; left aligned]: Stéphane Bancel, CEO (Speaker line for agenda item 5)
- footer at x 2, y 95.7, w 16.1, h 1.5 [Century Gothic, Regular; font size 1.49% of slide height; #FFFFFF; left aligned]: © 2026 Moderna, Inc. All rights reserved. (Sits on the sky-blue sidebar)
- logo at x 86.6, y 92.2, w 12.2, h 4.9 [#E31837]: Moderna logo: red lowercase wordmark moderna with registered mark above a row of sky-blue dashes (Image 359 by 81 pixels, placed at bottom-right)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 19.4, h 100.0: #2AACE2
- fill at x 23.2, y 63.8, w 4.8, h 8.6: #E21D39
- fill at x 23.2, y 32.4, w 4.8, h 8.6: #C0C0C0
- fill at x 23.2, y 16.7, w 4.8, h 8.6: #C0C0C0
- fill at x 23.2, y 16.7, w 4.8, h 8.6: #C0C0C0
- fill at x 23.2, y 79.5, w 4.8, h 8.6: #C0C0C0
- fill at x 23.2, y 48.4, w 4.8, h 8.6: #C0C0C0
- image at x 86.6, y 92.2, w 12.2, h 4.9: 359 by 81 pixels
- text at x 21.6, y 4.6, w 36.2, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: 3Q26 earnings call agenda
- text at x 31.0, y 17.5, w 15.8, h 3.7 [SegoeUI-Bold; font size 3.71; #1E2846]: Business Review
- text at x 31.0, y 22.7, w 16.0, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: Stéphane Bancel, CEO
- text at x 31.0, y 33.3, w 9.5, h 3.7 [SegoeUI-Bold; font size 3.71; #1E2846]: Financials
- text at x 31.0, y 38.5, w 12.5, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: Jamey Mock, CFO
- text at x 31.0, y 48.9, w 16.7, h 3.7 [SegoeUI-Bold; font size 3.71; #1E2846]: Business updates
- text at x 31.0, y 64.2, w 16.2, h 3.7 [SegoeUI-Bold; font size 3.71; #2AACE2]: Pipeline updates
- text at x 31.0, y 54.1, w 21.2, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: Stephen Hoge, M.D., President
- text at x 31.3, y 79.9, w 14.8, h 3.7 [SegoeUI-Bold; font size 3.72; #1E2846]: Looking Ahead
- text at x 31.0, y 69.4, w 37.4, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: David Berman, M.D., Ph.D., Chief Development Officer
- text at x 31.3, y 85.1, w 15.5, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: Stéphane Bancel, CEO
- text at x 2.0, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #FFFFFF]: © 2026 Moderna, Inc. All rights reserved.

### Slide 17

**Text**

Oncology therapeutics / Intismeran autogene / mRNA-4157 / In partnership with Merck / Phase 3 / Phase 2 / Phase 1 / • Adjuvant melanoma / fully enrolled / ESMO 2026: Presidential Symposium , ESMO 2026 1 / In press, New England Journal of Medicine / • Adjuvant non-small cell lung cancer (NSCLC) / fully enrolled / • Adjuvant NSCLC non-pCR post neoadjuvant / • Adjuvant NSCLC (Stage 1), intismeran / monotherapy and in combination with / KEYTRUDA QLEX / • Adjuvant muscle invasive bladder / cancer (MIBC) / fully enrolled / • Adjuvant renal cell carcinoma (RCC) / fully enrolled / • Non-muscle invasive bladder cancer / (NMIBC) / • First-line metastatic melanoma / • First-line metastatic squamous NSCLC / • Adjuvant pancreatic cancer / fully enrolled / ESMO 2026: Poster presentation 2 / • Peri-operative gastric cancer / fully enrolled / 3Q 2026 Update | Pipeline updates / New update / 1. https://irp.cdn-website.com/89dd0539/files/uploaded/Long_LBA1_ESMO+2026.pdf / 2. https://irp.cdn-website.com/89dd0539/files/uploaded/mRNA-4157-P101+Poster_ESMO+2026_Final.pdf / 17 / © 2026 Moderna, Inc. All rights reserved.

**Layout**

A single white rounded card sits on a white slide, with a left vertical blue sidebar about 2.7% wide carrying the rotated section label and slide number. The title Oncology therapeutics is top-left at x 5.2%, y 4.2%, with the card header Intismeran autogene centred above three columns. The columns are Phase 3 (wide, left), Phase 2 (middle) and Phase 1 (narrow, right), each under a light lavender heading bar. The footer holds a New update tag and two numbered footnotes at left, the copyright line bottom-left, and the Moderna logo bottom-right; the card's bottom edge is near y 87%.

**Visuals**

Visual elements: three light lavender (#CDD4E9) phase heading bars, a navy (#1E2846) header strip behind the card top edge, red (#E31837) right-pointing arrow icons marking three lines (before ESMO 2026 Presidential Symposium, before Adjuvant non-small cell lung cancer (NSCLC), and before ESMO 2026 Poster presentation) and one red arrow inside the New update tag, and the Moderna logo (wordmark in red with a dashed cyan underline, 359 by 81 pixels). Bullets are black round dots. No charts, photographs or diagrams.

**Design**

Background white #FFFFFF. Left sidebar solid #2AACE2 with the vertical label Pipeline updates in white Segoe UI Semibold and 3Q 2026 Update | in light blue #BFE6F6 Segoe UI Light. Title Oncology therapeutics in Segoe UI Bold, red #E31837, about 5.2% of slide height. Card title Intismeran autogene in Segoe UI Bold black #000000 about 4.1%. Subtitle mRNA-4157 in Segoe UI Light navy #1E2846 about 2.6%. Partnership line in Segoe UI Bold grey #A6A6A6 about 1.7%. Phase headings in Segoe UI Semibold navy #1E2846 about 2.6%. Body text in Segoe UI Light black #000000 about 2.6%, with italic sub-lines in Segoe UI Light Italic. Footnotes Segoe UI Light grey #7F7F7F about 1.2%. Footer label and copyright in Century Gothic, grey #898989 for the copyright. Shapes have square corners on the lavender bars, and the card and navy strip have rounded corners of about 2% radius, with a thin light grey outline on the card and no shadow visible.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: Full-slide background rectangle (Covers the slide, no outline.)
- shape at x 0, y 0, w 2.7, h 100 [#2AACE2]: Left vertical sidebar (Solid fill, no outline, square edges.)
- text at x 0.4, y 24.7, w 1.7, h 22.9 [Segoe UI Light, normal weight, not italic, no capitals, normal spacing, rotated 270 degrees reading bottom to top; font size 2.96% of slide height; #BFE6F6; left aligned]: 3Q 2026 Update | (Vertical sidebar label, lower part.)
- text at x 0.4, y 2.4, w 1.7, h 22.2 [Segoe UI Semibold, not italic, no capitals, normal spacing, rotated 270 degrees reading bottom to top; font size 2.96% of slide height; #FFFFFF; left aligned]: Pipeline updates (Vertical sidebar label, upper part.)
- shape at x 4.8, y 15.7, w 86.2, h 5.6 [#1E2846]: Navy header strip behind card top edge (Rounded top corners of about 2% radius, behind the white card, showing as a dark band above it.)
- shape at x 4.8, y 17.6, w 86.2, h 69.7 [#FFFFFF]: White content card (Rounded corners of about 2% radius, thin light grey outline, no visible shadow.)
- title at x 5.2, y 4.2, w 31, h 5.2 [Segoe UI Bold, normal weight, not italic, no capitals, normal spacing; font size 5.18% of slide height; #E31837; left aligned]: Oncology therapeutics
- subtitle at x 36.7, y 19.3, w 22.3, h 4.1 [Segoe UI Bold, normal weight, not italic, no capitals, normal spacing; font size 4.07% of slide height; #000000; center aligned]: Intismeran autogene
- subtitle at x 44.2, y 23.9, w 7.3, h 2.6 [Segoe UI Light, normal weight, not italic, no capitals, normal spacing; font size 2.6% of slide height; #1E2846; center aligned]: mRNA-4157
- caption at x 42.2, y 27, w 11.5, h 1.7 [Segoe UI Bold, normal weight, not italic, no capitals, normal spacing; font size 1.67% of slide height; #A6A6A6; center aligned]: In partnership with Merck
- shape at x 7, y 29.7, w 31.5, h 4.5 [#CDD4E9]: Phase 3 heading bar (Square corners, no outline.)
- shape at x 39.5, y 29.7, w 26.6, h 4.5 [#CDD4E9]: Phase 2 heading bar (Square corners, no outline.)
- shape at x 67.3, y 29.7, w 21.8, h 4.5 [#CDD4E9]: Phase 1 heading bar (Square corners, no outline.)
- text at x 20, y 31, w 5.1, h 2.6 [Segoe UI Semibold, normal weight, not italic, no capitals, normal spacing; font size 2.6% of slide height; #1E2846; center aligned]: Phase 3
- text at x 50.1, y 31, w 5.1, h 2.6 [Segoe UI Semibold, normal weight, not italic, no capitals, normal spacing; font size 2.6% of slide height; #1E2846; center aligned]: Phase 2
- text at x 75.8, y 31, w 4.9, h 2.6 [Segoe UI Semibold, normal weight, not italic, no capitals, normal spacing; font size 2.6% of slide height; #1E2846; center aligned]: Phase 1
- bullet list at x 8.1, y 37.5, w 27, h 36.6 [Segoe UI Light, normal weight, not italic, no capitals, normal spacing; italic lines in Segoe UI Light Italic; font size 2.6% of slide height; #000000; left aligned]: • Adjuvant melanoma / fully enrolled / ESMO 2026: Presidential Symposium , ESMO 2026 1 / In press, New England Journal of Medicine / • Adjuvant non-small cell lung cancer (NSCLC) / fully enrolled / • Adjuvant NSCLC non-pCR post neoadjuvant / • Adjuvant NSCLC (Stage 1), intismeran / monotherapy and in combination with / KEYTRUDA QLEX (Phase 3 column. Black round bullets in Century Gothic. Sub-lines fully enrolled and the ESMO and In press lines are italic and set in smaller type (about 2.0%) for the ESMO and In press lines. Line spacing about 3.1% of slide height between items.)
- bullet list at x 40.5, y 37.5, w 29, h 36.6 [Segoe UI Light, normal weight, not italic, no capitals, normal spacing; italic lines in Segoe UI Light Italic; font size 2.6% of slide height; #000000; left aligned]: • Adjuvant muscle invasive bladder / cancer (MIBC) / fully enrolled / • Adjuvant renal cell carcinoma (RCC) / fully enrolled / • Non-muscle invasive bladder cancer / (NMIBC) / • First-line metastatic melanoma / • First-line metastatic squamous NSCLC (Phase 2 column. Black round bullets in Century Gothic. Sub-lines fully enrolled are italic. Items are separated by larger gaps than their wrapped lines.)
- bullet list at x 68.8, y 37.5, w 19, h 17.9 [Segoe UI Light, normal weight, not italic, no capitals, normal spacing; italic lines in Segoe UI Light Italic; font size 2.6% of slide height; #000000; left aligned]: • Adjuvant pancreatic cancer / fully enrolled / ESMO 2026: Poster presentation 2 / • Peri-operative gastric cancer / fully enrolled (Phase 1 column. Black round bullets in Century Gothic. ESMO 2026 Poster presentation line is italic at about 2.0% with a red arrow icon.)
- text at x 9.1, y 44.5, w 23.6, h 2 [Segoe UI Light Italic, italic, not capitals, normal spacing; font size 2.04% of slide height; #000000; left aligned]: ESMO 2026: Presidential Symposium , ESMO 2026
- text at x 9.1, y 47.8, w 20.1, h 2 [Segoe UI Light Italic, italic, not capitals, normal spacing; font size 2.04% of slide height; #000000; left aligned]: In press, New England Journal of Medicine
- text at x 69.9, y 44.7, w 15.1, h 2 [Segoe UI Light Italic, italic, not capitals, normal spacing; font size 2.04% of slide height; #000000; left aligned]: ESMO 2026: Poster presentation
- icon at x 7.9, y 44.4, w 0.9, h 1.8 [#E31837]: Red right-pointing arrow marking the ESMO 2026 Presidential Symposium line (Solid filled block arrow, pointing right.)
- icon at x 7.9, y 52.4, w 0.9, h 1.8 [#E31837]: Red right-pointing arrow marking the Adjuvant non-small cell lung cancer (NSCLC) line (Solid filled block arrow, pointing right.)
- icon at x 68.6, y 44.4, w 0.9, h 1.8 [#E31837]: Red right-pointing arrow marking the ESMO 2026 Poster presentation line (Solid filled block arrow, pointing right.)
- text at x 32.7, y 44.4, w 0.3, h 1.4 [Segoe UI Light Italic, italic, superscript, normal spacing; font size 1.36% of slide height; #000000; left aligned]: 1
- text at x 85, y 44.6, w 0.4, h 1.4 [Segoe UI Light Italic, italic, superscript, normal spacing; font size 1.36% of slide height; #000000; left aligned]: 2
- shape at x 5.8, y 89.9, w 8.7, h 4.1 [#FFFFFF]: New update tag outline (Rounded rectangle with thin grey outline about 0.2% of slide height, white fill.)
- icon at x 6.5, y 91, w 1, h 1.6 [#E31837]: Red right-pointing arrow in New update tag (Solid filled block arrow, pointing right.)
- text at x 7.9, y 91.2, w 5.7, h 1.7 [Century Gothic, normal weight, not italic, no capitals, normal spacing; font size 1.67% of slide height; #000000; left aligned]: New update
- caption at x 15.9, y 90.2, w 24.7, h 1.2 [Segoe UI Light, normal weight, not italic, no capitals, normal spacing, URL underlined; font size 1.24% of slide height; #7F7F7F; left aligned]: 1. https://irp.cdn-website.com/89dd0539/files/uploaded/Long_LBA1_ESMO+2026.pdf
- caption at x 15.9, y 92.1, w 30.6, h 1.2 [Segoe UI Light, normal weight, not italic, no capitals, normal spacing, URL underlined; font size 1.24% of slide height; #7F7F7F; left aligned]: 2. https://irp.cdn-website.com/89dd0539/files/uploaded/mRNA-4157-P101+Poster_ESMO+2026_Final.pdf
- footer at x 5.6, y 95.7, w 16.1, h 1.5 [Century Gothic, normal weight, not italic, no capitals, normal spacing; font size 1.49% of slide height; #898989; left aligned]: © 2026 Moderna, Inc. All rights reserved.
- page number at x 0.8, y 95.5, w 1.2, h 1.8 [Century Gothic, bold, not italic, no capitals, normal spacing; font size 1.84% of slide height; #FFFFFF; left aligned]: 17 (Sits on the blue sidebar.)
- logo at x 86.6, y 92.2, w 12.2, h 4.9 [#E31837]: Moderna logo: red wordmark moderna with a dashed cyan underline (Image 359 by 81 pixels, no crop, placed at bottom right.)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 2.7, h 100.0: #2AACE2
- fill at x 4.8, y 15.7, w 86.2, h 5.6: #1E2846
- fill at x 4.8, y 17.6, w 86.2, h 69.7: #FFFFFF
- fill at x 7.0, y 29.7, w 31.5, h 4.5: #CDD4E9
- fill at x 39.5, y 29.7, w 26.6, h 4.5: #CDD4E9
- fill at x 67.3, y 29.7, w 21.8, h 4.5: #CDD4E9
- image at x 86.6, y 92.2, w 12.2, h 4.9: 359 by 81 pixels
- text at x 5.2, y 4.2, w 31.0, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: Oncology therapeutics
- text at x 0.4, y 2.4, w 1.7, h 22.2 [SegoeUI-Semibold; font size 2.96; #FFFFFF]: Pipeline updates
- text at x 36.7, y 19.3, w 22.3, h 4.1 [SegoeUI-Bold; font size 4.07; #000000]: Intismeran autogene
- text at x 44.2, y 23.9, w 7.3, h 2.6 [SegoeUI-Light; font size 2.60; #1E2846]: mRNA-4157
- text at x 0.4, y 24.7, w 1.7, h 22.9 [SegoeUI-Light; font size 2.96; #BFE6F6]: 3Q 2026 Update |
- text at x 20.0, y 31.0, w 5.1, h 2.6 [SegoeUI-Semibold; font size 2.60; #1E2846]: Phase 3
- text at x 50.1, y 31.0, w 5.1, h 2.6 [SegoeUI-Semibold; font size 2.60; #1E2846]: Phase 2
- text at x 75.8, y 31.0, w 4.9, h 2.6 [SegoeUI-Semibold; font size 2.60; #1E2846]: Phase 1
- text at x 8.1, y 37.5, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 9.1, y 37.5, w 13.1, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Adjuvant melanoma
- text at x 40.5, y 37.5, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 41.5, y 37.5, w 20.7, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Adjuvant muscle invasive bladder
- text at x 68.8, y 37.5, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 69.9, y 37.5, w 16.5, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Adjuvant pancreatic cancer
- text at x 9.1, y 40.6, w 7.6, h 2.6 [SegoeUI-LightItalic; font size 2.60; #000000]: fully enrolled
- text at x 41.5, y 40.6, w 8.5, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: cancer (MIBC)
- text at x 69.9, y 40.6, w 8.0, h 2.6 [SegoeUI-LightItalic; font size 2.60; #000000]: fully enrolled
- text at x 42.2, y 27.0, w 11.5, h 1.7 [SegoeUI-Bold; font size 1.67; #A6A6A6]: In partnership with Merck
- text at x 41.5, y 43.7, w 7.6, h 2.6 [SegoeUI-LightItalic; font size 2.60; #000000]: fully enrolled
- text at x 40.5, y 49.0, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 41.5, y 49.0, w 22.1, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Adjuvant renal cell carcinoma (RCC)
- text at x 68.8, y 49.7, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 69.9, y 49.7, w 17.3, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Peri-operative gastric cancer
- text at x 8.1, y 52.2, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 9.1, y 52.2, w 25.0, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Adjuvant non-small cell lung cancer (NSCLC)
- text at x 41.5, y 52.1, w 7.6, h 2.6 [SegoeUI-LightItalic; font size 2.60; #000000]: fully enrolled
- text at x 69.9, y 52.8, w 7.6, h 2.6 [SegoeUI-LightItalic; font size 2.60; #000000]: fully enrolled
- text at x 9.1, y 55.3, w 6.9, h 2.6 [SegoeUI-LightItalic; font size 2.60; #000000]: fully enrolled
- text at x 9.1, y 44.5, w 23.6, h 2.0 [SegoeUI-LightItalic; font size 2.04; #000000]: ESMO 2026: Presidential Symposium , ESMO 2026
- text at x 40.5, y 57.5, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 41.5, y 57.5, w 22.5, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Non-muscle invasive bladder cancer
- text at x 68.8, y 44.7, w 0.7, h 2.0 [CenturyGothic; font size 2.04; #000000]: •
- text at x 69.9, y 44.7, w 15.1, h 2.0 [SegoeUI-LightItalic; font size 2.04; #000000]: ESMO 2026: Poster presentation
- text at x 8.1, y 60.3, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 9.1, y 60.3, w 26.9, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Adjuvant NSCLC non-pCR post neoadjuvant
- text at x 9.1, y 47.8, w 20.1, h 2.0 [SegoeUI-LightItalic; font size 2.04; #000000]: In press, New England Journal of Medicine
- text at x 41.5, y 60.6, w 5.5, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: (NMIBC)
- text at x 8.1, y 65.3, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 9.1, y 65.3, w 22.6, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Adjuvant NSCLC (Stage 1), intismeran
- text at x 40.5, y 65.9, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 41.5, y 65.9, w 18.6, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: First-line metastatic melanoma
- text at x 9.1, y 68.4, w 23.8, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: monotherapy and in combination with
- text at x 9.1, y 71.5, w 10.4, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: KEYTRUDA QLEX
- text at x 40.5, y 71.3, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 41.5, y 71.3, w 23.0, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: First-line metastatic squamous NSCLC
- text at x 32.7, y 44.4, w 0.3, h 1.4 [SegoeUI-LightItalic; font size 1.36; #000000]: 1
- text at x 85.0, y 44.6, w 0.4, h 1.4 [SegoeUI-LightItalic; font size 1.36; #000000]: 2
- text at x 0.8, y 95.5, w 1.2, h 1.8 [CenturyGothic-Bold; font size 1.84; #FFFFFF]: 17
- text at x 7.9, y 91.2, w 5.7, h 1.7 [CenturyGothic; font size 1.67; #000000]: New update
- text at x 5.6, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #898989]: © 2026 Moderna, Inc. All rights reserved.
- text at x 15.9, y 90.2, w 24.7, h 1.2 [SegoeUI-Light; font size 1.24; #7F7F7F]: 1. https://irp.cdn-website.com/89dd0539/files/uploaded/Long_LBA1_ESMO+2026.pdf
- text at x 15.9, y 92.1, w 30.6, h 1.2 [SegoeUI-Light; font size 1.24; #7F7F7F]: 2. https://irp.cdn-website.com/89dd0539/files/uploaded/mRNA-4157-P101+Poster_ESMO+2026_Final.pdf

### Slide 18

**Review notes**

- Review: Many slides carry tiny type that cannot be read at presentation size, including the disclaimer on slide 2, the results table on slide 9, the survival curves and AE chart on slides 18 to 21, and the appendix on slides 30 to 32.

**Text**

Phase 3 results demonstrate a 42% reduction in the risk of / recurrence or death
RFS Primary Analysis: ITT
100
90
80
70
60
50
40
30
20
10
0
RFS (%)
HR 0.58 (95% CI 0.45–0.75)
P < 0.001 (two sided)a
82.2% (95% CI 79.3–84.8)
70.0% (95% CI 65.0–74.5)
 N Events, n (%)
Intismeran + pembrolizumab 757 136 (18.0%)
Placebo + pembrolizumab 380 111 (29.2%)
0 6 12 18 24 30 35
Months
No. at risk
757 683 646 618 136 10 0
380 341 302 282 72 3 0
aMultiplicity-adjusted significance level: two-sided 0.024692.
ITT: all randomized patients according to the arm to which they were assigned.
RFS: time from randomization to the first occurrence of any recurrence or death from any cause. Data cutoff date: June 30, 2026 (median study follow-up, 24.6 mo).
Presented by: Georgina V. Long, Melanoma Institute Australia
Content of this presentation is copyright and responsibility of the author. Permission is required for re-use.
Key takeaways
First positive Phase 3 study for / individualized neoantigen / therapy
First positive Phase 3 study / versus anti-PD1 in adjuvant / melanoma
© 2026 Moderna, Inc. All rights reserved.
18
3Q 2026 Update | Pipeline updates

**Layout**

Single-column title across the top-left with two columns below: a wide chart panel on the left (about two-thirds of the width) and a narrow key-takeaways column on the right, separated by a red vertical rule. The title sits top-left at about 4.4% from the top with a left margin of about 5.2%. A full-height blue sidebar runs down the left edge carrying the rotated section label, and the page number sits at bottom-left in the sidebar; the copyright footer sits bottom-left beside it, and the moderna logo sits bottom-right.

**Visuals**

Chart: Kaplan-Meier style step chart titled RFS Primary Analysis: ITT. Y axis labelled RFS (%) ranging 0 to 100 with ticks every 10. X axis labelled Months ranging 0 to 35 with labelled ticks at 0, 6, 12, 18, 24, 30 and 35. Series 1, teal (Intismeran + pembrolizumab, N=757, events 136 (18.0%)): about 100 at 0 months, about 87 at 12 months, about 84 at 18 months, about 82.2 at 24 months as printed label 82.2% (95% CI 79.3–84.8), ending about 72 to 73 at 34 months (estimated). Series 2, blue (Placebo + pembrolizumab, N=380, events 111 (29.2%)): about 100 at 0 months, about 80 at 12 months, about 75 at 18 months, about 70.0 at 24 months as printed label 70.0% (95% CI 65.0–74.5), flattening near 69 to 70 to 34 months (estimated). Highlighted point: a dashed black vertical reference line at 24 months with the two printed 24-month labels beside it. Table inside plot (acts as legend): header row grey #C8C8C8-ish with columns blank, N, Events n (%); row 1 Intismeran + pembrolizumab 757, 136 (18.0%); row 2 Placebo + pembrolizumab 380, 111 (29.2%). Below the axis, a No. at risk table with rows: teal 757, 683, 646, 618, 136, 10, 0 at 0, 6, 12, 18, 24, 30, 35 months; blue 380, 341, 302, 282, 72, 3, 0 at the same times. Annotation text HR 0.58 (95% CI 0.45–0.75) and P < 0.001 (two sided) in navy in the plot's lower-left. The chart is a bitmap image with a thin grey drop shadow, boxed, not cropped. Right column: no images. ESMO Madrid 2026 congress logo at bottom-right of the chart panel, showing a small blue MADRID 2026 tag and the multicoloured ESMO wordmark with the word congress in small red text.

**Design**

Background: Solid white #FFFFFF with a full-height blue #2AACE2 sidebar on the left edge (0 to 2.7% width). White background #FFFFFF. Title in SegoeUI-Bold, red #E31837, about 5.2% of slide height, two lines, left aligned. Left sidebar solid blue #2AACE2 with rotated white (#FFFFFF) SegoeUI-Semibold 'Pipeline updates' and light pale blue #BFE6F6 SegoeUI-Light '3Q 2026 Update |'. Key takeaways heading SegoeUI-Semibold black #000000 at about 3% of height. Takeaway body SegoeUI-Light black #000000 at about 3% of height. Red vertical rule #E31837 about 0.3% wide beside the takeaways. Thin grey horizontal divider #A0A0A0 between takeaway blocks. Footer CenturyGothic regular grey #898989 at about 1.5% of height. Page number CenturyGothic-Bold white #FFFFFF about 1.8%. Chart uses navy #0B3A6E-ish for annotation text, teal #14907F and blue #1E4D8F for curves and labels. Moderna logo in red #E31837 wordmark with cyan #2AACE2 dashed underline. No corner radii; chart image has a soft grey shadow.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 2.7, h 100 [#2AACE2]: Left full-height blue sidebar (Solid fill, no border, full slide height, flush to left edge.)
- caption at x 0.4, y 2.4, w 1.7, h 22.2 [SegoeUI-Semibold; font size 2.96% of slide height; #FFFFFF; center aligned]: Pipeline updates (Rotated 90 degrees reading bottom to top; the first word group of the sidebar label; sits after 3Q 2026 Update | on the same rotated line.)
- caption at x 0.4, y 24.7, w 1.7, h 22.9 [SegoeUI-Light; font size 2.96% of slide height; #BFE6F6; center aligned]: 3Q 2026 Update | (Rotated 90 degrees reading bottom to top, sits directly below Pipeline updates on the same rotated line.)
- page number at x 0.8, y 95.5, w 1.2, h 1.8 [CenturyGothic-Bold; font size 1.84% of slide height; #FFFFFF; left aligned]: 18 (Sits inside the blue sidebar at bottom-left.)
- title at x 5.2, y 4.4, w 80.7, h 10.8 [SegoeUI-Bold; font size 5.18% of slide height; #E31837; left aligned]: Phase 3 results demonstrate a 42% reduction in the risk of / recurrence or death (Two lines, first line y 4.4 w 80.7, second line recurrence or death at y 10.0 w 26.9, line spacing about 5.6% of height.)
- photo at x 5.3, y 20.6, w 65.9, h 65.9 [#FFFFFF]: Kaplan-Meier chart image: RFS Primary Analysis: ITT, with axes, curves, at-risk table, footnotes and ESMO logo baked in (Bitmap chart image 1758 by 989 pixels, boxed, not cropped, with a thin grey drop shadow. A second, slightly larger copy of the same image (891 by 506 pixels) sits at x 5.1, y 20.2, w 66.8, h 67.4 beneath it as a shadow layer. The chart is drawn on a white background with black axes.)
- logo at x 86.6, y 92.2, w 12.2, h 4.9: ESMO Madrid 2026 congress logo (Small blue MADRID 2026 tag, multicoloured ESMO wordmark, small red congress text. Sits over the lower-right corner of the chart image.)
- shape at x 73.2, y 22, w 0.4, h 33 [#E31837]: Red vertical rule beside key takeaways (Solid bar, no radius, runs from the Key takeaways heading to below the second takeaway.)
- title at x 75, y 21.8, w 10.9, h 3 [SegoeUI-Semibold; font size 2.96% of slide height; #000000; left aligned]: Key takeaways
- body at x 75.1, y 26.8, w 21.5, h 10 [SegoeUI-Light; font size 2.96% of slide height; #000000; left aligned]: First positive Phase 3 study for / individualized neoantigen / therapy (Three lines, line spacing about 3.5% of height.)
- line at x 75, y 40, w 16, h 0.2 [#A0A0A0]: Thin grey horizontal divider between takeaways (Hairline stroke, about 1 px, spans the width of the takeaway column.)
- body at x 75.1, y 44.5, w 19.2, h 10.6 [SegoeUI-Light; font size 2.96% of slide height; #000000; left aligned]: First positive Phase 3 study / versus anti-PD1 in adjuvant / melanoma (Three lines, line spacing about 3.5% of height.)
- logo at x 86.5, y 92.3, w 12.4, h 4.6 [#E31837]: moderna wordmark logo (Red lowercase moderna wordmark with a registered mark, above a row of short cyan #2AACE2 dashes.)
- footer at x 5.6, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49% of slide height; #898989; left aligned]: © 2026 Moderna, Inc. All rights reserved.

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 2.7, h 100.0: #2AACE2
- image at x 5.1, y 20.2, w 66.8, h 67.4: 891 by 506 pixels
- image at x 5.3, y 20.6, w 65.9, h 65.9: 1758 by 989 pixels
- image at x 86.6, y 92.2, w 12.2, h 4.9: 359 by 81 pixels
- text at x 5.2, y 4.4, w 80.7, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: Phase 3 results demonstrate a 42% reduction in the risk of
- text at x 5.2, y 10.0, w 26.9, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: recurrence or death
- text at x 0.4, y 2.4, w 1.7, h 22.2 [SegoeUI-Semibold; font size 2.96; #FFFFFF]: Pipeline updates
- text at x 75.0, y 21.8, w 10.9, h 3.0 [SegoeUI-Semibold; font size 2.96; #000000]: Key takeaways
- text at x 75.1, y 26.8, w 21.5, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: First positive Phase 3 study for
- text at x 75.1, y 30.3, w 18.3, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: individualized neoantigen
- text at x 0.4, y 24.7, w 1.7, h 22.9 [SegoeUI-Light; font size 2.96; #BFE6F6]: 3Q 2026 Update |
- text at x 75.1, y 33.9, w 5.3, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: therapy
- text at x 75.1, y 44.5, w 19.1, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: First positive Phase 3 study
- text at x 75.1, y 48.1, w 19.2, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: versus anti-PD1 in adjuvant
- text at x 75.1, y 51.6, w 7.4, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: melanoma
- text at x 0.8, y 95.5, w 1.2, h 1.8 [CenturyGothic-Bold; font size 1.84; #FFFFFF]: 18
- text at x 5.6, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #898989]: © 2026 Moderna, Inc. All rights reserved.

### Slide 19

**Review notes**

- Review: Many slides carry tiny type that cannot be read at presentation size, including the disclaimer on slide 2, the results table on slide 9, the survival curves and AE chart on slides 18 to 21, and the appendix on slides 30 to 32.
- Suggested repair: Enlarge or crop the unreadable tables and charts on slides 9, 19 to 21 and 30 to 32, and fill or merge the near-empty slides such as 23 and 32.

**Text**

Phase 2 results demonstrate greater RFS benefit with longer follow-up / 3Q 2026 Update | Pipeline updates / Primary analysis 1 / 3-year analysis 2 / 5-year analysis 3 / Recurrence-Free Survival, % / Time From First Dose of Pembrolizumab, Months / + Censored / Intismeran plus pembrolizumab / Pembrolizumab / (at-risk counts as shown in visuals) / Primary analysis / 3-year follow-up / 5-year follow-up / Phase 2 / 0.56 (median F/U: 23 months 4) / 0.51 (median F/U: 34.9 months) / 0.51 (median F/U: 60.3 months) / Phase 3 / 0.58 (median follow-up: 24.6 months) / TBD / TBD / 1. https://irp.cdn-website.com/89dd0539/files/uploaded/MMA-75572-AACR-23-mRNA4157combined_version-2.pdf / 2. https://irp.cdn-website.com/89dd0539/files/uploaded/asco-2024-adjuvant-melanoma.pdf / 3. https://irp.cdn-website.com/89dd0539/files/uploaded/Intismeran+5-yr+Update+Oral+Presentation_ASCO_28May2026.pdf / 4. Median follow-up: 23 months in active arm, 24 months in control arm / 19 / © 2026 Moderna, Inc. All rights reserved. / moderna

**Layout**

Full-width white slide with a thin vertical blue band on the far left (about 2.7% of width) carrying rotated section text. The two-line bold title sits top-left, starting at about 5% from the left edge and 4% from the top, with generous white space beneath it. Three equal columns hold a Kaplan-Meier chart each, with centred column headings above them; a full-width table with three value columns sits below the charts. Footnotes are small and left-aligned at the bottom, with the page number at bottom-left inside the blue band area and the copyright line beside it, and the moderna logo bottom-right.

**Visuals**

Three Kaplan-Meier survival plots, combined in one placed image spanning about 3% to 99% of width and 18.8% to 62.7% of height, each with its own heading above. Chart 1, Primary analysis: y-axis Recurrence-Free Survival, % from 0 to 100 in steps of 10; x-axis Time From First Dose of Pembrolizumab, Months from 0 to 48 in steps of 6. Chart 2, 3-year analysis: y-axis 0 to 100 in steps of 10; x-axis 0 to 54 in steps of 6. Chart 3, 5-year analysis: y-axis 0 to 100 in steps of 10; x-axis 0 to 66 in steps of 6. Each chart has two step curves with censoring tick marks: red (Intismeran plus pembrolizumab, 107 patients at start) and blue (Pembrolizumab, 50 patients at start). Legend at top-right of each plot reads + Censored. Primary chart: red about 80% at 24 months, about 77% at 30 months, about 72% at 37 months, about 58% at 47 months; blue about 78% at 18 months, about 64% at 24 months, about 56% from 33 months to 48 months. 3-year chart: red about 80% at 24 months, about 75% at 35 months, about 70% at 48 months; blue about 70% at 16 months, about 56% at 29 months, about 27% at 42 months. 5-year chart: red about 81% at 18 months, about 77% at 30 months, about 73% at 48 months, about 69% at 60 months; blue about 71% at 15 months, about 56% at 25 months, about 49% at 44 months to 60 months. At-risk tables beneath each plot, red row (Intismeran plus pembrolizumab) and blue row (Pembrolizumab) in matching colours. Primary: red 107, 88, 82, 49, 24, 8, 3, 0, 0; blue 50, 41, 37, 28, 11, 1, 1, 0, 0 at 0, 6, 12, 18, 24, 30, 36, 42, 48 months. 3-year: red 107, 87, 83, 77, 52, 29, 12, 6, 1, 0; blue 50, 41, 37, 29, 27, 10, 5, 2, 0, 0 at 0 to 54 months. 5-year: red 107, 89, 84, 78, 74, 70, 57, 55, 39, 20, 3, 0; blue 50, 41, 37, 29, 27, 22, 19, 17, 12, 7, 3, 0 at 0 to 66 months. Table with three value columns (Primary analysis, 3-year follow-up, 5-year follow-up) and two rows (Phase 2, Phase 3), light blue header band; Phase 2 values 0.56 (median F/U: 23 months 4), 0.51 (median F/U: 34.9 months), 0.51 (median F/U: 60.3 months); Phase 3 values 0.58 (median follow-up: 24.6 months), TBD, TBD. Moderna wordmark logo in red bottom-right with a dashed light-blue underline of alternating blue and light-blue dashes.

**Design**

Background: Solid white #FFFFFF. White background #FFFFFF. Vertical left band #2AACE2 with rotated text. Title in bold red #E31837 sans-serif (Segoe UI Bold). Column headings in black #000000 Segoe UI Semibold. Table header band #BFE6F6 with dark navy #1E2846 Segoe UI Semibold text; body text black #000000 Segoe UI regular. Table rules thin black line under Phase 2 row, thin grey vertical separators. Footnote text grey #A6A6A6 Segoe UI regular. Copyright in grey #898989 Century Gothic. Page number white Century Gothic Bold on the blue band. Chart red series #E31837 and blue series #2AACE2. Title about 5.2% of slide height, body and table text about 2.6%, footnotes about 1.5%. Flat design, no shadows, no gradients, square corners.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: Full-slide white background fill (Covers entire slide, no border)
- shape at x 0, y 0, w 2.7, h 100 [#2AACE2]: Vertical left band (Flat fill, no border, square corners, runs full slide height)
- title at x 5.1, y 4.1, w 83.2, h 10.8 [Segoe UI Bold; font size 5.18% of slide height; #E31837; left aligned]: Phase 2 results demonstrate greater RFS benefit with longer / follow-up (Two lines, line spacing about 1.0, wraps after longer)
- text at x 0.4, y 2.4, w 1.7, h 45 [Segoe UI Light / Semibold, rotated 90 degrees; font size 2.96% of slide height; #BFE6F6; left aligned]: 3Q 2026 Update | Pipeline updates (Rotated vertical text reading bottom to top; '3Q 2026 Update |' in Light #BFE6F6 and 'Pipeline updates' in Semibold #FFFFFF)
- text at x 14.3, y 22.9, w 13.8, h 3.3 [Segoe UI Semibold; font size 3.33% of slide height; #000000; center aligned]: Primary analysis 1 (Superscript 1 at x 28.1, y 22.8, size 2.22)
- text at x 45.7, y 22.9, w 12.5, h 3.3 [Segoe UI Semibold; font size 3.33% of slide height; #000000; center aligned]: 3-year analysis 2 (Superscript 2 at x 58.2, y 22.8, size 2.22)
- text at x 76.1, y 22.9, w 12.5, h 3.3 [Segoe UI Semibold; font size 3.33% of slide height; #000000; center aligned]: 5-year analysis 3 (Superscript 3 at x 88.7, y 22.8, size 2.22)
- shape at x 5.6, y 21.7, w 92.5, h 7.3 [#FFFFFF]: Column background panel behind primary analysis heading (White filled rectangle, no border)
- shape at x 36.5, y 21.7, w 31.1, h 5.8 [#FFFFFF]: Column background panel behind 3-year analysis heading (White filled rectangle, no border)
- shape at x 67, y 21.7, w 31.1, h 5.8 [#FFFFFF]: Column background panel behind 5-year analysis heading (White filled rectangle, no border)
- photo at x 3, y 18.8, w 96.3, h 43.9 [#FFFFFF]: Three Kaplan-Meier survival charts with at-risk tables, placed as one raster image (1275 by 327 pixels) (Plots on white, black axes and tick labels, red #E31837 and blue #2AACE2 step lines with + censoring marks, see visuals for values; not cropped, boxed with no border)
- shape at x 5.6, y 63.8, w 28.4, h 4.4 [#BFE6F6]: Table header band (Filled cell over Primary analysis heading, no border)
- shape at x 37.3, y 63.8, w 32.5, h 4.4 [#BFE6F6]: Table header band 3-year (Filled cell, no border)
- shape at x 69.8, y 63.8, w 27.8, h 4.4 [#BFE6F6]: Table header band 5-year (Filled cell, no border)
- text at x 9.6, y 64.9, w 10.7, h 2.6 [Segoe UI Semibold; font size 2.6% of slide height; #1E2846; left aligned]: Primary analysis (Table column header)
- text at x 38, y 64.9, w 11, h 2.6 [Segoe UI Semibold; font size 2.6% of slide height; #1E2846; left aligned]: 3-year follow-up (Table column header)
- text at x 70.6, y 64.9, w 11, h 2.6 [Segoe UI Semibold; font size 2.6% of slide height; #1E2846; left aligned]: 5-year follow-up (Table column header)
- text at x 4, y 69.2, w 3.8, h 2 [Segoe UI Semibold; font size 1.96% of slide height; #000000; left aligned]: Phase 2 (Row label)
- text at x 9.6, y 69.4, w 3.1, h 2.6 [Segoe UI; font size 2.6% of slide height; #000000; left aligned]: 0.56 (median F/U: 23 months 4) (Value 0.56 at size 2.60; parenthetical at x 12.7, y 70.0, size 1.84; superscript 4 at x 23.7, y 69.9, size 1.24)
- text at x 38, y 69.4, w 3.1, h 2.6 [Segoe UI; font size 2.6% of slide height; #000000; left aligned]: 0.51 (median F/U: 34.9 months) (Value at size 2.60; parenthetical at x 41.1, y 70.0, size 1.84)
- text at x 70.6, y 69.4, w 3.1, h 2.6 [Segoe UI; font size 2.6% of slide height; #000000; left aligned]: 0.51 (median F/U: 60.3 months) (Value at size 2.60; parenthetical at x 73.6, y 70.0, size 1.84)
- shape at x 4, y 73.5, w 92, h 0.1 [#000000]: Table rule under Phase 2 row (Thin black horizontal line, about 0.1% height, spanning table width)
- text at x 4, y 73.8, w 3.8, h 2 [Segoe UI Semibold; font size 1.96% of slide height; #000000; left aligned]: Phase 3 (Row label)
- text at x 9.6, y 73.9, w 3.1, h 2.6 [Segoe UI; font size 2.6% of slide height; #000000; left aligned]: 0.58 (median follow-up: 24.6 months) (Value at size 2.60; parenthetical at x 12.7, y 74.5, size 1.84)
- text at x 38, y 73.9, w 2.6, h 2.6 [Segoe UI; font size 2.6% of slide height; #000000; left aligned]: TBD (Table cell value)
- text at x 70.6, y 73.9, w 2.6, h 2.6 [Segoe UI; font size 2.6% of slide height; #000000; left aligned]: TBD (Table cell value)
- text at x 31.7, y 66.6, w 0.3, h 1.1 [Arial Bold; font size 1.11% of slide height; #E31837; left aligned]: a (Small red stray glyph inside primary chart area)
- text at x 5.1, y 82.1, w 29.9, h 3.3 [Segoe UI; font size 1.49% of slide height; #A6A6A6; left aligned]: 1. https://irp.cdn-website.com/89dd0539/files/uploaded/MMA-75572-AACR-23- / mRNA4157combined_version-2.pdf (Footnote, numbered list, underlined hyperlinks, line spacing about 1.0)
- text at x 5.1, y 85.7, w 34.3, h 1.5 [Segoe UI; font size 1.49% of slide height; #A6A6A6; left aligned]: 2. https://irp.cdn-website.com/89dd0539/files/uploaded/asco-2024-adjuvant-melanoma.pdf (Footnote, underlined hyperlink)
- text at x 5.1, y 87.5, w 26.5, h 3.3 [Segoe UI; font size 1.49% of slide height; #A6A6A6; left aligned]: 3. https://irp.cdn-website.com/89dd0539/files/uploaded/Intismeran+5- / yr+Update+Oral+Presentation_ASCO_28May2026.pdf (Footnote, underlined hyperlink, wraps after 5-)
- text at x 5.1, y 91, w 26.8, h 1.5 [Segoe UI; font size 1.49% of slide height; #A6A6A6; left aligned]: 4. Median follow-up: 23 months in active arm, 24 months in control arm (Footnote)
- page number at x 0.8, y 95.5, w 1.2, h 1.8 [Century Gothic Bold; font size 1.84% of slide height; #FFFFFF; left aligned]: 19 (Sits on the blue left band)
- footer at x 5.6, y 95.7, w 16.1, h 1.5 [Century Gothic; font size 1.49% of slide height; #898989; left aligned]: © 2026 Moderna, Inc. All rights reserved. (Copyright line)
- logo at x 86.6, y 92.2, w 12.2, h 4.9 [#E31837]: moderna wordmark logo, placed image (359 by 81 pixels) (Red lowercase wordmark with a dashed underline of alternating light blue and blue dashes beneath it)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 2.7, h 100.0: #2AACE2
- fill at x 8.9, y 63.8, w 28.4, h 4.4: #BFE6F6
- fill at x 37.3, y 63.8, w 32.5, h 4.4: #BFE6F6
- fill at x 69.8, y 63.8, w 27.8, h 4.4: #BFE6F6
- fill at x 5.6, y 21.7, w 92.5, h 7.3: #FFFFFF
- fill at x 36.5, y 21.7, w 31.1, h 5.8: #FFFFFF
- fill at x 67.0, y 21.7, w 31.1, h 5.8: #FFFFFF
- image at x 3.0, y 18.8, w 96.3, h 43.9: 1275 by 327 pixels
- image at x 86.6, y 92.2, w 12.2, h 4.9: 359 by 81 pixels
- text at x 5.1, y 4.1, w 83.2, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: Phase 2 results demonstrate greater RFS benefit with longer
- text at x 5.1, y 9.7, w 13.4, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: follow-up
- text at x 0.4, y 2.4, w 1.7, h 22.2 [SegoeUI-Semibold; font size 2.96; #FFFFFF]: Pipeline updates
- text at x 14.3, y 22.9, w 13.8, h 3.3 [SegoeUI-Semibold; font size 3.33; #000000]: Primary analysis
- text at x 45.7, y 22.9, w 12.5, h 3.3 [SegoeUI-Semibold; font size 3.33; #000000]: 3-year analysis
- text at x 76.1, y 22.9, w 12.5, h 3.3 [SegoeUI-Semibold; font size 3.33; #000000]: 5-year analysis
- text at x 28.1, y 22.8, w 0.5, h 2.2 [SegoeUI-Semibold; font size 2.22; #000000]: 1
- text at x 58.2, y 22.8, w 0.7, h 2.2 [SegoeUI-Semibold; font size 2.22; #000000]: 2
- text at x 88.7, y 22.8, w 0.7, h 2.2 [SegoeUI-Semibold; font size 2.22; #000000]: 3
- text at x 0.4, y 24.7, w 1.7, h 22.9 [SegoeUI-Light; font size 2.96; #BFE6F6]: 3Q 2026 Update |
- text at x 9.6, y 64.9, w 10.7, h 2.6 [SegoeUI-Semibold; font size 2.60; #1E2846]: Primary analysis
- text at x 38.0, y 64.9, w 11.0, h 2.6 [SegoeUI-Semibold; font size 2.60; #1E2846]: 3-year follow-up
- text at x 70.6, y 64.9, w 11.0, h 2.6 [SegoeUI-Semibold; font size 2.60; #1E2846]: 5-year follow-up
- text at x 9.6, y 69.4, w 3.1, h 2.6 [SegoeUI; font size 2.60; #000000]: 0.56
- text at x 38.0, y 69.4, w 3.1, h 2.6 [SegoeUI; font size 2.60; #000000]: 0.51
- text at x 70.6, y 69.4, w 3.1, h 2.6 [SegoeUI; font size 2.60; #000000]: 0.51
- text at x 9.6, y 73.9, w 3.1, h 2.6 [SegoeUI; font size 2.60; #000000]: 0.58
- text at x 38.0, y 73.9, w 2.6, h 2.6 [SegoeUI; font size 2.60; #000000]: TBD
- text at x 70.6, y 73.9, w 2.6, h 2.6 [SegoeUI; font size 2.60; #000000]: TBD
- text at x 4.0, y 69.2, w 3.8, h 2.0 [SegoeUI-Semibold; font size 1.96; #000000]: Phase 2
- text at x 4.0, y 73.8, w 3.8, h 2.0 [SegoeUI-Semibold; font size 1.96; #000000]: Phase 3
- text at x 12.7, y 70.0, w 11.7, h 1.8 [SegoeUI; font size 1.84; #000000]: (median F/U: 23 months )
- text at x 41.1, y 70.0, w 12.1, h 1.8 [SegoeUI; font size 1.84; #000000]: (median F/U: 34.9 months)
- text at x 73.6, y 70.0, w 12.1, h 1.8 [SegoeUI; font size 1.84; #000000]: (median F/U: 60.3 months)
- text at x 12.7, y 74.5, w 14.9, h 1.8 [SegoeUI; font size 1.84; #000000]: (median follow-up: 24.6 months)
- text at x 0.8, y 95.5, w 1.2, h 1.8 [CenturyGothic-Bold; font size 1.84; #FFFFFF]: 19
- text at x 5.1, y 82.1, w 29.9, h 1.5 [SegoeUI; font size 1.49; #A6A6A6]: 1. https://irp.cdn-website.com/89dd0539/files/uploaded/MMA-75572-AACR-23-
- text at x 23.7, y 69.9, w 0.4, h 1.2 [SegoeUI; font size 1.24; #000000]: 4
- text at x 6.2, y 83.9, w 13.1, h 1.5 [SegoeUI; font size 1.49; #A6A6A6]: mRNA4157combined_version-2.pdf
- text at x 5.1, y 85.7, w 34.3, h 1.5 [SegoeUI; font size 1.49; #A6A6A6]: 2. https://irp.cdn-website.com/89dd0539/files/uploaded/asco-2024-adjuvant-melanoma.pdf
- text at x 5.1, y 87.5, w 26.5, h 1.5 [SegoeUI; font size 1.49; #A6A6A6]: 3. https://irp.cdn-website.com/89dd0539/files/uploaded/Intismeran+5-
- text at x 6.2, y 89.3, w 19.8, h 1.5 [SegoeUI; font size 1.49; #A6A6A6]: yr+Update+Oral+Presentation_ASCO_28May2026.pdf
- text at x 31.7, y 66.6, w 0.3, h 1.1 [Arial-BoldMT; font size 1.11; #E31837]: a
- text at x 5.1, y 91.0, w 26.8, h 1.5 [SegoeUI; font size 1.49; #A6A6A6]: 4. Median follow-up: 23 months in active arm, 24 months in control arm
- text at x 5.6, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #898989]: © 2026 Moderna, Inc. All rights reserved.

### Slide 20

**Review notes**

- Review: Many slides carry tiny type that cannot be read at presentation size, including the disclaimer on slide 2, the results table on slide 9, the survival curves and AE chart on slides 18 to 21, and the appendix on slides 30 to 32.
- Suggested repair: Enlarge or crop the unreadable tables and charts on slides 9, 19 to 21 and 30 to 32, and fill or merge the near-empty slides such as 23 and 32.

**Text**

Pipeline updates
3Q 2026 Update |
mITT analysis shows a greater RFS benefit among patients who
received intismeran as planned
mITT population excludes
participants who did not receive
at least one dose of intismeran
or placebo as planned
RFS Sensitivity Analysis: mITT
RFS (%)
100
90
80
70
60
50
40
30
20
10
0
HR 0.51 (95% CI 0.39–0.67)
84.2% (95% CI 81.3–86.7)
70.4% (95% CI 65.3–74.9)
N
Events,a n (%)
Intismeran + pembrolizumab 726 116a (16.0%)
Placebo + pembrolizumab 365 106b (29.0%)
0 6 12 18 24 30 35
Months
No. at risk
726 674 638 611 133 9 0
365 333 294 275 71 2 0
a31 patients in the intismeran + pembrolizumab arm were excluded from the mITT population due to AEs (n=13), recurrence (n=10), or other reason (n=8). RFS events occurred in 20 (64.5%) of the 31 patients who did not receive intismeran as planned. b15 patients in the placebo + pembrolizumab arm were excluded from the mITT population due to AEs (n=5), recurrence (n=4), or other reason (n=6). RFS events occurred in and 5 (33.3%) of 15 patients who did not receive placebo as planned. mITT: all randomized patients who received intismeran or placebo as assigned. RFS: time from randomization to the first occurrence of any recurrence or death from any cause. Data cutoff date: June 30, 2026 (median study follow-up, 24.6 mo).
Presented by: Georgina V. Long, Melanoma Institute Australia
Content of this presentation is copyright and responsibility of the author. Permission is required for re-use.
a. Randomization stratification factors applied to all stratified analyses.
© 2026 Moderna, Inc. All rights reserved.
20

**Layout**

Two-zone layout on a white slide: a full-height blue vertical sidebar runs along the left edge carrying the rotated section label, with the title set top-left in two left-aligned lines beneath a top margin of about 4 percent. A large framed chart image occupies the left-centre (about 5 to 72 percent of width, 20 to 88 percent of height), with a single red-ruled text callout in a narrow right column (about 73 to 97 percent) aligned to the chart top; the footnote caption sits below the chart, the copyright line and page number sit in the footer band at the bottom, and the Moderna logo sits bottom right.

**Visuals**

One Kaplan-Meier survival chart, a raster image (the file contains a 1758 by 989 pixel version and an overlapping 891 by 506 pixel copy in the same box), placed at x 4.9 to 71.7 percent and y 20.0 to 87.4 percent, boxed with a thin light grey drop shadow, full-width of its box with no crop. Chart title printed inside: 'RFS Sensitivity Analysis: mITT' in bold dark navy #0B2A4A at top left. Chart type: line (Kaplan-Meier step curves) with censoring tick marks. Y axis: 'RFS (%)', range 0 to 100 with ticks every 10, labelled 0, 10, 20 ... 100. X axis: 'Months', range 0 to 35 with labelled ticks at 0, 6, 12, 18, 24, 30, 35. Series 1: Intismeran + pembrolizumab, teal-green line #00897B, labelled 84.2% (95% CI 81.3-86.7) at 24 months; plateaus near 85 to 90 percent and steps down to about 82 percent around 28 months and about 74 percent near 33 months. Series 2: Placebo + pembrolizumab, blue line #1F4FA0, labelled 70.4% (95% CI 65.3-74.9) at the end of follow-up; falls to about 84 percent near 8 months, about 80 percent near 12 months, about 75 percent near 18 months, and about 70 percent from 27 months onward. Highlighted point: a vertical black dashed reference line at 24 months. Annotation: 'HR 0.51 (95% CI 0.39-0.67)' in navy at upper left of the plot area. Embedded table at lower left of plot area with a light grey header row and two data rows: columns 'Events,a n (%)' with header cells 'N' and 'Events,a n (%)'; row 1 'Intismeran + pembrolizumab' N 726, events 116a (16.0%); row 2 'Placebo + pembrolizumab' N 365, events 106b (29.0%). Below the x axis a 'No. at risk' table: row 1 teal values 726, 674, 638, 611, 133, 9, 0 at months 0, 6, 12, 18, 24, 30, 35; row 2 blue values 365, 333, 294, 275, 71, 2, 0. Legend: none; series are identified by the coloured labels in the table. Footnote paragraph in small grey text at the bottom of the image, with a bold 'Presented by' line and a copyright line. A small ESMO and Madrid 2026 congress logo sits at the bottom right corner of the image box.

**Design**

Background: Solid white #FFFFFF across the whole slide. Clean white corporate slide. Title is bold sans-serif (Segoe UI Bold) in red #E31837, two lines, about 5.2 percent of slide height for the cap-height size. Body callout is light sans-serif (Segoe UI Light) in black #000000 at about 3.0 percent of slide height. Sidebar is a flat blue #2AACE2 strip with a rotated label: 'Pipeline updates' in semibold white #FFFFFF and '3Q 2026 Update |' in light #BFE6F6. Accent colour is red #E31837 for the title and callout rule. Footer text is light grey sans-serif, copyright in CenturyGothic #898989 about 1.5 percent of height; caption in grey #A6A6A6 about 2.0 percent. Lines and shapes: callout rule is a solid red bar about 0.4 percent wide with square ends; chart box has a faint grey drop shadow; no rounded corners; no gradients.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 2.7, h 100 [#2AACE2]: Vertical sidebar bar on the left edge, full slide height (Flat fill, no border, no shadow, sits behind the rotated label.)
- text at x 0.4, y 2.4, w 1.7, h 22.2 [Segoe UI Semibold, rotated 270 degrees reading bottom to top; font size 2.96% of slide height; #FFFFFF; center aligned]: Pipeline updates (Rotated 270 degrees, sits on the blue sidebar, lower-case except initial P.)
- text at x 0.4, y 24.7, w 1.7, h 22.9 [Segoe UI Light, rotated 270 degrees reading bottom to top; font size 2.96% of slide height; #BFE6F6; center aligned]: 3Q 2026 Update | (Rotated 270 degrees, directly after the Pipeline updates label on the same sidebar line.)
- title at x 5.2, y 4.1, w 87.2, h 10.8 [Segoe UI Bold, sentence case, no letter-spacing change; font size 5.18% of slide height; #E31837; left aligned]: mITT analysis shows a greater RFS benefit among patients who / received intismeran as planned (Two lines, line 1 at y 4.1 and line 2 at y 9.7, line pitch about 5.6 percent of height.)
- chart at x 4.9, y 20, w 66.8, h 67.4 [#FFFFFF]: Kaplan-Meier RFS sensitivity analysis chart (mITT) with inset N and events table, at-risk table and footnote, as described in visuals (Raster image, boxed, faint grey drop shadow, no rounding, not cropped, sits over the white background.)
- shape at x 73.2, y 22.2, w 0.4, h 14.1 [#E31837]: Vertical red accent rule beside the callout text (Solid bar, square ends, no shadow; estimated position from the rendered slide.)
- body at x 74.9, y 22.6, w 22.7, h 13.7 [Segoe UI Light, regular weight; font size 2.96% of slide height; #000000; left aligned]: mITT population excludes / participants who did not receive / at least one dose of intismeran / or placebo as planned (Line spacing about 3.6 percent of height, ragged right, no bullets.)
- caption at x 5.2, y 88.2, w 33.8, h 2 [Segoe UI Regular, sentence case; font size 1.96% of slide height; #A6A6A6; left aligned]: a. Randomization stratification factors applied to all stratified analyses.
- logo at x 86.6, y 92.2, w 12.2, h 4.9 [#E31837]: Moderna wordmark logo, lower-case 'moderna' in red with registered mark, above a row of dashed cyan underline segments (Raster image 359 by 81 pixels; dashed underline in light cyan #2AACE2 below the wordmark; placed bottom right, no background box.)
- footer at x 5.6, y 95.7, w 16.1, h 1.5 [CenturyGothic, regular weight; font size 1.49% of slide height; #898989; left aligned]: © 2026 Moderna, Inc. All rights reserved.
- page number at x 0.8, y 95.5, w 1.2, h 1.8 [CenturyGothic, bold weight; font size 1.84% of slide height; #FFFFFF; left aligned]: 20 (Sits on the blue sidebar.)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 2.7, h 100.0: #2AACE2
- image at x 4.9, y 20.0, w 66.8, h 67.4: 891 by 506 pixels
- image at x 5.1, y 20.4, w 65.9, h 65.9: 1758 by 989 pixels
- image at x 86.6, y 92.2, w 12.2, h 4.9: 359 by 81 pixels
- text at x 5.2, y 4.1, w 87.2, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: mITT analysis shows a greater RFS benefit among patients who
- text at x 5.2, y 9.7, w 42.5, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: received intismeran as planned
- text at x 0.4, y 2.4, w 1.7, h 22.2 [SegoeUI-Semibold; font size 2.96; #FFFFFF]: Pipeline updates
- text at x 74.9, y 22.6, w 18.3, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: mITT population excludes
- text at x 74.9, y 26.2, w 22.7, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: participants who did not receive
- text at x 74.9, y 29.8, w 21.3, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: at least one dose of intismeran
- text at x 0.4, y 24.7, w 1.7, h 22.9 [SegoeUI-Light; font size 2.96; #BFE6F6]: 3Q 2026 Update |
- text at x 74.9, y 33.3, w 15.5, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: or placebo as planned
- text at x 5.2, y 88.2, w 33.8, h 2.0 [SegoeUI; font size 1.96; #A6A6A6]: a. Randomization stratification factors applied to all stratified analyses.
- text at x 0.8, y 95.5, w 1.2, h 1.8 [CenturyGothic-Bold; font size 1.84; #FFFFFF]: 20
- text at x 5.6, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #898989]: © 2026 Moderna, Inc. All rights reserved.

### Slide 21

**Review notes**

- Review: Many slides carry tiny type that cannot be read at presentation size, including the disclaimer on slide 2, the results table on slide 9, the survival curves and AE chart on slides 18 to 21, and the appendix on slides 30 to 32.
- Suggested repair: Enlarge or crop the unreadable tables and charts on slides 9, 19 to 21 and 30 to 32, and fill or merge the near-empty slides such as 23 and 32.

**Text**

Safety findings were consistent with the known profiles of / the individual therapies / 3Q 2026 Update | / Pipeline updates / AEs of Interest for Pembrolizumab, Incidence ≥1% / Intismeran did not potentiate pembrolizumab-associated AEs / Intismeran + Pembrolizumab (N = 755) / Placebo + Pembrolizumab (N = 380) / Any 36.0 34.7 / Hypothyroidism 15.9 16.1 / Hyperthyroidism 9.9 8.2 / Infusion reactions 3.3 1.1 / Colitis 2.6 3.2 / Gastritis 2.1 0.8 / Adrenal insufficiency 1.7 4.2 / Pneumonitis 1.7 2.1 / Hepatitis 1.6 2.1 / Severe skin reactions 1.6 0.3 / Hypophysitis 1.5 1.1 / Type 1 diabetes mellitus 1.5 1.1 / Myositis 1.2 1.6 / Thyroiditis 1.2 0.8 / 100 90 80 70 60 50 40 30 20 10 0 10 20 30 40 50 60 70 80 90 100 / Incidence, % / Grade 1–2 / Grade 3–5 / Grade 1–2 / Grade 3–5 / As-treated population: all randomized patients who received at ≥1 dose of study treatment. Data cutoff date: June 30, 2026 (median study follow-up, 24.6 mo). / Presented by: Georgina V. Long, Melanoma Institute Australia / Content of this presentation is copyright and responsibility of the author. Permission is required for re-use. / AEs of interest for intismeran were / consistent with expected profile / • The most common AEs in the / intismeran + KEYTRUDA arm were / pyrexia (52.2%), injection site pain / (51.0%), and fatigue (38.5%) / • AEs were generally low-grade, / transient, and managed with standard / supportive care / 21 / © 2026 Moderna, Inc. All rights reserved.

**Layout**

Two-column layout on a white slide with a full-height blue sidebar at the left edge carrying the rotated section label. The two-line red title sits top-left, starting at about x 5.3% and y 4%, left-aligned. The left column holds the chart image in a boxed frame from about x 5% to 56%, y 24% to 77%. A thin vertical grey divider runs at about x 61% from y 23% to 77%. The right column is left-aligned at x 65.3% with a bold heading and two bullet points, vertically centred around y 29% to 67%. The moderna logo sits bottom-right at x 86.6%, y 92%, and the copyright footer and slide number 21 sit bottom-left in the margin.

**Visuals**

One chart (image): a horizontal butterfly (back-to-back bar) chart titled AEs of Interest for Pembrolizumab, Incidence ≥1%, with subtitle Intismeran did not potentiate pembrolizumab-associated AEs. Left side is Intismeran + Pembrolizumab (N = 755), right side is Placebo + Pembrolizumab (N = 380). Category axis lists 14 AEs top to bottom: Any, Hypothyroidism, Hyperthyroidism, Infusion reactions, Colitis, Gastritis, Adrenal insufficiency, Pneumonitis, Hepatitis, Severe skin reactions, Hypophysitis, Type 1 diabetes mellitus, Myositis, Thyroiditis. Horizontal axis is labelled Incidence, %, ranging from 100 on the left to 0 at centre to 100 on the right, with ticks every 10. Each bar is stacked by grade. Printed values, intismeran (left) then placebo (right): Any 36.0 / 34.7; Hypothyroidism 15.9 / 16.1; Hyperthyroidism 9.9 / 8.2; Infusion reactions 3.3 / 1.1; Colitis 2.6 / 3.2; Gastritis 2.1 / 0.8; Adrenal insufficiency 1.7 / 4.2; Pneumonitis 1.7 / 2.1; Hepatitis 1.6 / 2.1; Severe skin reactions 1.6 / 0.3; Hypophysitis 1.5 / 1.1; Type 1 diabetes mellitus 1.5 / 1.1; Myositis 1.2 / 1.6; Thyroiditis 1.2 / 0.8. Legend below the axis: Grade 1–2 light green swatch, Grade 3–5 teal swatch, Grade 1–2 light blue swatch, Grade 3–5 dark blue swatch. No highlighted points. The chart image has a faint drop shadow and a small ESMO congress logo at its bottom-right corner. The moderna wordmark in red with a row of dashed light blue and cyan underline dashes is a logo at bottom-right.

**Design**

Background: Solid white #FFFFFF. Clean white background with a saturated blue sidebar on the left edge. Title in bold red sans-serif (Segoe UI Bold style), about 5.2% of slide height per line. Heading and bullets in black Segoe UI Light/Semibold, about 3.3% and 3.0% of slide height. Bullet markers are small red dots. Sidebar label is white Segoe UI Semibold for Pipeline updates and light blue Segoe UI Light for 3Q 2026 Update, rotated 90 degrees counter-clockwise. Accent colours: sidebar #2AACE2, title red #E31837, body black #000000. Footer grey #898989 in CenturyGothic. Chart uses greens (#66CDAA light, #00806A dark) for intismeran and blues (#7FB2E5 light, #1F4E9A dark) for placebo. Divider is a thin light grey line. No rounded corners on shapes; the chart frame has a soft shadow.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: Full-slide background fill, white (Covers the whole slide, no border.)
- shape at x 0, y 0, w 2.7, h 100 [#2AACE2]: Left vertical sidebar strip (Full height, flush to left edge, no border or radius.)
- text at x 0.4, y 24.7, w 1.7, h 22.9 [Segoe UI Light, regular, rotated 90 degrees counter-clockwise, not capitals; font size 2.96% of slide height; #BFE6F6; left aligned]: 3Q 2026 Update | (Vertical text in the sidebar, reads bottom to top, sits below Pipeline updates.)
- text at x 0.4, y 2.4, w 1.7, h 22.2 [Segoe UI Semibold, rotated 90 degrees counter-clockwise, not capitals; font size 2.96% of slide height; #FFFFFF; left aligned]: Pipeline updates (Vertical text in the sidebar, reads bottom to top, sits at the top of the sidebar.)
- image at x 5.1, y 24.5, w 51.1, h 51.7 [#FFFFFF]: Chart frame: drop-shadowed white rectangle holding the chart image (Rectangle with square corners and a soft grey drop shadow to the bottom and right, opacity 100%.)
- chart at x 5.3, y 24.9, w 50.2, h 50.2 [#1F4E9A]: AEs of Interest for Pembrolizumab, Incidence ≥1% butterfly bar chart image (1339 by 753 pixels) (Placed image, not cropped, fully visible inside the frame. Dominant colours: navy title, greens and blues for bars, white background. Contains the text and ESMO logo listed in text.)
- title at x 5.3, y 4.1, w 80.7, h 10.8 [Segoe UI Bold, bold, not capitals, no letter-spacing; font size 5.18% of slide height; #E31837; left aligned]: Safety findings were consistent with the known profiles of / the individual therapies (Two lines, line 1 at y 4.1 and line 2 at y 9.7 with about 1.0 times line spacing.)
- line at x 61, y 22.8, w 0.1, h 54.6 [#BFBFBF]: Vertical thin divider line (Stroke about 1 px light grey, solid, no shadow.)
- subtitle at x 65.3, y 29.2, w 29.9, h 7.3 [Segoe UI Semibold, semibold, not capitals, no letter-spacing; font size 3.33% of slide height; #000000; left aligned]: AEs of interest for intismeran were / consistent with expected profile (Two lines at y 29.2 and y 33.2, line 1 w 29.9 and line 2 w 27.2.)
- bullet list at x 65.3, y 39.9, w 24.5, h 13.7 [Segoe UI Light, light, not capitals, no letter-spacing; font size 2.96% of slide height; #000000; left aligned]: • The most common AEs in the / intismeran + KEYTRUDA arm were / pyrexia (52.2%), injection site pain / (51.0%), and fatigue (38.5%) (Bullet marker is a solid red dot in ArialMT at x 65.3, text indented to x 66.8, line pitch about 3.6% of height, paragraph gap before the next bullet.)
- bullet list at x 65.3, y 58.6, w 27.4, h 10.1 [Segoe UI Light, light, not capitals, no letter-spacing; font size 2.96% of slide height; #000000; left aligned]: • AEs were generally low-grade, / transient, and managed with standard / supportive care (Bullet marker is a solid red dot in ArialMT at x 65.3, text indented to x 66.8, line pitch about 3.6% of height.)
- logo at x 86.6, y 92.2, w 12.2, h 4.9 [#E31837]: moderna wordmark logo with dashed underline (red wordmark, cyan and light blue dashes) (Placed image 359 by 81 pixels, bottom-right corner, wordmark in red #E31837 with a row of dashes in light blue to cyan.)
- page number at x 0.8, y 95.5, w 1.2, h 1.8 [CenturyGothic-Bold, bold, not capitals, no letter-spacing; font size 1.84% of slide height; #FFFFFF; left aligned]: 21 (Sits on the blue sidebar near the bottom.)
- footer at x 5.6, y 95.7, w 16.1, h 1.5 [CenturyGothic, regular, not capitals, no letter-spacing; font size 1.49% of slide height; #898989; left aligned]: © 2026 Moderna, Inc. All rights reserved. (Single line footer in grey.)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 2.7, h 100.0: #2AACE2
- image at x 5.1, y 24.5, w 51.1, h 51.7: 682 by 389 pixels
- image at x 5.3, y 24.9, w 50.2, h 50.2: 1339 by 753 pixels
- image at x 86.6, y 92.2, w 12.2, h 4.9: 359 by 81 pixels
- text at x 5.3, y 4.1, w 80.7, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: Safety findings were consistent with the known profiles of
- text at x 5.3, y 9.7, w 32.4, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: the individual therapies
- text at x 0.4, y 2.4, w 1.7, h 22.2 [SegoeUI-Semibold; font size 2.96; #FFFFFF]: Pipeline updates
- text at x 65.3, y 29.2, w 29.9, h 3.3 [SegoeUI-Semibold; font size 3.33; #000000]: AEs of interest for intismeran were
- text at x 65.3, y 33.2, w 27.2, h 3.3 [SegoeUI-Semibold; font size 3.33; #000000]: consistent with expected profile
- text at x 0.4, y 24.7, w 1.7, h 22.9 [SegoeUI-Light; font size 2.96; #BFE6F6]: 3Q 2026 Update |
- text at x 65.3, y 39.9, w 0.6, h 3.0 [ArialMT; font size 2.96; #E31837]: •
- text at x 66.8, y 39.9, w 21.0, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: The most common AEs in the
- text at x 66.8, y 43.5, w 24.2, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: intismeran + KEYTRUDA arm were
- text at x 66.8, y 47.0, w 23.9, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: pyrexia (52.2%), injection site pain
- text at x 66.8, y 50.6, w 19.3, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: (51.0%), and fatigue (38.5%)
- text at x 65.3, y 58.6, w 0.6, h 3.0 [ArialMT; font size 2.96; #E31837]: •
- text at x 66.8, y 58.6, w 21.5, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: AEs were generally low-grade,
- text at x 66.8, y 62.2, w 26.9, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: transient, and managed with standard
- text at x 66.8, y 65.7, w 10.8, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: supportive care
- text at x 0.8, y 95.5, w 1.2, h 1.8 [CenturyGothic-Bold; font size 1.84; #FFFFFF]: 21
- text at x 5.6, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #898989]: © 2026 Moderna, Inc. All rights reserved.

### Slide 22

**Text**

Oncology therapeutics
3Q 2026 Update | Pipeline updates
22
Cancer antigen
therapies
mRNA-4359
Phase 2
Phase 2 in first-line metastatic melanoma, second-line+ metastatic melanoma, and first-line metastatic NSCLC
mRNA-4194
Phase 1/2
Phase 1/2 study dosing in Lynch Syndrome
mRNA-4106 / mRNA-4200
Phase 1
Phase 1 study dosing in advanced solid tumors:
mRNA-4106
mRNA-4200
T-cell
engager
mRNA-2808
Phase 1/2
Phase 1/2 study in
multiple myeloma dosing
Abstract accepted for
oral presentation at
ASH 2026
Cell therapy-
enhancer +
anzu-cel
mRNA-4203 + IMA203
Phase 1
Cell therapy-enhancer + anzu-cel (anzutresgene autoleucel, IMA203) Phase 1 study dosing
In collaboration with Immatics
New update
moderna
© 2026 Moderna, Inc. All rights reserved.

**Layout**

Three rounded white cards sit side by side in the main area: a wide left card (about 44% of slide width) and two narrower cards (about 20% each) to its right, with the cards starting at about 15% and ending near 87% of slide height. The title 'Oncology therapeutics' sits top-left at about 4% from the top, left-aligned to x 5.3%. A narrow blue vertical sidebar runs down the left edge with rotated text; the slide number sits at its bottom. A 'New update' tag sits below the left card at bottom-left, the copyright line sits bottom-left beneath it, and the Moderna logo sits bottom-right.

**Visuals**

No photographs or charts. Visual elements: (1) three card containers, each with a dark navy top bar and white rounded body with a thin light-grey outline; (2) three light lavender-grey phase tags (Phase 2, Phase 1/2, Phase 1 in the left card; Phase 1/2 in the middle card; Phase 1 in the right card) drawn as flat rectangles with no rounding; (3) small bullet glyphs (round dots) before body lines; (4) two solid red right-pointing arrow icons: one beside 'Abstract accepted for' in the middle card, one inside the 'New update' tag; (5) the Moderna logo at bottom-right: lowercase red wordmark 'moderna' (#E31837) above a row of short dashes in light cyan (#2AACE2 to pale blue) that alternate with gaps. No other icons or images.

**Design**

Background: Solid white #FFFFFF. Clean white corporate slide with a cyan sidebar. Background white #FFFFFF. Title 'Oncology therapeutics' in Segoe UI Bold, red #E31837, about 5.2% of slide height (cap height large, roughly 0.7 of that). Card headings in Segoe UI Bold navy #1E2846 at about 3.7% of slide height. Sub-heads (drug codes) in Segoe UI Semibold navy #1E2846 at about 2.6%. Body text in Segoe UI Light black #000000 at about 2.6%. Phase tags in Segoe UI Semibold navy #1E2846 at about 2.2%, on fill #CDD4E9. Card top bars navy #1E2846, roughly 5% of slide height tall, with rounded upper corners (radius about 1.5% of slide height). Card bodies white with light grey outline (#E6E6E6 approx) and rounded corners of about the same radius. Sidebar fill #2AACE2 with white bold text 'Pipeline updates' and pale blue #BFE6F6 light text '3Q 2026 Update |', both rotated. No shadows or gradients.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 2.7, h 100 [#2AACE2]: Blue vertical sidebar along the left edge, full height (Flat fill, no outline, no shadow.)
- title at x 5.3, y 4.4, w 31, h 5.2 [Segoe UI Bold; font size 5.18% of slide height; #E31837; left aligned]: Oncology therapeutics
- shape at x 6.1, y 15, w 43.6, h 5.1 [#1E2846]: Left card top bar, navy (Upper corners rounded, radius about 1.5% of slide height; sits behind the card body.)
- shape at x 6.1, y 16.7, w 43.6, h 70.4 [#FFFFFF]: Left card body, white rounded rectangle (Thin light grey outline about 0.1% of slide height, rounded corners about 1.5%, no shadow.)
- shape at x 51.7, y 15, w 20, h 5.1 [#1E2846]: Middle card top bar, navy (Upper corners rounded, sits behind the card body.)
- shape at x 51.7, y 16.7, w 20, h 70.4 [#FFFFFF]: Middle card body, white rounded rectangle (Thin light grey outline, rounded corners about 1.5%, no shadow.)
- shape at x 73.8, y 14.9, w 20, h 5.1 [#1E2846]: Right card top bar, navy (Upper corners rounded, sits behind the card body.)
- shape at x 73.8, y 16.6, w 20, h 70.5 [#FFFFFF]: Right card body, white rounded rectangle (Thin light grey outline, rounded corners about 1.5%, no shadow.)
- title at x 20.6, y 18.8, w 15.3, h 7.8 [Segoe UI Bold; font size 3.71% of slide height; #1E2846; center aligned]: Cancer antigen / therapies
- title at x 57.7, y 18.8, w 8, h 7.8 [Segoe UI Bold; font size 3.71% of slide height; #1E2846; center aligned]: T-cell / engager
- subtitle at x 58, y 27.1, w 7.6, h 2.6 [Segoe UI Light; font size 2.6% of slide height; #1E2846; center aligned]: mRNA-2808
- title at x 77.5, y 18.7, w 12.6, h 11.8 [Segoe UI Bold; font size 3.71% of slide height; #1E2846; center aligned]: Cell therapy- / enhancer + / anzu-cel
- subtitle at x 76.8, y 31.1, w 14.1, h 2.6 [Segoe UI Light; font size 2.6% of slide height; #1E2846; center aligned]: mRNA-4203 + IMA203
- shape at x 7.5, y 32.4, w 8.8, h 4 [#CDD4E9]: Phase 2 tag fill (Flat rectangle, no rounding, no outline.)
- text at x 9.7, y 33.4, w 4.3, h 2.2 [Segoe UI Semibold; font size 2.22% of slide height; #1E2846; center aligned]: Phase 2
- subtitle at x 7.4, y 28.5, w 8.2, h 2.6 [Segoe UI Semibold; font size 2.6% of slide height; #1E2846; left aligned]: mRNA-4359
- shape at x 7.9, y 52, w 8.8, h 4 [#CDD4E9]: Phase 1/2 tag fill (left card, second drug) (Flat rectangle, no outline.)
- text at x 9.6, y 52.8, w 5.4, h 2.2 [Segoe UI Semibold; font size 2.22% of slide height; #1E2846; center aligned]: Phase 1/2
- subtitle at x 8.3, y 48.1, w 8, h 2.6 [Segoe UI Semibold; font size 2.6% of slide height; #1E2846; left aligned]: mRNA-4194
- shape at x 7.8, y 69.2, w 8.8, h 4 [#CDD4E9]: Phase 1 tag fill (left card, third drug) (Flat rectangle, no outline.)
- text at x 10.1, y 70.1, w 4.1, h 2.2 [Segoe UI Semibold; font size 2.22% of slide height; #1E2846; center aligned]: Phase 1
- subtitle at x 8.2, y 65.3, w 17.5, h 2.6 [Segoe UI Semibold; font size 2.6% of slide height; #1E2846; left aligned]: mRNA-4106 / mRNA-4200
- body at x 7.9, y 38.8, w 35.7, h 5.6 [Segoe UI Light; font size 2.6% of slide height; #000000; left aligned]: • Phase 2 in first-line metastatic melanoma, second-line+ / metastatic melanoma, and first-line metastatic NSCLC (Round bullet dot, line spacing about 3.2% of slide height.)
- body at x 8.2, y 58.5, w 27.5, h 2.6 [Segoe UI Light; font size 2.6% of slide height; #000000; left aligned]: • Phase 1/2 study dosing in Lynch Syndrome (Round bullet dot.)
- body at x 8.2, y 75.2, w 28.7, h 10.3 [Segoe UI Light; font size 2.6% of slide height; #000000; left aligned]: Phase 1 study dosing in advanced solid tumors: / • mRNA-4106 / • mRNA-4200 (Lead-in sentence unbulleted, followed by two round-bulleted lines at about 3.7% line pitch.)
- title at x 53.7, y 45.2, w 16.9, h 5.7 [Segoe UI Light; font size 2.6% of slide height; #000000; left aligned]: Phase 1/2 study in / multiple myeloma dosing (First line has round bullet dot; second line is a continuation without bullet.)
- icon at x 53.7, y 53.7, w 1.2, h 1.8 [#E31837]: Red right-pointing arrow icon beside Abstract accepted (Solid filled arrow shape.)
- body at x 55.2, y 53.6, w 13.5, h 8.9 [Segoe UI Light; font size 2.6% of slide height; #000000; left aligned]: Abstract accepted for / oral presentation at / ASH 2026
- body at x 75.9, y 45.1, w 17, h 11.9 [Segoe UI Light; font size 2.6% of slide height; #000000; left aligned]: • Cell therapy-enhancer + anzu-cel (anzutresgene / autoleucel, IMA203) / Phase 1 study dosing (Round bullet dot on first line only.)
- caption at x 77.6, y 58.1, w 13.7, h 1.7 [Century Gothic Bold; font size 1.67% of slide height; #A6A6A6; left aligned]: In collaboration with Immatics
- shape at x 75.4, y 37.6, w 16.8, h 4 [#CDD4E9]: Phase 1 tag fill (right card) (Flat rectangle, no outline.)
- text at x 81.7, y 38.5, w 4.1, h 2.2 [Segoe UI Semibold; font size 2.22% of slide height; #1E2846; center aligned]: Phase 1
- shape at x 53.3, y 37.7, w 16.8, h 4 [#CDD4E9]: Phase 1/2 tag fill (middle card) (Flat rectangle, no outline.)
- text at x 59.1, y 38.8, w 5.4, h 2.2 [Segoe UI Semibold; font size 2.22% of slide height; #1E2846; center aligned]: Phase 1/2
- shape at x 6.1, y 88.7, w 8.8, h 4.2 [#FFFFFF]: New update tag box, white with grey outline (Thin grey outline about 0.1% of slide height, corner radius about 1%, no shadow; contains red arrow icon and label.)
- icon at x 6.8, y 90, w 1, h 1.8 [#E31837]: Red right-pointing arrow icon inside New update tag (Solid filled arrow shape.)
- text at x 8.2, y 90.2, w 5, h 1.7 [Segoe UI; font size 1.67% of slide height; #000000; left aligned]: New update
- logo at x 86.6, y 92.2, w 12.2, h 4.9 [#E31837]: Moderna logo: red lowercase wordmark moderna with a row of cyan dashes beneath (Raster image 359 by 81 pixels, placed unboxed on white; dashes in pale cyan.)
- page number at x 0.8, y 95.5, w 1.2, h 1.8 [Century Gothic Bold; font size 1.84% of slide height; #FFFFFF; left aligned]: 22 (Sits on the blue sidebar.)
- footer at x 5.6, y 95.7, w 16.1, h 1.5 [Century Gothic; font size 1.49% of slide height; #898989; left aligned]: © 2026 Moderna, Inc. All rights reserved.
- text at x 0.4, y 2.4, w 1.7, h 22.2 [Segoe UI Semibold; font size 2.96% of slide height; #FFFFFF; left aligned]: Pipeline updates (Rotated 90 degrees to read bottom to top, sits on blue sidebar.)
- text at x 0.4, y 24.7, w 1.7, h 22.9 [Segoe UI Light; font size 2.96% of slide height; #BFE6F6; left aligned]: 3Q 2026 Update | (Rotated 90 degrees to read bottom to top, sits on blue sidebar.)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 2.7, h 100.0: #2AACE2
- fill at x 6.1, y 15.0, w 43.6, h 5.1: #1E2846
- fill at x 6.1, y 16.7, w 43.6, h 70.4: #FFFFFF
- fill at x 51.7, y 15.0, w 20.0, h 5.1: #1E2846
- fill at x 51.7, y 16.7, w 20.0, h 70.4: #FFFFFF
- fill at x 53.3, y 37.7, w 16.8, h 4.0: #CDD4E9
- fill at x 73.8, y 14.9, w 20.0, h 5.1: #1E2846
- fill at x 73.8, y 16.6, w 20.0, h 70.5: #FFFFFF
- fill at x 75.4, y 37.6, w 16.8, h 4.0: #CDD4E9
- image at x 86.6, y 92.2, w 12.2, h 4.9: 359 by 81 pixels
- text at x 5.3, y 4.4, w 31.0, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: Oncology therapeutics
- text at x 0.4, y 2.4, w 1.7, h 22.2 [SegoeUI-Semibold; font size 2.96; #FFFFFF]: Pipeline updates
- text at x 20.6, y 18.8, w 15.3, h 3.7 [SegoeUI-Bold; font size 3.71; #1E2846]: Cancer antigen
- text at x 59.1, y 18.8, w 6.0, h 3.7 [SegoeUI-Bold; font size 3.71; #1E2846]: T-cell
- text at x 77.5, y 18.7, w 12.6, h 3.7 [SegoeUI-Bold; font size 3.71; #1E2846]: Cell therapy-
- text at x 23.4, y 22.9, w 9.1, h 3.7 [SegoeUI-Bold; font size 3.71; #1E2846]: therapies
- text at x 57.7, y 22.9, w 8.0, h 3.7 [SegoeUI-Bold; font size 3.71; #1E2846]: engager
- text at x 78.3, y 22.8, w 11.6, h 3.7 [SegoeUI-Bold; font size 3.71; #1E2846]: enhancer +
- text at x 79.7, y 26.8, w 8.2, h 3.7 [SegoeUI-Bold; font size 3.72; #1E2846]: anzu-cel
- text at x 58.0, y 27.1, w 7.6, h 2.6 [SegoeUI-Light; font size 2.60; #1E2846]: mRNA-2808
- text at x 7.4, y 28.5, w 8.2, h 2.6 [SegoeUI-Semibold; font size 2.60; #1E2846]: mRNA-4359
- text at x 0.4, y 24.7, w 1.7, h 22.9 [SegoeUI-Light; font size 2.96; #BFE6F6]: 3Q 2026 Update |
- text at x 76.8, y 31.1, w 14.1, h 2.6 [SegoeUI-Light; font size 2.60; #1E2846]: mRNA-4203 + IMA203
- text at x 7.9, y 38.8, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 9.4, y 38.8, w 8.8, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Phase 2 in first
- text at x 9.7, y 33.4, w 4.3, h 2.2 [SegoeUI-Semibold; font size 2.22; #1E2846]: Phase 2
- text at x 18.3, y 38.8, w 25.3, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: -line metastatic melanoma, second-line+
- text at x 9.4, y 41.9, w 32.6, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: metastatic melanoma, and first-line metastatic NSCLC
- text at x 53.7, y 45.2, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 55.2, y 45.2, w 11.4, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Phase 1/2 study in
- text at x 59.1, y 38.8, w 5.4, h 2.2 [SegoeUI-Semibold; font size 2.22; #1E2846]: Phase 1/2
- text at x 75.9, y 45.1, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 77.4, y 45.1, w 7.3, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Cell therapy
- text at x 81.7, y 38.5, w 4.1, h 2.2 [SegoeUI-Semibold; font size 2.22; #1E2846]: Phase 1
- text at x 84.7, y 45.1, w 8.0, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: -enhancer +
- text at x 8.3, y 48.1, w 8.0, h 2.6 [SegoeUI-Semibold; font size 2.60; #1E2846]: mRNA-4194
- text at x 55.2, y 48.3, w 15.4, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: multiple myeloma dosing
- text at x 77.4, y 48.2, w 14.3, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: anzu-cel (anzutresgene
- text at x 77.4, y 51.3, w 12.5, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: autoleucel, IMA203)
- text at x 53.7, y 53.6, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 55.2, y 53.6, w 13.5, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Abstract accepted for
- text at x 77.4, y 54.4, w 12.7, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Phase 1 study dosing
- text at x 55.2, y 56.8, w 12.3, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: oral presentation at
- text at x 8.2, y 58.5, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 9.7, y 58.5, w 26.0, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Phase 1/2 study dosing in Lynch Syndrome
- text at x 55.2, y 59.9, w 6.0, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: ASH 2026
- text at x 9.6, y 52.8, w 5.4, h 2.2 [SegoeUI-Semibold; font size 2.22; #1E2846]: Phase 1/2
- text at x 8.2, y 65.3, w 17.5, h 2.6 [SegoeUI-Semibold; font size 2.60; #1E2846]: mRNA-4106 / mRNA-4200
- text at x 8.2, y 75.2, w 28.7, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Phase 1 study dosing in advanced solid tumors:
- text at x 8.2, y 78.9, w 0.5, h 2.6 [ArialMT; font size 2.60; #000000]: •
- text at x 9.3, y 78.9, w 7.4, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: mRNA-4106
- text at x 8.2, y 82.6, w 0.5, h 2.6 [ArialMT; font size 2.60; #000000]: •
- text at x 9.3, y 82.6, w 4.0, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: mRNA
- text at x 10.1, y 70.1, w 4.1, h 2.2 [SegoeUI-Semibold; font size 2.22; #1E2846]: Phase 1
- text at x 13.3, y 82.6, w 4.0, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: -4200
- text at x 77.6, y 58.1, w 13.7, h 1.7 [CenturyGothic-Bold; font size 1.67; #A6A6A6]: In collaboration with Immatics
- text at x 0.8, y 95.5, w 1.2, h 1.8 [CenturyGothic-Bold; font size 1.84; #FFFFFF]: 22
- text at x 8.2, y 90.2, w 5.0, h 1.7 [SegoeUI; font size 1.67; #000000]: New update
- text at x 5.6, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #898989]: © 2026 Moderna, Inc. All rights reserved.

### Slide 23

**Review notes**

- Review: Several pages are sparse or poorly filled, such as slide 23 with two near-empty cards, slide 15 and slide 32, and the agenda is repeated five times.

**Text**

Rare disease therapeutics pipeline / 3Q 2026 Update | Pipeline updates / PA / mRNA-3927 / Phase 2 / • In a registrational study; target enrollment reached / MMA / mRNA-3705 / Phase 2 / • Company deferred decision on pivotal trial until PA readout / 23 / © 2026 Moderna, Inc. All rights reserved.

**Layout**

Two equal portrait cards sit side by side in the centre-left of the content area, with the title top-left above them and a thin vertical colour bar along the left edge. The title is left-aligned at about 5% from the left edge and the cards are centred as a pair, leaving empty white space to the right. Page number bottom-left inside the bar, copyright footer bottom-left beside it, and the Moderna logo bottom-right.

**Visuals**

Two rounded-corner portrait cards, each with a blue top tab. Card 1 (left): tab #6393C0, white body with a faint light-grey outline, title PA, subtitle mRNA-3927, a light blue-grey phase label bar reading Phase 2, and one bullet. Card 2 (right): identical structure with title MMA, subtitle mRNA-3705, Phase 2 label, and one bullet. No chart, photograph or icon. Bottom-right logo: the Moderna wordmark in red #E31837 lowercase, with a row of short dashes beneath it in a light-to-dark cyan-blue gradient.

**Design**

Background: Solid white #FFFFFF. Plain white slide with a saturated sky-blue vertical bar #2AACE2 down the left edge (about 2.7% wide). Title in bold red #E31837, sans-serif (Segoe UI Bold), about 5.2% of slide height. Body text in black #000000, Segoe UI Light, about 2.6% of slide height. Card headings in bold #6393C0 (Segoe UI Bold, 3.7%), subtitles in light #6393C0 (Segoe UI Light, 2.6%), phase labels in semibold #6393C0 (Segoe UI Semibold, 2.2%) on #DCE6F0 bars. Sidebar text is white semibold and pale #BFE6F6 light, rotated vertically. Cards have square-ish rounded corners with a soft light-grey outline and no visible shadow. Bullets are solid black dots in Century Gothic.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: Full-slide white background rectangle (Covers the whole slide, no outline.)
- shape at x 0, y 0, w 2.7, h 100 [#2AACE2]: Left vertical colour bar (Full-height bar, no outline, no shadow.)
- shape at x 22.9, y 16.5, w 20, h 5.1 [#6393C0]: PA card top tab (Rounded top corners, radius about 1% of slide width, sits behind the white card body and extends above it.)
- shape at x 22.9, y 18.2, w 20, h 69.5 [#FFFFFF]: PA card body (Rounded rectangle with faint light-grey outline about 0.1% wide, rounded corners, no shadow. Overlaps the PA tab at its top.)
- shape at x 24.5, y 30.2, w 16.8, h 4 [#DCE6F0]: PA Phase 2 label bar (Plain rectangle, square corners, no outline.)
- shape at x 50.8, y 16.5, w 20, h 5.1 [#6393C0]: MMA card top tab (Rounded top corners matching PA tab, behind card body.)
- shape at x 50.8, y 18.2, w 20, h 69.5 [#FFFFFF]: MMA card body (Rounded rectangle with faint light-grey outline, rounded corners, no shadow. Overlaps the MMA tab at its top.)
- shape at x 52.3, y 30.2, w 16.8, h 4 [#DCE6F0]: MMA Phase 2 label bar (Plain rectangle, square corners, no outline.)
- title at x 5.1, y 4.1, w 46.6, h 5.2 [Segoe UI Bold; font size 5.18% of slide height; #E31837; left aligned]: Rare disease therapeutics pipeline (Single line, sans-serif bold, no letter-spacing change.)
- caption at x 0.4, y 2.4, w 1.7, h 22.2 [Segoe UI Semibold, rotated 90 degrees, reads bottom to top; font size 2.96% of slide height; #FFFFFF; center aligned]: Pipeline updates (Vertical text in the left bar, placed after the 3Q 2026 Update text in the same run.)
- caption at x 0.4, y 24.7, w 1.7, h 22.9 [Segoe UI Light, rotated 90 degrees, reads bottom to top; font size 2.96% of slide height; #BFE6F6; center aligned]: 3Q 2026 Update | (Vertical text in the left bar, same line as Pipeline updates.)
- body at x 31.6, y 20.6, w 2.6, h 3.7 [Segoe UI Bold; font size 3.72% of slide height; #6393C0; center aligned]: PA (Card heading.)
- body at x 29.1, y 24.9, w 7.5, h 2.6 [Segoe UI Light; font size 2.6% of slide height; #6393C0; center aligned]: mRNA-3927 (Card subtitle.)
- body at x 30.7, y 31.2, w 4.3, h 2.2 [Segoe UI Semibold; font size 2.22% of slide height; #6393C0; center aligned]: Phase 2 (Phase label on the PA label bar.)
- bullet list at x 25.4, y 36.7, w 13.4, h 8.9 [Segoe UI Light; font size 2.6% of slide height; #000000; left aligned]: In a registrational / study; target / enrollment reached (Single bullet, solid black dot in Century Gothic at x 25.4, text hanging at x 26.9. Line spacing about 3.1% of slide height.)
- body at x 58.1, y 20.6, w 5.5, h 3.7 [Segoe UI Bold; font size 3.72% of slide height; #6393C0; center aligned]: MMA (Card heading.)
- body at x 57.1, y 24.9, w 7.5, h 2.6 [Segoe UI Light; font size 2.6% of slide height; #6393C0; center aligned]: mRNA-3705 (Card subtitle.)
- body at x 58.6, y 31.2, w 4.3, h 2.2 [Segoe UI Semibold; font size 2.22% of slide height; #6393C0; center aligned]: Phase 2 (Phase label on the MMA label bar.)
- bullet list at x 53.1, y 36.9, w 14, h 8.9 [Segoe UI Light; font size 2.6% of slide height; #000000; left aligned]: Company deferred / decision on pivotal / trial until PA readout (Single bullet, solid black dot in Century Gothic at x 53.1, text hanging at x 54.6. Line spacing about 3.1% of slide height.)
- logo at x 86.6, y 92.2, w 12.2, h 4.9 [#E31837]: Moderna logo: red lowercase wordmark with dashed cyan-blue underline (Placed image, 359 by 81 pixels. Dashes below the wordmark run from light sky blue to deeper cyan.)
- page number at x 0.8, y 95.5, w 1.2, h 1.8 [Century Gothic Bold; font size 1.84% of slide height; #FFFFFF; center aligned]: 23 (Sits on the left blue bar.)
- footer at x 5.6, y 95.7, w 16.1, h 1.5 [Century Gothic Regular; font size 1.49% of slide height; #898989; left aligned]: © 2026 Moderna, Inc. All rights reserved. (Copyright line.)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 2.7, h 100.0: #2AACE2
- fill at x 22.9, y 16.5, w 20.0, h 5.1: #6393C0
- fill at x 22.9, y 18.2, w 20.0, h 69.5: #FFFFFF
- fill at x 24.5, y 30.2, w 16.8, h 4.0: #DCE6F0
- fill at x 50.8, y 16.5, w 20.0, h 5.1: #6393C0
- fill at x 50.8, y 18.2, w 20.0, h 69.5: #FFFFFF
- fill at x 52.3, y 30.2, w 16.8, h 4.0: #DCE6F0
- image at x 86.6, y 92.2, w 12.2, h 4.9: 359 by 81 pixels
- text at x 5.1, y 4.1, w 46.6, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: Rare disease therapeutics pipeline
- text at x 0.4, y 2.4, w 1.7, h 22.2 [SegoeUI-Semibold; font size 2.96; #FFFFFF]: Pipeline updates
- text at x 31.6, y 20.6, w 2.6, h 3.7 [SegoeUI-Bold; font size 3.72; #6393C0]: PA
- text at x 58.1, y 20.6, w 5.5, h 3.7 [SegoeUI-Bold; font size 3.72; #6393C0]: MMA
- text at x 29.1, y 24.9, w 7.5, h 2.6 [SegoeUI-Light; font size 2.60; #6393C0]: mRNA-3927
- text at x 57.1, y 24.9, w 7.5, h 2.6 [SegoeUI-Light; font size 2.60; #6393C0]: mRNA-3705
- text at x 0.4, y 24.7, w 1.7, h 22.9 [SegoeUI-Light; font size 2.96; #BFE6F6]: 3Q 2026 Update |
- text at x 25.4, y 36.7, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 26.9, y 36.7, w 10.9, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: In a registrational
- text at x 30.7, y 31.2, w 4.3, h 2.2 [SegoeUI-Semibold; font size 2.22; #6393C0]: Phase 2
- text at x 53.1, y 36.9, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #000000]: •
- text at x 54.6, y 36.9, w 11.9, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Company deferred
- text at x 58.6, y 31.2, w 4.3, h 2.2 [SegoeUI-Semibold; font size 2.22; #6393C0]: Phase 2
- text at x 26.9, y 39.8, w 8.0, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: study; target
- text at x 54.6, y 40.0, w 11.9, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: decision on pivotal
- text at x 26.9, y 42.9, w 11.9, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: enrollment reached
- text at x 54.6, y 43.2, w 12.4, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: trial until PA readout
- text at x 0.8, y 95.5, w 1.2, h 1.8 [CenturyGothic-Bold; font size 1.84; #FFFFFF]: 23
- text at x 5.6, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #898989]: © 2026 Moderna, Inc. All rights reserved.

### Slide 24

**Text**

3Q26 earnings call agenda / Business Review / Stéphane Bancel, CEO / Financials / Jamey Mock, CFO / Business updates / Stephen Hoge, M.D., President / Pipeline updates / David Berman, M.D., Ph.D., Chief Development Officer / Looking Ahead / Stéphane Bancel, CEO / © 2026 Moderna, Inc. All rights reserved.

**Layout**

A full-height solid sky-blue sidebar occupies the left 19.4% of the slide, with the content area to its right on white. The title sits top-left of the content area at about 4.6% from the top, left-aligned at x 21.6%. Five agenda rows are stacked vertically in a single column, each with a circular line icon at x 23.2% and a bold heading with a light descriptor line to its right at x 31%. The fifth row, Looking Ahead, is enclosed in a red rounded outline. The footer copyright sits at bottom-left inside the blue sidebar, and the moderna logo sits bottom-right with a margin of about 1.5% from the right edge. No slide number is shown.

**Visuals**

Five circular line icons in light grey (#C0C0C0) outline strokes, each about 4.8% wide, placed in a column at x 23.2%: the first at y 16.7% shows a wavy line chart (business review); the second at y 32.4% shows a presentation board with bar chart and pie chart (financials); the third at y 48.4% shows three rulers or measuring tools arranged diagonally (business updates); the fourth at y 63.8% shows a scientist at a microscope beside a hexagon molecule cluster (pipeline updates). The fifth icon at y 79.5% is a red (#E21D39) circle outline containing two rows of blue (#2AACE2) rounded capsule shapes each followed by a red outlined arrow pointing right (looking ahead). Below-right: moderna wordmark logo in red (#E21D39) lowercase letters with a row of short dashed cyan (#2AACE2) lines underneath, placed at x 86.6% y 92.2% w 12.2% h 4.9%. No photographs or charts.

**Design**

Background white (#FFFFFF) with a solid sky-blue (#2AACE2) vertical band on the left. Title in bold sans-serif (Segoe UI Bold) in crimson red #E31837, about 5.2% of slide height. Heading text in bold Segoe UI in navy #1E2846, about 3.7% of slide height. Descriptor text in Segoe UI Light in black #000000, about 3.0% of slide height. The highlighted Looking Ahead heading is Segoe UI Bold in sky blue #2AACE2 at about 3.7%, and its descriptor is black Segoe UI Light. Footer is CenturyGothic in white #FFFFFF at about 1.5%. Icons use grey #C0C0C0 line strokes, thin, with the highlighted icon in red #E21D39 and blue #2AACE2. The red highlight box has a red #E21D39 stroke about 3 px wide with rounded corners of roughly 1.5% of slide width, no fill, no shadow. No gradients or shadows.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 19.4, h 100 [#2AACE2]: Left sidebar rectangle, full height, solid fill (Solid fill, no outline, no shadow, sits behind the footer text.)
- shape at x 21.05, y 77, w 57.4, h 14 [#FFFFFF]: Red rounded rectangle highlighting the Looking Ahead row (No fill (transparent), outline stroke #E21D39 about 3 px, corner radius about 1.5% of slide width, encloses the fifth icon and its text.)
- icon at x 23.2, y 16.7, w 4.8, h 8.6 [#C0C0C0]: Grey circle icon with wavy line chart (business review) (Circle outline stroke #C0C0C0 about 2 px, no fill, line icon inside in same grey.)
- icon at x 23.2, y 32.4, w 4.8, h 8.6 [#C0C0C0]: Grey circle icon with presentation board, bar chart and pie chart (financials) (Circle outline stroke #C0C0C0 about 2 px, no fill, line icon inside in same grey.)
- icon at x 23.2, y 48.4, w 4.8, h 8.6 [#C0C0C0]: Grey circle icon with three diagonal rulers (business updates) (Circle outline stroke #C0C0C0 about 2 px, no fill, line icon inside in same grey.)
- icon at x 23.2, y 63.8, w 4.8, h 8.6 [#C0C0C0]: Grey circle icon with scientist at microscope and hexagon molecules (pipeline updates) (Circle outline stroke #C0C0C0 about 2 px, no fill, line icon inside in same grey.)
- icon at x 23.2, y 79.5, w 4.8, h 8.6 [#E21D39]: Red circle icon with two rows of blue capsules and red arrows (looking ahead) (Circle outline stroke #E21D39 about 2 px, no fill; inner glyph has blue #2AACE2 capsules and red #E21D39 outlined right arrows.)
- title at x 21.6, y 4.6, w 36.2, h 5.2 [Segoe UI, bold; font size 5.18% of slide height; #E31837; left aligned]: 3Q26 earnings call agenda (Single line, no italics, no capitals or letter-spacing change.)
- body at x 31, y 17.5, w 15.8, h 3.7 [Segoe UI, bold; font size 3.71% of slide height; #1E2846; left aligned]: Business Review (Agenda heading, first row.)
- body at x 31, y 22.7, w 16, h 3 [Segoe UI, light; font size 2.96% of slide height; #000000; left aligned]: Stéphane Bancel, CEO (Descriptor line below heading.)
- body at x 31, y 33.3, w 9.5, h 3.7 [Segoe UI, bold; font size 3.71% of slide height; #1E2846; left aligned]: Financials (Agenda heading, second row.)
- body at x 31, y 38.5, w 12.5, h 3 [Segoe UI, light; font size 2.96% of slide height; #000000; left aligned]: Jamey Mock, CFO (Descriptor line below heading.)
- body at x 31, y 48.9, w 16.7, h 3.7 [Segoe UI, bold; font size 3.71% of slide height; #1E2846; left aligned]: Business updates (Agenda heading, third row.)
- body at x 31, y 54.1, w 21.2, h 3 [Segoe UI, light; font size 2.96% of slide height; #000000; left aligned]: Stephen Hoge, M.D., President (Descriptor line below heading.)
- body at x 31, y 64.2, w 16.2, h 3.7 [Segoe UI, bold; font size 3.71% of slide height; #1E2846; left aligned]: Pipeline updates (Agenda heading, fourth row.)
- body at x 31, y 69.4, w 37.4, h 3 [Segoe UI, light; font size 2.96% of slide height; #000000; left aligned]: David Berman, M.D., Ph.D., Chief Development Officer (Descriptor line below heading.)
- body at x 31.3, y 79.9, w 14.8, h 3.7 [Segoe UI, bold; font size 3.72% of slide height; #2AACE2; left aligned]: Looking Ahead (Highlighted agenda heading, fifth row.)
- body at x 31.3, y 85.1, w 15.5, h 3 [Segoe UI, light; font size 2.96% of slide height; #000000; left aligned]: Stéphane Bancel, CEO (Descriptor line below highlighted heading.)
- footer at x 2, y 95.7, w 16.1, h 1.5 [CenturyGothic, regular; font size 1.49% of slide height; #FFFFFF; left aligned]: © 2026 Moderna, Inc. All rights reserved. (Sits on the sky-blue sidebar.)
- logo at x 86.6, y 92.2, w 12.2, h 4.9 [#E21D39]: moderna wordmark logo with dashed cyan underline (Red lowercase wordmark with registered mark, above a row of short dashed cyan #2AACE2 lines; image 359 by 81 pixels.)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 19.4, h 100.0: #2AACE2
- fill at x 23.2, y 63.8, w 4.8, h 8.6: #C0C0C0
- fill at x 23.2, y 79.5, w 4.8, h 8.6: #E21D39
- fill at x 23.2, y 32.4, w 4.8, h 8.6: #C0C0C0
- fill at x 23.2, y 16.7, w 4.8, h 8.6: #C0C0C0
- fill at x 23.2, y 16.7, w 4.8, h 8.6: #C0C0C0
- fill at x 23.2, y 48.4, w 4.8, h 8.6: #C0C0C0
- image at x 86.6, y 92.2, w 12.2, h 4.9: 359 by 81 pixels
- text at x 21.6, y 4.6, w 36.2, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: 3Q26 earnings call agenda
- text at x 31.0, y 17.5, w 15.8, h 3.7 [SegoeUI-Bold; font size 3.71; #1E2846]: Business Review
- text at x 31.0, y 22.7, w 16.0, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: Stéphane Bancel, CEO
- text at x 31.0, y 33.3, w 9.5, h 3.7 [SegoeUI-Bold; font size 3.71; #1E2846]: Financials
- text at x 31.0, y 38.5, w 12.5, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: Jamey Mock, CFO
- text at x 31.0, y 48.9, w 16.7, h 3.7 [SegoeUI-Bold; font size 3.71; #1E2846]: Business updates
- text at x 31.0, y 64.2, w 16.2, h 3.7 [SegoeUI-Bold; font size 3.71; #1E2846]: Pipeline updates
- text at x 31.0, y 54.1, w 21.2, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: Stephen Hoge, M.D., President
- text at x 31.3, y 79.9, w 14.8, h 3.7 [SegoeUI-Bold; font size 3.72; #2AACE2]: Looking Ahead
- text at x 31.0, y 69.4, w 37.4, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: David Berman, M.D., Ph.D., Chief Development Officer
- text at x 31.3, y 85.1, w 15.5, h 3.0 [SegoeUI-Light; font size 2.96; #000000]: Stéphane Bancel, CEO
- text at x 2.0, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #FFFFFF]: © 2026 Moderna, Inc. All rights reserved.

### Slide 25

**Text**

2026 value drivers / Looking Ahead / 3Q 2026 Update | / Commercial + / financial performance / Potential / approvals / Potential clinical / milestones / Updated expected 2026 / revenue growth to 15-25%, / exceeding previous expectation of up to 10% / 2026 adjusted cash / cost¹ target: $3.8B / improvement by $0.2B from / previous framework / 2026 cash and investments / outlook² raised to $8.1-8.3B / increase driven by improved operational / execution and convertible note proceeds / • mNEXSPIKE in EU, / Japan, Switzerland, / Taiwan / mCOMBRIAX/mCOFLU in / EU, Canada, Japan / Flu (mRNA-1010) in the / U.S., Canada, EU / Intismeran / Five-year Phase 2 adjuvant melanoma data / Positive Phase 3 adjuvant melanoma data presented at / Presidential Symposium ESMO 2026 / • Phase 2 adjuvant renal cell carcinoma data; event-driven / Phase 1 adjuvant pancreatic poster presentation at / ESMO 2026 / • BLA submission / mRNA-2808 abstract accepted for oral presentation at / ASH on Dec 12th / • PA registrational study data / New update / 1. Excluding $0.9B for litigation settlement charge. Cash costs = GAAP expenses − stock-based compensation − depreciation and amortization / 2. Excludes any further drawdowns from the Company’s remaining $0.9B available under its credit facility / © 2026 Moderna, Inc. All rights reserved. / 25 / moderna

**Layout**

Three-column card layout below a left-aligned title: a narrow blue vertical sidebar runs down the left edge (about 2.7% of width) with rotated text, and three white bordered cards span from about 12.6% to 86.8% of slide height, widths about 24.8%, 22.1% and 42.2% of slide width, starting at x 5.2, 31.7 and 55.2. Each card has a centred red-ringed icon above a centred two-line black heading. The title sits top-left at x 5.9, y 3.4. A footer row at the bottom holds the New update tag and two footnotes at left, the copyright line under the tag, the page number in the blue sidebar, and the moderna logo at bottom right. Left margin about 5%, right margin about 2.7%.

**Visuals**

Three line icons, all with a red (#E21D39) circular ring. Icon 1 (card 1, centred near x 13.6 to 20.4, y 15.8 to 27.9): a blue-outlined dashboard window with red and blue dashed text lines, a red and blue bar chart and a blue pie chart. Icon 2 (card 2, near x 38.9 to 47.3, y 14.4 to 29.4): blue concentric target rings with a red dart arrow stuck in the centre and a blue circle containing a red check mark. Icon 3 (card 3, near x 72.1 to 80.5, y 14.4 to 29.3): a blue clipboard with a red medical cross at top, red check-mark list lines and a blue magnifying glass with red handle overlapping the lower right. Red check-mark icons (red filled circles with white tick) precede each country name in the Potential approvals column (mNEXSPIKE: EU, Japan, Switzerland, Taiwan; mCOMBRIAX/mCOFLU: EU, Canada, Japan; Flu: U.S., Canada, EU) and each Intismeran sub-item in the Potential clinical milestones column (Five-year Phase 2 adjuvant melanoma data; Positive Phase 3 adjuvant melanoma data presented at Presidential Symposium ESMO 2026; Phase 1 adjuvant pancreatic poster presentation at ESMO 2026). Solid red right-pointing arrows mark the bullet lines Updated expected 2026 revenue growth, 2026 adjusted cash cost target, 2026 cash and investments outlook, the mNEXSPIKE and mCOMBRIAX/mCOFLU and Flu approvals, Intismeran, and mRNA-2808. Black filled dots mark Phase 2 adjuvant renal cell carcinoma data, BLA submission, and PA registrational study data. A small red right arrow sits inside the New update tag. The moderna logo at bottom right (about x 86.6, y 92.2, 12.2 by 4.9) is a red lowercase wordmark with a row of short cyan dashes beneath it. No photographs.

**Design**

Background: Solid white #FFFFFF. Clean white corporate slide with a sky-blue sidebar. Title in bold red sans (Segoe UI Bold style) #E31837, about 5.2% of slide height. Card headings in light-weight black sans (Segoe UI Light) #000000, about 3.7% of height. Bold semibold black lead phrases (Segoe UI Semibold) about 2.6% of height. Body lines in Segoe UI Light #000000 about 2.6%. Italic sub-notes in Segoe UI Light Italic about 2.0%. Accent red #E31837 for arrows and check marks, cyan #2AACE2 for sidebar and icon line work, light cyan #BFE6F6 for sidebar subtitle text. Footnotes and footer in grey #7F7F7F and #898989, about 1.5% of height. Cards have white fill, thin light-grey (#BFBFBF) 1 px outline with square corners, no shadow. The New update tag is a white box with a thin grey outline and square corners. No gradients.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: Slide background fill, white covers the whole slide
- shape at x 0, y 0, w 2.7, h 100 [#2AACE2]: Left vertical sidebar bar, solid sky blue, full height (no outline, square corners)
- shape at x 5.2, y 12.6, w 24.8, h 74.2 [#FFFFFF]: Card 1 container, white rectangle with thin grey outline (outline #BFBFBF 1 px, square corners, no shadow)
- shape at x 31.7, y 12.6, w 22.1, h 74.2 [#FFFFFF]: Card 2 container, white rectangle with thin grey outline (outline #BFBFBF 1 px, square corners, no shadow)
- shape at x 55.2, y 12.6, w 42.2, h 74.2 [#FFFFFF]: Card 3 container, white rectangle with thin grey outline (outline #BFBFBF 1 px, square corners, no shadow)
- icon at x 13.6, y 15.8, w 6.8, h 12.1 [#E21D39]: Icon 1: dashboard, bar chart and pie chart in a red ring (red ring stroke about 2 px, interior white, blue and red line art)
- icon at x 38.9, y 14.4, w 8.4, h 15 [#E21D39]: Icon 2: target with red dart and blue check circle in a red ring (image 224 by 224 px, red ring stroke, blue line art)
- icon at x 72.1, y 14.4, w 8.4, h 14.9 [#E21D39]: Icon 3: clipboard with red medical cross, checklist and magnifier in a red ring (image 223 by 223 px, red ring stroke, blue line art)
- title at x 5.9, y 3.4, w 25, h 5.2 [Segoe UI Bold; font size 5.18% of slide height; #E31837; left aligned]: 2026 value drivers
- subtitle at x 0.5, y 2.4, w 1.7, h 20.2 [Segoe UI Semibold, rotated 90 degrees reading upward; font size 2.96% of slide height; #FFFFFF; left aligned]: Looking Ahead
- caption at x 0.5, y 22.6, w 1.7, h 22.9 [Segoe UI Light, rotated 90 degrees reading upward; font size 2.96% of slide height; #BFE6F6; left aligned]: 3Q 2026 Update |
- title at x 8.1, y 30.3, w 18.9, h 8.1 [Segoe UI Light; font size 3.71% of slide height; #000000; center aligned]: Commercial + / financial performance (two lines, centred, line spacing about 4.4% of height)
- title at x 38.6, y 30.2, w 8.9, h 8.2 [Segoe UI Light; font size 3.71% of slide height; #000000; center aligned]: Potential / approvals (two lines, centred)
- title at x 69.4, y 30.3, w 14.3, h 8.1 [Segoe UI Light; font size 3.71% of slide height; #000000; center aligned]: Potential clinical / milestones (two lines, centred)
- body at x 7.7, y 41.8, w 21, h 6.5 [Segoe UI Semibold with italic sub-line in Segoe UI Light Italic; font size 2.6% of slide height; #000000; left aligned]: Updated expected 2026 / revenue growth to 15-25%, / exceeding previous expectation of up to 10% (red right arrow icon at x 7.7 y 41.8 before line one; bold lead lines, italic sub-line 1.96 em; wrapped and left aligned)
- body at x 7.7, y 53.7, w 19, h 8.5 [Segoe UI Semibold with italic sub-line in Segoe UI Light Italic; font size 2.6% of slide height; #000000; left aligned]: 2026 adjusted cash / cost¹ target: $3.8B / improvement by $0.2B from / previous framework (red right arrow icon at x 7.7 y 53.7; superscript 1 after cost; italic sub-lines 1.96 em)
- body at x 7.7, y 67, w 19, h 9 [Segoe UI Semibold with italic sub-line in Segoe UI Light Italic; font size 2.6% of slide height; #000000; left aligned]: 2026 cash and investments / outlook² raised to $8.1-8.3B / increase driven by improved operational / execution and convertible note proceeds (red right arrow icon at x 7.7 y 67.0; superscript 2 after outlook; italic sub-lines 1.96 em)
- body at x 34.2, y 41.7, w 17, h 7.6 [Segoe UI Light with Segoe UI Semibold for mNEXSPIKE; font size 2.6% of slide height; #000000; left aligned]: • mNEXSPIKE in EU, / Japan, Switzerland, / Taiwan (black round bullet, check-mark icons precede EU, Japan, Switzerland, Taiwan; line spacing about 3.1% of height)
- body at x 34.2, y 56.6, w 17, h 5.5 [Segoe UI Semibold for mCOMBRIAX/mCOFLU, Segoe UI Light for rest; font size 2.6% of slide height; #000000; left aligned]: mCOMBRIAX/mCOFLU in / EU, Canada, Japan (red right arrow icon at x 34.2 y 56.6; check-mark icons precede EU, Canada, Japan)
- body at x 34.2, y 68.3, w 17, h 5.2 [Segoe UI Semibold for Flu, Segoe UI Light for rest; font size 2.6% of slide height; #000000; left aligned]: Flu (mRNA-1010) in the / U.S., Canada, EU (red right arrow icon at x 34.2 y 68.3; check-mark icons precede U.S., Canada, EU)
- body at x 59.1, y 40.3, w 7, h 2.6 [Segoe UI Semibold; font size 2.6% of slide height; #000000; left aligned]: Intismeran (red right arrow icon at x 57.6 y 40.3)
- body at x 60.8, y 44.5, w 26.3, h 2.6 [Segoe UI Light; font size 2.6% of slide height; #000000; left aligned]: Five-year Phase 2 adjuvant melanoma data (red check-mark icon at x 57.6 y 44.5)
- body at x 60.8, y 48.8, w 33.7, h 5.7 [Segoe UI Light; font size 2.6% of slide height; #000000; left aligned]: Positive Phase 3 adjuvant melanoma data presented at / Presidential Symposium ESMO 2026 (red check-mark icon at x 57.6 y 48.8; line spacing about 3.1% of height)
- body at x 59.3, y 56.1, w 35.9, h 2.6 [Segoe UI Light; font size 2.6% of slide height; #000000; left aligned]: • Phase 2 adjuvant renal cell carcinoma data; event-driven (black round bullet at x 59.3)
- body at x 60.8, y 60.3, w 31, h 5.7 [Segoe UI Light; font size 2.6% of slide height; #000000; left aligned]: Phase 1 adjuvant pancreatic poster presentation at / ESMO 2026 (red check-mark icon at x 57.6 y 60.3)
- body at x 59.3, y 67.7, w 11, h 2.6 [Segoe UI Light; font size 2.6% of slide height; #000000; left aligned]: • BLA submission (black round bullet at x 59.3)
- body at x 59.1, y 73, w 34, h 5.7 [Segoe UI Semibold for mRNA-2808, Segoe UI Light for rest; font size 2.6% of slide height; #000000; left aligned]: mRNA-2808 abstract accepted for oral presentation at / ASH on Dec 12th (red right arrow icon at x 57.6 y 73.0; second line indented to x 59.1)
- body at x 59.1, y 81.4, w 16, h 2.6 [Segoe UI Semibold for PA, Segoe UI Light for rest; font size 2.6% of slide height; #000000; left aligned]: • PA registrational study data (black round bullet at x 57.6 y 82.2)
- shape at x 5.2, y 89.2, w 8.8, h 4.1 [#FFFFFF]: New update tag, white rounded-corner-free box with red right arrow (outline #BFBFBF 1 px, square corners; red arrow icon at about x 5.9 y 90.5, 2.0 by 1.6 in #E31837)
- body at x 7.3, y 90.7, w 5, h 1.7 [Segoe UI Regular; font size 1.67% of slide height; #000000; left aligned]: New update
- footer at x 14.9, y 89.8, w 50, h 1.5 [Segoe UI Light; font size 1.49% of slide height; #7F7F7F; left aligned]: 1. Excluding $0.9B for litigation settlement charge. Cash costs = GAAP expenses − stock-based compensation − depreciation and amortization
- footer at x 14.9, y 91.5, w 36.7, h 1.5 [Segoe UI Light; font size 1.49% of slide height; #7F7F7F; left aligned]: 2. Excludes any further drawdowns from the Company’s remaining $0.9B available under its credit facility
- footer at x 5.6, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49% of slide height; #898989; left aligned]: © 2026 Moderna, Inc. All rights reserved.
- page number at x 0.8, y 95.5, w 1.2, h 1.8 [CenturyGothic-Bold; font size 1.84% of slide height; #FFFFFF; left aligned]: 25 (white text on sky-blue sidebar)
- logo at x 86.6, y 92.2, w 12.2, h 4.9 [#E21D39]: moderna wordmark logo with cyan dashed underline (image 359 by 81 px; red lowercase wordmark, row of short cyan dashes beneath)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 2.7, h 100.0: #2AACE2
- fill at x 5.2, y 12.6, w 24.8, h 74.2: #FFFFFF
- fill at x 13.6, y 15.8, w 6.8, h 12.1: #E21D39
- image at x 38.9, y 14.4, w 8.4, h 15.0: 224 by 224 pixels
- image at x 72.1, y 14.4, w 8.4, h 14.9: 223 by 223 pixels
- image at x 86.6, y 92.2, w 12.2, h 4.9: 359 by 81 pixels
- text at x 5.9, y 3.4, w 25.0, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: 2026 value drivers
- text at x 0.5, y 2.4, w 1.7, h 20.2 [SegoeUI-Semibold; font size 2.96; #FFFFFF]: Looking Ahead
- text at x 11.4, y 30.3, w 12.9, h 3.7 [SegoeUI-Light; font size 3.71; #000000]: Commercial +
- text at x 39.1, y 30.2, w 8.1, h 3.7 [SegoeUI-Light; font size 3.71; #000000]: Potential
- text at x 69.4, y 30.3, w 14.3, h 3.7 [SegoeUI-Light; font size 3.71; #000000]: Potential clinical
- text at x 8.1, y 34.7, w 18.9, h 3.7 [SegoeUI-Light; font size 3.71; #000000]: financial performance
- text at x 38.6, y 34.7, w 8.4, h 3.7 [SegoeUI-Light; font size 3.71; #000000]: approvals
- text at x 71.7, y 34.7, w 9.2, h 3.7 [SegoeUI-Light; font size 3.71; #000000]: milestones
- text at x 0.5, y 22.6, w 1.7, h 22.9 [SegoeUI-Light; font size 2.96; #BFE6F6]: 3Q 2026 Update |
- text at x 57.6, y 40.3, w 0.7, h 2.6 [Wingdings-Regular; font size 2.60; #E31837]: 
- text at x 59.1, y 40.3, w 7.0, h 2.6 [SegoeUI-Semibold; font size 2.60; #000000]: Intismeran
- text at x 7.7, y 41.8, w 0.9, h 2.6 [CenturyGothic; font size 2.60; #E31837]: ●
- text at x 9.1, y 41.8, w 16.2, h 2.6 [SegoeUI-Semibold; font size 2.60; #000000]: Updated expected 2026
- text at x 34.2, y 41.7, w 0.7, h 2.6 [Wingdings-Regular; font size 2.60; #000000]: 
- text at x 35.7, y 41.7, w 7.8, h 2.6 [SegoeUI-Semibold; font size 2.60; #000000]: mNEXSPIKE
- text at x 43.9, y 41.7, w 5.5, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: in EU,
- text at x 36.9, y 44.8, w 13.5, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Japan, Switzerland,
- text at x 59.3, y 44.5, w 0.6, h 2.6 [SegoeUI-Light; font size 2.60; #7F7F7F]: •
- text at x 60.8, y 44.5, w 26.3, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Five-year Phase 2 adjuvant melanoma data
- text at x 9.1, y 45.0, w 18.2, h 2.6 [SegoeUI-Semibold; font size 2.60; #000000]: revenue growth to 15-25%,
- text at x 36.9, y 47.9, w 4.0, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Taiwan
- text at x 59.3, y 48.8, w 0.6, h 2.6 [SegoeUI-Light; font size 2.60; #7F7F7F]: •
- text at x 60.8, y 48.8, w 33.7, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Positive Phase 3 adjuvant melanoma data presented at
- text at x 60.8, y 51.9, w 22.0, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Presidential Symposium ESMO 2026
- text at x 7.7, y 53.7, w 0.5, h 2.6 [ArialMT; font size 2.60; #E31837]: •
- text at x 9.2, y 53.7, w 13.0, h 2.6 [SegoeUI-Semibold; font size 2.60; #000000]: 2026 adjusted cash
- text at x 59.3, y 56.1, w 35.9, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: • Phase 2 adjuvant renal cell carcinoma data; event-driven
- text at x 9.2, y 56.8, w 11.9, h 2.6 [SegoeUI-Semibold; font size 2.60; #000000]: cost target: $3.8B
- text at x 34.2, y 56.6, w 0.7, h 2.6 [Wingdings-Regular; font size 2.60; #000000]: 
- text at x 35.7, y 56.6, w 15.1, h 2.6 [SegoeUI-Semibold; font size 2.60; #000000]: mCOMBRIAX/mCOFLU
- text at x 51.2, y 56.6, w 3.9, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: in
- text at x 37.3, y 59.7, w 12.9, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: EU, Canada, Japan
- text at x 59.3, y 60.3, w 0.6, h 2.6 [SegoeUI-Light; font size 2.60; #7F7F7F]: •
- text at x 60.8, y 60.3, w 31.0, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: Phase 1 adjuvant pancreatic poster presentation at
- text at x 9.1, y 47.9, w 19.9, h 2.0 [SegoeUI-LightItalic; font size 1.96; #000000]: exceeding previous expectation of up to 10%
- text at x 60.8, y 63.4, w 7.2, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: ESMO 2026
- text at x 7.7, y 67.0, w 0.5, h 2.6 [ArialMT; font size 2.60; #E31837]: •
- text at x 9.2, y 67.0, w 18.2, h 2.6 [SegoeUI-Semibold; font size 2.60; #000000]: 2026 cash and investments
- text at x 59.3, y 67.7, w 11.0, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: • BLA submission
- text at x 34.2, y 68.3, w 0.7, h 2.6 [Wingdings-Regular; font size 2.60; #000000]: 
- text at x 35.7, y 68.3, w 2.0, h 2.6 [SegoeUI-Semibold; font size 2.60; #000000]: Flu
- text at x 38.1, y 68.3, w 12.2, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: (mRNA-1010) in the
- text at x 9.2, y 70.1, w 18.2, h 2.6 [SegoeUI-Semibold; font size 2.60; #000000]: outlook raised to $8.1-8.3B
- text at x 37.3, y 71.4, w 11.3, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: U.S., Canada, EU
- text at x 59.1, y 73.0, w 8.1, h 2.6 [SegoeUI-Semibold; font size 2.60; #000000]: mRNA-2808
- text at x 67.6, y 73.0, w 25.6, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: abstract accepted for oral presentation at
- text at x 59.1, y 76.1, w 10.3, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: ASH on Dec 12th
- text at x 9.2, y 59.8, w 12.9, h 2.0 [SegoeUI-LightItalic; font size 1.96; #000000]: improvement by $0.2B from
- text at x 59.1, y 81.4, w 1.7, h 2.6 [SegoeUI-Semibold; font size 2.60; #000000]: PA
- text at x 61.2, y 81.4, w 14.6, h 2.6 [SegoeUI-Light; font size 2.60; #000000]: registrational study data
- text at x 9.2, y 62.2, w 8.9, h 2.0 [SegoeUI-LightItalic; font size 1.96; #000000]: previous framework
- text at x 11.9, y 56.8, w 0.4, h 1.7 [SegoeUI-Semibold; font size 1.73; #000000]: 1
- text at x 9.2, y 73.1, w 18.3, h 2.0 [SegoeUI-LightItalic; font size 1.96; #000000]: increase driven by improved operational
- text at x 9.2, y 75.5, w 18.0, h 2.0 [SegoeUI-LightItalic; font size 1.96; #000000]: execution and convertible note proceeds
- text at x 14.3, y 70.1, w 0.5, h 1.7 [SegoeUI-Semibold; font size 1.73; #000000]: 2
- text at x 57.6, y 73.7, w 0.6, h 1.7 [CenturyGothic; font size 1.69; #000000]: ●
- text at x 57.6, y 82.2, w 0.6, h 1.7 [CenturyGothic; font size 1.69; #000000]: ●
- text at x 0.8, y 95.5, w 1.2, h 1.8 [CenturyGothic-Bold; font size 1.84; #FFFFFF]: 25
- text at x 7.3, y 90.7, w 5.0, h 1.7 [SegoeUI; font size 1.67; #000000]: New update
- text at x 14.9, y 89.8, w 50.0, h 1.5 [SegoeUI-Light; font size 1.49; #7F7F7F]: 1. Excluding $0.9B for litigation settlement charge. Cash costs = GAAP expenses − stock-based compensation − depreciation and amortization
- text at x 14.9, y 91.5, w 36.7, h 1.5 [SegoeUI-Light; font size 1.49; #7F7F7F]: 2. Excludes any further drawdowns from the Company’s remaining $0.9B available under its credit facility
- text at x 5.6, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #898989]: © 2026 Moderna, Inc. All rights reserved.

### Slide 26

**Text**

Upcoming events / Moderna Analyst Day / November 12, 2026 / In-person at Moderna Marlborough Facility (by RSVP) / Webcast / Looking Ahead / 3Q 2026 Update | / 26 / © 2026 Moderna, Inc. All rights reserved.

**Layout**

Two-zone layout: a full-height sky-blue panel occupies the left 30.2% of the slide and holds a large white calendar icon centred vertically, with the vertical 'Looking Ahead' and '3Q 2026 Update |' labels and the page number at the panel's left edge. The white right area holds the red title 'Upcoming events' top-left at x 32.5%, aligned to a left edge at about 32.5%, and a single bordered card (x 31.8%, y 33.2%, w 49%, h 33.6%) containing the event details left-aligned at x 34.5%. The moderna logo sits bottom-right at about 86.6% to 98.8% horizontally and 92.2% to 97.1% vertically, and the copyright line sits bottom-left inside the white area's margin at y 95.7%.

**Visuals**

One white line icon of a calendar with a check mark: a rounded rectangle calendar body with two binder rings at the top, a horizontal header bar, a 3x2 grid of rounded square day cells, and a large circle with a white checkmark overlapping the bottom-right corner of the calendar body. The icon is drawn in solid white on the #2AACE2 blue panel, centred at about x 6.7% to 23.5%, y 35.0% to 77.2%. Two small red line icons inside the card: a map pin (location marker) beside the in-person line, and a laptop-style screen with a globe showing a webcast beside the Webcast line. A thin red horizontal rule under the event title. The moderna wordmark in red with a row of short cyan dashes beneath it, bottom-right.

**Design**

Background white #FFFFFF on the right and a sky-blue #2AACE2 panel on the left. Title 'Upcoming events' in Segoe UI Bold, red #E31837, about 5.2% of slide height. Event heading 'Moderna Analyst Day' in Segoe UI Bold, black #000000, about 3.7% of slide height. Body lines in Segoe UI Light, black #000000, about 3.3% of slide height. Vertical side labels in Segoe UI Semibold/Light, white #FFFFFF and pale blue #BFE6F6. Page number in Century Gothic Bold white. Copyright in Century Gothic regular grey #898989, about 1.5% of slide height. Accent red #E31837 for the title, the underline rule and the two icons. Card has a white fill with a thin light grey border (about #EDEDED), square-ish rounded corners of small radius, no shadow. No gradients.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 30.2, h 100: Left sky-blue panel covering the full height of the left side (Solid fill #2AACE2, no border, sits behind the calendar icon and vertical labels. A narrower overlapping fill of the same colour at the left 2.7% edge.)
- icon at x 6.7, y 35, w 16.8, h 42.2 [#FFFFFF]: White calendar with check mark icon: calendar body, binder rings, header bar, 3x2 day cells and check-mark circle (Solid white line-style icon on the blue panel. Calendar body from x 6.7% y 42.1% w 16.8% h 21.8%; rings and header from x 6.7% y 35.0% w 16.8% h 8.6%; check-mark circle overlapping the bottom-right from x 17.4% y 53.0% w 8.0% h 14.2%.)
- caption at x 0.5, y 2.4, w 1.7, h 20.2 [Segoe UI Semibold; font size 2.96% of slide height; #FFFFFF; left aligned]: Looking Ahead (Vertical side label rotated to read bottom-to-top on the blue panel, white, not capitalised.)
- caption at x 0.5, y 22.6, w 1.7, h 22.9 [Segoe UI Light; font size 2.96% of slide height; #BFE6F6; left aligned]: 3Q 2026 Update | (Vertical side label rotated to read bottom-to-top on the blue panel, pale blue, the trailing vertical bar is part of the text.)
- title at x 32.5, y 8.3, w 23.9, h 5.2 [Segoe UI Bold; font size 5.18% of slide height; #E31837; left aligned]: Upcoming events (Bold sans-serif, sentence case, no letter-spacing.)
- shape at x 31.8, y 33.2, w 49, h 33.6 [#FFFFFF]: Event card with thin border (White rounded rectangle with a thin light grey border about #EDEDED, small corner radius, no shadow, sits over the white background.)
- body at x 34.5, y 38.4, w 21.1, h 3.7 [Segoe UI Bold; font size 3.71% of slide height; #000000; left aligned]: Moderna Analyst Day
- line at x 34.5, y 42.8, w 25, h 0.4 [#E31837]: Red underline beneath Moderna Analyst Day (Straight horizontal rule about 0.3% of slide height thick, runs from under the start to near the end of the heading.)
- body at x 34.5, y 45, w 15.3, h 3.3 [Segoe UI Light; font size 3.33% of slide height; #000000; left aligned]: November 12, 2026
- icon at x 34.5, y 51.3, w 1.9, h 3.6 [#E31837]: Map pin location marker (Red outline map pin icon to the left of the in-person line.)
- body at x 37.5, y 51.2, w 41.9, h 3.3 [Segoe UI Light; font size 3.33% of slide height; #000000; left aligned]: In-person at Moderna Marlborough Facility (by RSVP)
- icon at x 34.5, y 57.4, w 2.3, h 3.6 [#E31837]: Laptop screen with globe webcast icon (Red outline icon of a laptop-style screen with a small globe overlapping its corner, to the left of the Webcast line.)
- body at x 37.5, y 57.5, w 6.7, h 3.3 [Segoe UI Light; font size 3.33% of slide height; #000000; left aligned]: Webcast
- logo at x 86.6, y 92.2, w 12.2, h 4.9 [#E31837]: moderna logo with dashed underline (Red lowercase wordmark moderna with a small registered mark, with a row of short cyan dashes beneath it. Raster image 359 by 81 pixels.)
- page number at x 0.8, y 95.5, w 1.2, h 1.8 [Century Gothic Bold; font size 1.84% of slide height; #FFFFFF; left aligned]: 26 (Sits on the blue panel at the bottom-left.)
- footer at x 5.6, y 95.7, w 16.1, h 1.5 [Century Gothic; font size 1.49% of slide height; #898989; left aligned]: © 2026 Moderna, Inc. All rights reserved.

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 2.7, h 100.0: #2AACE2
- fill at x 0.0, y 0.0, w 30.2, h 100.0: #2AACE2
- fill at x 6.7, y 42.1, w 16.8, h 21.8: #FFFFFF
- fill at x 6.7, y 35.0, w 16.8, h 8.6: #FFFFFF
- fill at x 17.4, y 53.0, w 8.0, h 14.2: #FFFFFF
- image at x 86.6, y 92.2, w 12.2, h 4.9: 359 by 81 pixels
- text at x 32.5, y 8.3, w 23.9, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: Upcoming events
- text at x 0.5, y 2.4, w 1.7, h 20.2 [SegoeUI-Semibold; font size 2.96; #FFFFFF]: Looking Ahead
- text at x 34.5, y 38.4, w 21.1, h 3.7 [SegoeUI-Bold; font size 3.71; #000000]: Moderna Analyst Day
- text at x 0.5, y 22.6, w 1.7, h 22.9 [SegoeUI-Light; font size 2.96; #BFE6F6]: 3Q 2026 Update |
- text at x 34.5, y 45.0, w 15.3, h 3.3 [SegoeUI-Light; font size 3.33; #000000]: November 12, 2026
- text at x 37.5, y 51.2, w 41.9, h 3.3 [SegoeUI-Light; font size 3.33; #000000]: In-person at Moderna Marlborough Facility (by RSVP)
- text at x 37.5, y 57.5, w 6.7, h 3.3 [SegoeUI-Light; font size 3.33; #000000]: Webcast
- text at x 0.8, y 95.5, w 1.2, h 1.8 [CenturyGothic-Bold; font size 1.84; #FFFFFF]: 26
- text at x 5.6, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #898989]: © 2026 Moderna, Inc. All rights reserved.

### Slide 27

**Text**

Our mission / Deliver the greatest possible impact / to people through mRNA medicines / 27 / © 2026 Moderna, Inc. All rights reserved.

**Layout**

Single-column composition on a white field with a full-height blue vertical bar at the left edge (about 2.7% of width). The kicker 'Our mission' is centred horizontally at about 28% of slide height, with the two-line statement centred below it at about 42% to 61%, leaving the lower third empty. The footer sits along the bottom at about 95.5% to 97.3% height: slide number at the left inside the blue bar, copyright line starting at about 5.6% width, and the Moderna logo at bottom right, about 3% from the right and bottom edges. No header or title placeholder is used.

**Visuals**

Two non-text elements. (1) A Moderna wordmark logo at bottom right, lowercase 'moderna' in red #E31B3B with a registered mark, above a row of short dashed underline segments in cyan #2AACE2 that step lightly across its width. (2) A full-slide blue vertical bar at the left edge in #2AACE2, a flat solid shape with no border or shadow. No photographs, charts, or diagrams are present.

**Design**

Background: Solid white #FFFFFF with a full-height cyan #2AACE2 bar at the left edge. Plain white background with no gradient or texture. A single cyan #2AACE2 vertical bar runs the full slide height at the left edge, about 2.7% of slide width. Kicker 'Our mission' is set in a light-weight geometric sans in red #E31B3B, about 5.7% of slide height. The statement is set in a light-weight geometric sans (Century Gothic-like) in black #000000 at about 9.5% of slide height, with the emphasised words 'Deliver', 'people' and 'medicines' in a bold weight in red #E31B3B. Body and statement text are set on a single centred axis. Footer copyright is Century Gothic regular at about 1.5% of slide height in grey #898989. Slide number is Century Gothic Bold at about 1.8% in white #FFFFFF on the blue bar. No corner radii, shadows, or gradients.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 2.7, h 100 [#2AACE2]: Full-height vertical colour bar at left edge of slide (Flat solid rectangle, no border, no shadow, no rounding; sits behind the slide number.)
- title at x 42.6, y 27.6, w 15.5, h 4.4 [Light geometric sans (Century Gothic-like), regular weight, sentence case; font size 5.7% of slide height; #E31B3B; center aligned]: Our mission (Line spacing single; part of a placed image (2473 by 893 px) spanning x 9.8 to 91.4 and y 20.6 to 73.0 that also carries the statement below; the image has no visible border, box, or tint.)
- body at x 10.5, y 42.5, w 79.8, h 19 [Light geometric sans (Century Gothic-like), regular weight; 'Deliver', 'people', 'medicines' in bold weight; font size 9.5% of slide height; #000000; center aligned]: Deliver the greatest possible impact / to people through mRNA medicines (Two centred lines with the emphasised words in bold red #E31B3B; line spacing about 1.2; part of the same placed image as the kicker, so the text is raster, not live text.)
- footer at x 5.6, y 95.7, w 16.1, h 1.5 [Century Gothic, regular weight, sentence case, no letter-spacing; font size 1.49% of slide height; #898989; left aligned]: © 2026 Moderna, Inc. All rights reserved. (Single line at bottom left, baseline aligned with the slide number.)
- page number at x 0.8, y 95.5, w 1.2, h 1.8 [Century Gothic Bold, bold weight; font size 1.84% of slide height; #FFFFFF; left aligned]: 27 (White numeral placed on the cyan bar at bottom left.)
- logo at x 86.6, y 92.2, w 12.2, h 4.9 [#E31B3B]: Moderna wordmark logo with registered mark and dashed cyan underline (Placed image 359 by 81 px; red #E31B3B wordmark with cyan #2AACE2 dashes beneath; no background box.)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 2.7, h 100.0: #2AACE2
- image at x 9.8, y 20.6, w 81.6, h 52.4: 2473 by 893 pixels
- image at x 86.6, y 92.2, w 12.2, h 4.9: 359 by 81 pixels
- text at x 0.8, y 95.5, w 1.2, h 1.8 [CenturyGothic-Bold; font size 1.84; #FFFFFF]: 27
- text at x 5.6, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #898989]: © 2026 Moderna, Inc. All rights reserved.

### Slide 28

**Text**

Q&A
moderna
© 2026 Moderna, Inc. All rights reserved.

**Layout**

Two-zone layout: a full-height vertical blue band fills the left 19.4% of the slide, and the white content area sits to its right. The Q&A title is left-aligned at about 22.9% from the left and sits at roughly the vertical middle of the slide (42% to 50% of its height). The copyright footer sits in the bottom-left of the blue band, and the Moderna logo sits in the bottom-right corner. No slide number is shown.

**Visuals**

One logo: the Moderna wordmark, set in lowercase red letters with a row of short, evenly spaced cyan dashes running beneath it, placed at the bottom-right corner (about 86.6% from left, 92.2% from top, 12.2% wide by 4.9% high; source image 359 by 81 pixels). One flat decorative shape: a solid vertical blue rectangle (#2AACE2) covering the left 19.4% of the slide, full height, with no border or gradient. No photographs, charts, tables, or diagrams.

**Design**

Background: Solid white #FFFFFF across the whole slide, with a solid #2AACE2 vertical band over its left 19.4%. Plain flat design with no gradients, shadows, or textures. Background is white. The title 'Q&A' is set in a bold humanist sans-serif, closest to Segoe UI Bold, in red #E31837, at about 8.3% of slide height. The copyright line is set in a light geometric sans-serif, closest to Century Gothic regular, in white #FFFFFF, at about 1.5% of slide height. The blue band is solid #2AACE2 with square corners. The logo uses red #E31837-like tones for the wordmark and cyan #00B5E2-like tones for the dashes.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 19.4, h 100 [#2AACE2]: Left vertical blue band, full height, covering the left 19.4% of the slide (Solid fill #2AACE2, no border, square corners, no shadow, fully opaque.)
- title at x 22.9, y 42.1, w 10.8, h 8.3 [Segoe UI, Bold, upright, no capitals styling, normal letter-spacing (closest: Segoe UI Bold sans-serif); font size 8.34% of slide height; #E31837; left aligned]: Q&A (Single line, red bold sans-serif characters, ampersand in the same weight; sits centered vertically on the slide.)
- logo at x 86.6, y 92.2, w 12.2, h 4.9 [#E31837]: Moderna logo: lowercase red wordmark 'moderna' with a row of short cyan dashes beneath it (Placed image, 359 by 81 pixels, bottom-right corner, not cropped. Wordmark in red #E31837-like; dashes in cyan #00B5E2-like tones, graded slightly lighter at left. Registered-trademark mark at top-right of the wordmark.)
- caption at x 2, y 95.7, w 16.1, h 1.5 [Century Gothic, Regular, upright, normal letter-spacing (closest: Century Gothic sans-serif); font size 1.49% of slide height; #FFFFFF; left aligned]: © 2026 Moderna, Inc. All rights reserved. (Single line copyright notice printed in white over the blue band, bottom-left, placed as a footer.)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 19.4, h 100.0: #2AACE2
- image at x 86.6, y 92.2, w 12.2, h 4.9: 359 by 81 pixels
- text at x 22.9, y 42.1, w 10.8, h 8.3 [SegoeUI-Bold; font size 8.34; #E31837]: Q&A
- text at x 2.0, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #FFFFFF]: © 2026 Moderna, Inc. All rights reserved.

### Slide 29

**Text**

Appendix / Moderna’s Pipeline / © 2026 Moderna, Inc. All rights reserved.

**Layout**

Two-zone layout: a full-height blue vertical band occupies the left 19.4% of the slide width, with the white content area to its right. A two-line section title sits left-aligned at x 23.1%, vertically centred around y 36% to 54%. The copyright footer sits bottom-left inside the blue band, and the Moderna logo sits bottom-right, both near the bottom edge with margins of roughly 2% to 3%. No slide number is visible.

**Visuals**

Logo: Moderna wordmark in lowercase red (#E31837) letters with a row of short light-blue to cyan (#2AACE2) dashes beneath it, at the bottom-right corner. No photographs, charts, or diagrams.

**Design**

Background white #FFFFFF with a full-height left band in sky blue #2AACE2 covering the left 19.4% of the slide, with no border. Title line 'Appendix' in bold Segoe UI-style sans-serif, red #E31837, approximately 8.3% of slide height for cap height and ascenders. Subtitle 'Moderna’s Pipeline' in light weight Segoe UI-style sans-serif, red #E31837, same size as title. Footer in Century Gothic-style geometric sans-serif, regular weight, white #FFFFFF, about 1.5% of slide height. Shapes are plain rectangles with square corners, no shadows, no gradients.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 19.4, h 100 [#2AACE2]: Full-height vertical blue band on the left side of the slide (Plain rectangle, square corners, no shadow, fully opaque; sits behind all text, bounded on the right at x 19.4%.)
- title at x 23.1, y 36.1, w 21.3, h 8.3 [Segoe UI, Bold; font size 8.33% of slide height; #E31837; left aligned]: Appendix (Upright, no italics, no capitals, normal letter-spacing; sits directly above the subtitle line.)
- subtitle at x 23.1, y 46.1, w 36.9, h 8.3 [Segoe UI, Light; font size 8.33% of slide height; #E31837; left aligned]: Moderna’s Pipeline (Upright, no italics, no capitals, normal letter-spacing; curly apostrophe in 'Moderna’s'.)
- footer at x 2, y 95.7, w 16.1, h 1.5 [Century Gothic, Regular; font size 1.49% of slide height; #FFFFFF; left aligned]: © 2026 Moderna, Inc. All rights reserved. (Sits inside the blue band; white text on sky blue, no background behind it.)
- logo at x 86.6, y 92.2, w 12.2, h 4.9 [#E31837]: Moderna logo: red lowercase wordmark 'moderna' with registered mark, above a row of light-blue to cyan dashes (Image 359 by 81 pixels, placed at bottom-right on white background; dashes run in a gradient from pale blue to cyan #2AACE2-like tone.)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 19.4, h 100.0: #2AACE2
- image at x 86.6, y 92.2, w 12.2, h 4.9: 359 by 81 pixels
- text at x 23.1, y 36.1, w 21.3, h 8.3 [SegoeUI-Bold; font size 8.33; #E31837]: Appendix
- text at x 23.1, y 46.1, w 36.9, h 8.3 [SegoeUI-Light; font size 8.33; #E31837]: Moderna’s Pipeline
- text at x 2.0, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #FFFFFF]: © 2026 Moderna, Inc. All rights reserved.

### Slide 30

**Review notes**

- Review: Many slides carry tiny type that cannot be read at presentation size, including the disclaimer on slide 2, the results table on slide 9, the survival curves and AE chart on slides 18 to 21, and the appendix on slides 30 to 32.
- Suggested repair: Enlarge or crop the unreadable tables and charts on slides 9, 19 to 21 and 30 to 32, and fill or merge the near-empty slides such as 23 and 32.

**Text**

Moderna’s pipeline: Infectious diseases
Infectious disease vaccines
Ph 1
Ph 2
Ph 3
Commercial
Respiratory viruses
COVID-19 vaccine
Spikevax®
COVID-19 vaccine
mNEXSPIKE®
RSV vaccine
mRESVIA®
Flu + COVID vaccine
mCOMBRIAX®
Flu vaccine
mFLUSIVA®
Pandemic Flu vaccine (in collaboration with CEPI*)
mRNA-1018
RSV + hMPV vaccine
mRNA-1365
RSV vaccine for adolescents + pediatrics
mRNA-1345
Enteric viruses
Norovirus vaccines
mRNA-1403
mRNA-1405
Latent viruses
CMV vaccine for transplant recipients
mRNA-1647
EBV vaccine to prevent infectious mononucleosis
mRNA-1189
EBV vaccine in multiple sclerosis
mRNA-1195
HIV vaccine (in collaboration with IAVI)
mRNA-1645
Bacterial
Lyme disease vaccines
mRNA-1975
mRNA-1982
Public health
Bundibugyo ebolavirus vaccine
mRNA-1469
Nipah vaccine
mRNA-1215
Mpox vaccine
mRNA-1769
© 2026 Moderna, Inc. All rights reserved.
30

**Layout**

Full-width white slide with a thin vertical blue bar on the left edge (about 2.7% of width). The title sits top-left at about 5.5% from the left and 5.3% from the top, above a single boxed table image that spans from about 5.6% to 77% horizontally and from about 11.6% to 89% vertically, left-aligned to the title edge. The table has a light blue header band with a column header row, then grouped rows separated by thin dark rules. Footer: slide number 30 in white on the blue bar at bottom-left, copyright line left-aligned at about 5.6% from left and 95.7% from top, and the moderna logo at bottom-right (about 86.6% to 98.8% horizontally, 92.2% to 97.1% vertically). Right side of the slide beyond the table is empty.

**Visuals**

One table image (2005 by 1225 pixels) with a column header band and horizontal progress bars. Columns: a section label column in red (Respiratory viruses, Enteric viruses, Latent viruses, Bacterial, Public health), a bold program-name column, a bold-free code column (Spikevax®, mNEXSPIKE®, mRESVIA®, mCOMBRIAX®, mFLUSIVA®, mRNA codes), and a progress-bar column with four phase headers Ph 1, Ph 2, Ph 3 and Commercial. Each bar is a blue (#29ABE2) rounded fill inside a light grey (#D9D9D9) rounded track with a white inner edge. Rows and bar lengths: COVID-19 vaccine Spikevax® full to Commercial; COVID-19 vaccine mNEXSPIKE® full to Commercial; RSV vaccine mRESVIA® full to Commercial; Flu + COVID vaccine mCOMBRIAX® full to Commercial; Flu vaccine mFLUSIVA® full to Commercial; Pandemic Flu vaccine (in collaboration with CEPI*) mRNA-1018 about 75% of track, about Ph 3; RSV + hMPV vaccine mRNA-1365 about 20%, about Ph 1; RSV vaccine for adolescents + pediatrics mRNA-1345 about 50%, about Ph 2; Norovirus vaccines mRNA-1403 about 75%; Norovirus vaccines mRNA-1405 about 50%; CMV vaccine for transplant recipients mRNA-1647 about 50%; EBV vaccine to prevent infectious mononucleosis mRNA-1189 about 50%; EBV vaccine in multiple sclerosis mRNA-1195 about 50%; HIV vaccine (in collaboration with IAVI) mRNA-1645 about 20%; Lyme disease vaccines mRNA-1975 about 50%; Lyme disease vaccines mRNA-1982 about 50%; Bundibugyo ebolavirus vaccine mRNA-1469 about 20%; Nipah vaccine mRNA-1215 about 20%; Mpox vaccine mRNA-1769 about 50%. Bar lengths are estimates, no values printed. No legend and no highlighted points. Small icon at top-left of the header band: a red-outlined circle containing two blue-and-white capsule or pill shapes. Footnote-style text (CEPI*) is embedded in the Pandemic Flu row.

**Design**

Background: Solid white #FFFFFF. White background #FFFFFF with a sky-blue vertical bar #2AACE2 on the left edge. Title in bold humanist sans (Segoe UI Bold style) in red #E31837, about 5.2% of slide height. Table header band in pale blue #BEE6F7 with navy #1B2A4A bold header text (about 2.8% of slide height). Row labels bold dark grey-black #1A1A1A, codes regular #1A1A1A, roughly 1.6% of slide height. Section labels in bold red #E31837. Thin black rules #000000 between groups and dark grey #333333 hairlines between rows. Progress bars blue #29ABE2 on grey #D9D9D9 rounded tracks. Footer copyright in light grey #898989 Century Gothic, about 1.5% of slide height. Slide number white bold Century Gothic on blue bar. Logo in red #E31837 with dashed blue underline in #2AACE2.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: Full-slide white background fill (Covers the whole slide, no outline, no shadow.)
- shape at x 0, y 0, w 2.7, h 100 [#2AACE2]: Vertical left accent bar (Solid fill, no outline, full slide height, carries the slide number.)
- table at x 5.6, y 11.6, w 71.5, h 77.7 [Century Gothic, Bold for program names, Regular for codes; font size 1.6% of slide height; #1A1A1A; left aligned]: Infectious disease vaccines pipeline table image: header row Infectious disease vaccines with Ph 1, Ph 2, Ph 3, Commercial columns; section groups Respiratory viruses, Enteric viruses, Latent viruses, Bacterial, Public health; rows COVID-19 vaccine Spikevax® / COVID-19 vaccine mNEXSPIKE® / RSV vaccine mRESVIA® / Flu + COVID vaccine mCOMBRIAX® / Flu vaccine mFLUSIVA® / Pandemic Flu vaccine (in collaboration with CEPI*) mRNA-1018 / RSV + hMPV vaccine mRNA-1365 / RSV vaccine for adolescents + pediatrics mRNA-1345 / Norovirus vaccines mRNA-1403 / mRNA-1405 / CMV vaccine for transplant recipients mRNA-1647 / EBV vaccine to prevent infectious mononucleosis mRNA-1189 / EBV vaccine in multiple sclerosis mRNA-1195 / HIV vaccine (in collaboration with IAVI) mRNA-1645 / Lyme disease vaccines mRNA-1975 / mRNA-1982 / Bundibugyo ebolavirus vaccine mRNA-1469 / Nipah vaccine mRNA-1215 / Mpox vaccine mRNA-1769 (Raster image 2005 by 1225 pixels placed unboxed on white, no border. Header band pale blue #BEE6F7 spanning about x 5.6 to 76.4 and y 12.9 to 19.1. Rows about 3.5% of slide height apart, separated by thin dark hairlines; thick black rules separate the five groups. Progress bars occupy x about 39 to 76 of the slide, blue #29ABE2 fills on grey #D9D9D9 rounded tracks with white inner outline, bar height about 1.6% of slide height. Column labels Ph 1, Ph 2, Ph 3 and Commercial in bold navy #1B2A4A near the top of the header band.)
- icon at x 6, y 14, w 2.4, h 4.2 [#E31837]: Red-outlined circular icon with two capsule or pill shapes, representing vaccine (Circle outline in red #E31837 with blue #2AACE2 and white capsule shapes inside, sits at the left of the header text on the pale blue band.)
- title at x 5.5, y 5.3, w 53.4, h 5.2 [Segoe UI, Bold; font size 5.18% of slide height; #E31837; left aligned]: Moderna’s pipeline: Infectious diseases (Single line, no capitals beyond the first letter, sits above the table with no underline.)
- page number at x 0.8, y 95.5, w 1.2, h 1.8 [Century Gothic, Bold; font size 1.84% of slide height; #FFFFFF; left aligned]: 30 (Sits on the blue left bar, white text.)
- footer at x 5.6, y 95.7, w 16.1, h 1.5 [Century Gothic, Regular; font size 1.49% of slide height; #898989; left aligned]: © 2026 Moderna, Inc. All rights reserved. (Single line copyright notice.)
- logo at x 86.6, y 92.2, w 12.2, h 4.9 [#E31837; right aligned]: Moderna logo: lowercase red wordmark moderna with a dashed light blue underline (Raster image 326 by 73 pixels, placed unboxed in the bottom-right corner; underline is a row of short dashes in #2AACE2.)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 2.7, h 100.0: #2AACE2
- image at x 5.6, y 11.6, w 71.5, h 77.7: 2005 by 1225 pixels
- image at x 86.6, y 92.2, w 12.2, h 4.9: 326 by 73 pixels
- text at x 5.5, y 5.3, w 53.4, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: Moderna’s pipeline: Infectious diseases
- text at x 0.8, y 95.5, w 1.2, h 1.8 [CenturyGothic-Bold; font size 1.84; #FFFFFF]: 30
- text at x 5.6, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #898989]: © 2026 Moderna, Inc. All rights reserved.

### Slide 31

**Review notes**

- Review: Many slides carry tiny type that cannot be read at presentation size, including the disclaimer on slide 2, the results table on slide 9, the survival curves and AE chart on slides 18 to 21, and the appendix on slides 30 to 32.
- Suggested repair: Enlarge or crop the unreadable tables and charts on slides 9, 19 to 21 and 30 to 32, and fill or merge the near-empty slides such as 23 and 32.

**Text**

Moderna’s pipeline: Oncology / Oncology therapeutics / Ph 1 / Ph 2 / Ph 3 / Commercial / Intismeran autogene / (partnered with Merck) / Adjuvant melanoma / mRNA-4157 / Adjuvant NSCLC / mRNA-4157 / Adjuvant NSCLC non-pCR post neoadjuvant / mRNA-4157 / Adjuvant Stage 1 NSCLC / mRNA-4157 / Adjuvant renal cell carcinoma (RCC) / mRNA-4157 / Adjuvant bladder cancer (MIBC) / mRNA-4157 / Bladder cancer (NMIBC) / mRNA-4157 / Metastatic melanoma / mRNA-4157 / First-line metastatic squamous NSCLC / mRNA-4157 / Early and advanced solid tumors / mRNA-4157 / Cancer antigen therapies / Advanced solid tumors / mRNA-4359 / Solid tumors / mRNA-4106 / Solid tumors / mRNA-4200 / Lynch Syndrome / mRNA-4194 / T-cell engagers / Multiple myeloma / mRNA-2808 / Cell therapy enhancers / Solid tumors (in collaboration with Immatics) / mRNA-4203 + anzu-cel (IMA203) / Abbreviations: NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma; MIBC, muscle-invasive bladder cancer; NMIBC, non-muscle invasive bladder cancer / 31 / © 2026 Moderna, Inc. All rights reserved.

**Layout**

Single full-width content slide on a white field with a solid sky-blue vertical band along the entire left edge (about 2.7% of the width). The title sits top-left at about 5.4% from the left and 5.3% from the top, left aligned. A boxed table graphic spans roughly 5.7% to 78.6% horizontally and 11.6% to 89.8% vertically, with the abbreviations line beneath it, left aligned at about 6.5%. The slide number sits in the blue band at bottom-left, the copyright line bottom-left after the band, and the Moderna wordmark bottom-right at about 86.6% to 98.8% horizontally.

**Visuals**

One raster image of a pipeline table (1998 by 1206 px) occupying the central area. Columns: therapy group (red bold labels, left column), programme name (bold black), molecule code (regular black), and a horizontal phase bar track with stage headers Ph 1, Ph 2, Ph 3 and Commercial across the top. Each bar is a rounded blue (#29A9E0) fill inside a rounded light grey outlined track. Rows and values: Intismeran autogene (partnered with Merck), 10 rows all mRNA-4157: Adjuvant melanoma, bar about to the late Ph 3 to Commercial zone; Adjuvant NSCLC, same; Adjuvant NSCLC non-pCR post neoadjuvant, same; Adjuvant Stage 1 NSCLC, same; Adjuvant renal cell carcinoma (RCC), bar about to mid Ph 2 to Ph 3 zone; Adjuvant bladder cancer (MIBC), same; Bladder cancer (NMIBC), same; Metastatic melanoma, same; First-line metastatic squamous NSCLC, same; Early and advanced solid tumors, bar about to late Ph 1 to Ph 2 zone. Cancer antigen therapies: Advanced solid tumors mRNA-4359, bar about mid Ph 2 to Ph 3; Solid tumors mRNA-4106, bar about Ph 1 to Ph 2; Solid tumors mRNA-4200, same; Lynch Syndrome mRNA-4194, same. T-cell engagers: Multiple myeloma mRNA-2808, bar about Ph 1 to Ph 2. Cell therapy enhancers: Solid tumors (in collaboration with Immatics) mRNA-4203 + anzu-cel (IMA203), bar about Ph 1 to Ph 2. Bar lengths are estimates; the slide prints no numeric values. Thick black horizontal rules separate the therapy groups. A small circular magnifier-style icon with red ring sits left of the table header. No legend or highlighted points. Flat, even lighting; no photographs.

**Design**

Background: Solid white #FFFFFF. White background; sky blue #2AACE2 left band; table header band light blue #BDE6F7; table text dark navy #1B2A41 and bold for programme names; group labels and title red #E31837; bars blue #29A9E0 with light grey #BFBFBF outlines; abbreviations and copyright in grey #A6A6A6 and #898989. Title in Segoe UI Bold, about 5.2% of slide height (cap height about 3.6%). Body and table text in a Segoe UI/Helvetica-like sans-serif, about 1.7% to 2% of slide height. Slide number in Century Gothic Bold white. Thin rules, rounded bar ends, no shadows or gradients.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: Full-slide white background fill (Solid fill, no outline, behind everything.)
- shape at x 0, y 0, w 2.7, h 100 [#2AACE2]: Vertical sky-blue band along the left edge (Solid fill, no outline, full height.)
- title at x 5.4, y 5.3, w 40.9, h 5.2 [Segoe UI Bold, bold, normal case; font size 5.18% of slide height; #E31837; left aligned]: Moderna’s pipeline: Oncology
- table at x 5.7, y 11.6, w 72.9, h 78.2 [#E6F6FC]: Oncology therapeutics pipeline table, placed raster image 1998 by 1206 px, containing the header band, phase columns Ph 1 / Ph 2 / Ph 3 / Commercial, therapy group labels, programme names, molecule codes and blue phase bars listed in visuals (Placed image, rectangular crop, no shadow, opacity 100%. Header band light blue #BDE6F7 with navy title text and red-ringed icon; bars blue #29A9E0; rules dark grey and black.)
- caption at x 6.5, y 85.8, w 65.8, h 1.7 [Segoe UI, regular; font size 1.67% of slide height; #A6A6A6; left aligned]: Abbreviations: NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma; MIBC, muscle-invasive bladder cancer; NMIBC, non-muscle invasive bladder cancer
- page number at x 0.8, y 95.5, w 1.2, h 1.8 [Century Gothic, bold; font size 1.84% of slide height; #FFFFFF; left aligned]: 31 (Sits on the blue band.)
- footer at x 5.6, y 95.7, w 16.1, h 1.5 [Century Gothic, regular; font size 1.49% of slide height; #898989; left aligned]: © 2026 Moderna, Inc. All rights reserved.
- logo at x 86.6, y 92.2, w 12.2, h 4.9 [#E31837]: Moderna wordmark logo in red lowercase letters with a row of dashed blue underline segments beneath (Placed raster image 326 by 73 px, no background box.)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 2.7, h 100.0: #2AACE2
- image at x 5.7, y 11.6, w 72.9, h 78.2: 1998 by 1206 pixels
- image at x 86.6, y 92.2, w 12.2, h 4.9: 326 by 73 pixels
- text at x 5.4, y 5.3, w 40.9, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: Moderna’s pipeline: Oncology
- text at x 6.5, y 85.8, w 65.8, h 1.7 [SegoeUI; font size 1.67; #A6A6A6]: Abbreviations: NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma; MIBC, muscle-invasive bladder cancer; NMIBC, non-muscle invasive bladder cancer
- text at x 0.8, y 95.5, w 1.2, h 1.8 [CenturyGothic-Bold; font size 1.84; #FFFFFF]: 31
- text at x 5.6, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #898989]: © 2026 Moderna, Inc. All rights reserved.

### Slide 32

**Review notes**

- Review: Many slides carry tiny type that cannot be read at presentation size, including the disclaimer on slide 2, the results table on slide 9, the survival curves and AE chart on slides 18 to 21, and the appendix on slides 30 to 32.
- Review: Several pages are sparse or poorly filled, such as slide 23 with two near-empty cards, slide 15 and slide 32, and the agenda is repeated five times.
- Suggested repair: Enlarge or crop the unreadable tables and charts on slides 9, 19 to 21 and 30 to 32, and fill or merge the near-empty slides such as 23 and 32.

**Text**

Moderna’s pipeline: Rare diseases
Rare disease therapeutics / Ph 1 / Ph 2 / Ph 3 / Commercial
Rare diseases
Propionic acidemia / mRNA-3927
Methylmalonic acidemia / mRNA-3705
32
© 2026 Moderna, Inc. All rights reserved.

**Layout**

Single-column layout on a white field with a full-height vertical blue bar on the left edge (about 2.7% of slide width). The title sits top-left, left-aligned at about 5.4% x and 5.2% y, above a pipeline table graphic occupying the upper-left area (about 5.3% to 76.2% x, 12.1% to 36.2% y). The lower two-thirds of the slide is empty. The slide number sits white on the blue bar at bottom-left, the copyright line sits bottom-left beside it, and the Moderna logo sits bottom-right at about 86.6% x and 92.2% y.

**Visuals**

One raster image of a pipeline table, placed unboxed on the white background, roughly 70.9% of slide width by 24.1% of slide height. It has a light blue header band spanning the image width, with a red-outlined circular icon containing a blue DNA double-helix at its left and the header label 'Rare disease therapeutics' in dark navy. Four phase column headings sit at the right of the header: Ph 1, Ph 2, Ph 3 and Commercial. Below the header, a red category label 'Rare diseases' sits at the left, followed by two rows separated by a thin black horizontal rule. Row 1: 'Propionic acidemia' in bold, 'mRNA-3927' in regular weight, and a progress bar. Row 2: 'Methylmalonic acidemia' in bold, 'mRNA-3705' in regular weight, and a progress bar. Each progress bar is a rounded pill with a light grey outline and white track, with a blue #2AACE2 fill running from its left end to about 50% of its length, identical in both rows. The bars sit under the span from Ph 1 to Ph 3 with no axis, scale values, or numeric labels. No legend and no highlighted points. The Moderna logo is a separate red wordmark with a dashed blue underline at bottom-right.

**Design**

Background: Solid white #FFFFFF. White background. Title in bold red #E31837 humanist sans-serif (Segoe UI Bold), about 5.2% of slide height for the cap-height line. Table header text in dark navy #1B2A41 bold sans; row labels in near-black #111111; mRNA codes in regular weight dark grey #222222. Accent colours: red #E31837 for the title and 'Rare diseases' category label, blue #2AACE2 for the left bar and progress bar fills, pale blue #BEE6F7 for the table header band. Table text about 2 to 3% of slide height. Shapes are flat with no shadows or gradients; progress bars use fully rounded ends; the header icon is a red circle outline. Slide number and copyright in small sans-serif, copyright in grey #898989.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 2.7, h 100 [#2AACE2]: Full-height vertical left accent bar (Flat rectangle, no border, no shadow, runs full slide height at the left edge.)
- title at x 5.4, y 5.2, w 46, h 5.2 [Segoe UI Bold, bold, sentence case; font size 5.18% of slide height; #E31837; left aligned]: Moderna’s pipeline: Rare diseases
- photo at x 5.3, y 12.1, w 70.9, h 24.1 [#BEE6F7]: Pipeline table image: light blue header band with DNA icon, header label, phase column headings and two progress-bar rows (Raster image 1998 by 382 pixels, unboxed, no shadow, placed over white; pale blue header band spans the full image width; the image contains the text, icon and bars listed in the other elements.)
- icon at x 5.75, y 14.4, w 2.35, h 4.2 [#E31837]: Red-outlined circle containing a blue DNA double-helix (Circle outline in red about 2 pt, blue #2AACE2 helix glyph inside, transparent fill.)
- subtitle at x 8.8, y 15.3, w 19.9, h 2.8 [Segoe UI-style geometric sans, semi-bold; font size 3% of slide height; #1B2A41; left aligned]: Rare disease therapeutics
- body at x 50.9, y 15.8, w 1.75, h 1.4 [Sans-serif bold; font size 2% of slide height; #1B2A41; center aligned]: Ph 1
- body at x 57.9, y 15.8, w 1.9, h 1.4 [Sans-serif bold; font size 2% of slide height; #1B2A41; center aligned]: Ph 2
- body at x 64.9, y 15.8, w 1.9, h 1.4 [Sans-serif bold; font size 2% of slide height; #1B2A41; center aligned]: Ph 3
- body at x 70.2, y 15.8, w 5.3, h 1.4 [Sans-serif bold; font size 2% of slide height; #1B2A41; center aligned]: Commercial
- body at x 5.75, y 22.2, w 8.05, h 2 [Sans-serif semi-bold; font size 2.4% of slide height; #E31837; left aligned]: Rare diseases
- body at x 16.95, y 20.6, w 9.6, h 2 [Sans-serif bold; font size 2.2% of slide height; #111111; left aligned]: Propionic acidemia
- body at x 39.25, y 20.6, w 5.65, h 2 [Sans-serif regular; font size 2.2% of slide height; #222222; left aligned]: mRNA-3927
- shape at x 48.2, y 20.4, w 27.45, h 2.05 [#2AACE2]: Progress bar, row 1, rounded pill track with blue fill to about 50% (Pill-shaped track with white fill and light grey #BDBDBD outline about 1 pt; blue #2AACE2 fill from left end to about 50% of track length; no tick marks or labels.)
- line at x 16.5, y 23.3, w 59.8, h 0.1 [#111111]: Thin black horizontal rule separating the two rows (Straight line about 1 pt, spans from under Propionic acidemia to the right edge of the table.)
- body at x 16.95, y 24.3, w 12.2, h 2 [Sans-serif bold; font size 2.2% of slide height; #111111; left aligned]: Methylmalonic acidemia
- body at x 39.25, y 24.3, w 5.65, h 2 [Sans-serif regular; font size 2.2% of slide height; #222222; left aligned]: mRNA-3705
- shape at x 48.2, y 24, w 27.45, h 2.1 [#2AACE2]: Progress bar, row 2, rounded pill track with blue fill to about 50% (Pill-shaped track with white fill and light grey #BDBDBD outline about 1 pt; blue #2AACE2 fill from left end to about 50% of track length; no tick marks or labels.)
- logo at x 86.6, y 92.2, w 12.2, h 4.9 [#E31837]: Moderna wordmark logo in red with dashed blue underline (Raster image 326 by 73 pixels; red #E31837 lowercase wordmark over a row of short dashes in light blue #2AACE2.)
- page number at x 0.8, y 95.5, w 1.2, h 1.8 [Century Gothic, bold; font size 1.84% of slide height; #FFFFFF; center aligned]: 32 (Sits on the blue left bar.)
- footer at x 5.6, y 95.7, w 16.1, h 1.5 [Century Gothic, regular; font size 1.49% of slide height; #898989; left aligned]: © 2026 Moderna, Inc. All rights reserved.

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 2.7, h 100.0: #2AACE2
- image at x 5.3, y 12.1, w 70.9, h 24.1: 1998 by 382 pixels
- image at x 86.6, y 92.2, w 12.2, h 4.9: 326 by 73 pixels
- text at x 5.4, y 5.2, w 46.0, h 5.2 [SegoeUI-Bold; font size 5.18; #E31837]: Moderna’s pipeline: Rare diseases
- text at x 0.8, y 95.5, w 1.2, h 1.8 [CenturyGothic-Bold; font size 1.84; #FFFFFF]: 32
- text at x 5.6, y 95.7, w 16.1, h 1.5 [CenturyGothic; font size 1.49; #898989]: © 2026 Moderna, Inc. All rights reserved.
